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General introduction 
and aims of the thesis
Based on: 
De Martino MC, van Koetsveld PM, Pivonello R & Hofland LJ.
Neuroendocrinology 2010;92 (Suppl 1):28-34
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General introduction 9
The ADRenAl glAnDs
Adrenals are two symmetric endocrine glands (about 2x5x1 cm; weight approximately 4 
g) with a pyramidal shape, placed on the top of the kidneys in the retroperitoneum. Each 
adrenal has two distinct structures: the external part is named adrenal cortex and the 
internal medulla, producing different hormones (Figure 1). The anatomy of these glands 
was firstly described by Bartholomeo Eustacius almost 450 years ago.1
Adrenal cortex
The adrenal cortex cells originate from mesoderm and in adult humans are organized 
in three zones or layers that, from the external to the internal, are named, zona glo-
merulosa (15%), zona fasciculata (75%) and zona reticularis (10%). In these zones, cells 
are organized in different histological structures that can be recognized microscopically. 
The adrenal cortex produces steroid hormones, which are derived from their common 
precursor cholesterol and have a common cyclopentano-perhydro-phenanthrene 
structure. The different adrenal cortex zones produce different steroids, depending on 
the differential expression of specific enzymes involved in steroid hormone synthesis. 
The zona glomerulosa is the site for production of mineralocorticoids, particularly al-
dosterone, that has a central role in the long-term regulation of blood pressure under 
the principal control of angiotensin II.1 The zona fasciculata is the site for production of 
glucocorticoids, among which cortisol represents the most important in humans. Gluco-
corticoids are regulated by ACTH and they have an important role in the systemic stress 
response, cardiovascular function and regulation of metabolism.1 The zona reticularis 
produces the adrenal androgens (DHEA; DHEA-S and androstenedione), which play a 
role particularly in premenopausal women, but rarely in some pathological conditions, 
their excess can have a clinical significance in men as well.1
figure 1. The anatomy of adrenal glands. Adapted from Anatomy & Physiology, Connexions Web site. 
http://cnx.org/content/col11496/1.6/, Jun 19, 2013.
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Adrenal medulla
The cells forming the adrenal medulla are called chromaffin cells because they stain 
brown with chromium salts. These cells originate from the embryonic neural crest and 
can be considered as modified neurons that are mainly regulated directly by the sym-
pathetic nervous system through preganglionic fibers originating in the thoracic spinal 
cord. Therefore, the adrenal medulla can be considered as a specialized sympathetic 
ganglion that releases its secretions directly into the blood. The adrenal medulla oc-
cupies the central portion of the adrenal gland and accounts for 10% of the total gland 
volume and produces catecholamine (epinephrine, norepinephrine and dopamine). In 
humans, catecholamines regulate many cardiovascular and metabolic processes.1
ADRenAl glAnD TuMORs
Primary adrenal tumors (AT) include benign and malignant adrenocortical tumors (ACT) 
and benign and malignant tumors of the adrenal medulla named pheochromocytomas 
(PCC).2, 3 Both benign and malignant ATs can be hormonally inactive or they can be 
hormone-secreting, resulting in specific clinical syndromes including hyperaldosteron-
ism or Conn’s syndrome, hypercortisolism or Cushing’s syndrome, virilizing or feminizing 
syndrome in case of ACTs and catecholamine excess syndrome in case of PCCs. The 
clinical symptoms and signs can be also related to mass effects that generally occur 
in malignant ATs because of their growth and/or metastases. However, ATs can also 
be clinically silent and discovered occasionally during diagnostic imaging procedure 
performed for indications other than an evaluation for adrenal disease. These adrenal 
masses (generally 1 cm or more in diameter) accidentally discovered are defined as 
incidentalomas. Adrenal masses are quite common with an overall frequency of about 
6% (range, 1-32) and 4% (up to 10% in elderly patients) in radiological and in autopsy 
studies respectively.4, 5 Most ATs are benign, hormonally inactive and clinically silent, 
and are often discovered incidentally.4, 5 However, they can require long-term clinical 
follow-up.6 On the other hand, malignant ATs are rare and aggressive with poor prog-
nosis and scant treatment options.7 The surgical removal of the tumor represents the 
treatment of choice for hormone-secreting tumors and for adrenal masses with a clinical 
and radiological suspicion of malignancy malignancy.2, 8, 9 However, in malignant ATs, 
surgery allows a complete remission only in patients with a diagnosis during the early 
stages of disease.3, 7, 10 In benign AT, medical treatment is currently restricted to the use 
of symptomatic drugs such as spironolactone and adrenal blocking agents in ACTs of 
the cortex and anti-adrenergic agents in PCCs. New treatment options are required for 
malignant ACTs and PCCs.
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Adrenocortical carcinomas
Epidemiology
In contrast to the high prevalence of benign ATs, the malignant tumor of the adrenal 
cortex, named adrenocortical carcinoma (ACC), is rare.11-13 The incidence of ACC is about 
0.5-2 new cases/million/year, with an increased occurrence during the 5th-6th decades 
of life.11-14 A second peak of increased incidence during childhood has also been de-
scribed.13, 15-18 Apart from some genetic factors that are discussed below, to date no risk 
factors have been identified that clearly predispose for the development of ACC.
Genetic aspects
Several genetic syndromes have been associated with the development of adrenal 
hyperplasia/neoplasia.19 Most ACCs are sporadic and although adrenal malignancies 
have been described only in few cases with a proven genetic background, the study of 
these syndromes has supported the potential role of some molecular pathways in ACC 
pathogenesis.
The Beckwith–Wiedemann syndrome (BWS) is a genetic syndrome associated with 
ACC, together with different childhood tumors and a somatic overgrowth syndrome.19, 20 
BWS is caused by various epigenetic and/or genetic alterations that involve genes on 
chromosomal locus 11p15, which contains the genes CDKN1C, IGF2 and H19, structur-
ally organized in a cluster.19, 20 In patients with BWS deregulation of imprinted genes 
on chromosomal locus 11p15 leads to a biallelic expression of IGF2 and inactivation of 
CDKN1C and H19,.20 IGF2 encodes for the insulin-like growth factor 2, a growth factor 
mainly expressed during fetal life and involved in fetal growth that is thought to play 
a growth-promoting role in various malignancies. The transcriptional product of H19 is 
a noncoding RNA acting as a transcriptional repressor of IGF2. CDKN1C encodes for the 
cyclin-dependent kinase inhibitor 1C (p57, Kip2), a strong inhibitor of several G1 cyclin/
Cdk complexes and a negative regulator of cell proliferation.19 Although the estimated 
prevalence of BWS in patients with ACC is very low and restricted to the childhood,19, 21 
IGF2 has been reported to be over-expressed in about 70-90% of the sporadic ACCs, as 
compared with normal adrenals or benign ACTs.22-31
ACC develops in 3-10% of patients with Li-Fraumeni syndrome (LFS), an autosomal 
dominant disorder characterized by an increased susceptibility to early-onset develop-
ment of several types of cancer, including breast cancer, soft tissue sarcomas, brain, and 
hematologic cancers.19, 32, 33 About 70% of the patients with LFS harbor a germline muta-
tion in the tumor suppressor gene TP53 encoding for p53. P53 is a protein considered 
“the guardian of the genome” because it plays a central role in the activation of pathways 
involved in apoptosis, cell cycle arrest and DNA repair in response to genotoxic stress 
and oncogene activation, preventing genome mutation and preserving stability.19, 33, 34 
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A high frequency (50-80%) of germline TP53 mutations has been described in children 
with ACC.18, 35-37 An increased frequency of these mutations contributes to the increased 
incidence of childhood ACC in some regions such as the southern Brazil.13, 15-18 Two recent 
non-Brazilian studies reported that germline TP53 mutations are present in 3.9 and 5.8% 
of the respective adult ACC population.38, 39 Therefore, the role of germline TP53 muta-
tions in the pathogenesis of adult ACC seems less important than in childhood ACC.33 
Somatic TP53 mutations have been described in 15-70% of ACC samples,40-46 supporting 
a potential role of p53 pathway in a subset of ACCs.
The Gardner’s syndrome or familial colorectal polyposis (FAP) is an autosomal 
dominant form of polyposis characterized by the presence of multiple polyps in the 
colon with an increased risk for early onset colon cancer and to develop other tumors 
outside the colon including gastric carcinoma, periampullary carcinoma, astrocytoma, 
fibrosarcoma, small intestine carcinoid and papillary thyroid carcinoma.47, 48 It has been 
recognized that a substantial proportion of patients develop bilateral adrenocortical 
nodular hyperplasia, which are characteristically non-functional and benign, but ACCs 
have also been described.21, 49-51 FAP is caused by germline inactivating mutations of the 
APC gene, which encodes for a downstream regulator of the Wnt/β-catenin pathway, 
functioning as a classic tumor suppressor gene by antagonizing Wnt/β-catenin activa-
tion52-55 (Nishisho et al.,1991). Canonical Wnt signalling relies on accumulation of the 
multifunctional β-catenin protein which translocates to the nucleus and regulates the 
transcription of target genes.52 Mutations of CTNNB1 (β-catenin gene) induce a constitu-
tive of β-catenin target genes.55 Although the estimated prevalence of FAP in patients 
with ACC is very low,19 CTNNB1 mutations have been frequently described (16-31%) in 
ACCs.44, 51, 56-60 These evidences support a potential role of Wnt/β-catenin pathway in a 
subset of ACTs.
Other genetic syndromes potentially predisposing for ACC include: Lynch syndrome, 
Multiple Endocrine Neoplasia 1 and Neurofibromatosis 1.19, 21, 61 Other syndromes such as 
Carney’s complex and McCune–Albright, are predominantly related to benign adrenal 
pathology but no to ACC.13, 19
Clinical presentation and diagnosis
The clinical presentation of ACC mainly includes clinical symptoms related to hormone 
excess, nonspecific symptoms related to tumor growth and only rarely cachexia.13, 14 
Hypercortisolism is present in more than half of ACC patients and Cushing’s syndrome 
is the most common clinical presentation of these tumors.13, 14 Hyperandrogenism, as-
sociated or not with hypercortisolism, is also frequent (in about one-third of cases) and 
causes virilization syndrome particularly in women (acne, hirsutism, androgenetic ef-
fluvium, oligomenorrhea) and children (precocious pseudopuberty) with ACCs.13, 14 Less 
frequently, ACC can be associated to hyperestrogenism, causing feminization syndrome 
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in men. Autonomous aldosterone secretion (causing hypertension and hypokalemia) is 
rare in ACC.13, 14
In 2005 the European Network for the Study of Adrenal Tumors (ENSAT) suggested 
a preoperative laboratory workup with evaluation of (precursor) hormone excess and 
urinary steroid metabolite profile in all patients with a suspicion of ACC (Table 1) (www.
ensat.org/).14 This extensive panel can be useful to support the adrenocortical origin, to 
suggest malignancy and to document hypercortisolism, although the cost effectiveness 
of this approach has not been proved yet.62
At the time of diagnosis, unfortunately most ACC are large tumors and already at an 
advanced stage of disease.11, 13 Therefore, an appropriate evaluation using computed 
tomography (CT) and/or magnetic resonance imaging (MRI) to define the tumor burden 
is required.7, 13, 63 F-18/flourodeoxyglucose-positron emission tomography (FDG-PET) 
can help to detect suspect malignancy when an adrenal lesion is radiologically uncer-
tain,7, 62 while other diagnostic techniques such as bone scintigraphy are required only in 
Table 1 preoperative laboratory workup in patients with ACC suggested by ENSAT
hormonal work up   
Glucocorticoid excess
(minimum 3 out of 4 tests)
•	 dexamethasone	suppression	test	(1	mg,	23:00	h)
•	 excretion	of	free	urinary	cortisol	(24h	urine)
•	 basal	cortisol	(serum)
•	 basal	ACTH	(plasma)
Sexual steroids and steroid precursors
•	 DHEA-S	(serum)
•	 17-OH-progesterone	(serum)
•	 androstenedione	(serum)
•	 testosterone	(serum)
•	 	17-beta-estradiol	(serum,	only	in	men	and	postmenopausal	women)
Mineralocorticoid excess
•	 potassium	(serum)
•	 	aldosterone/renin	ratio	(only	in	patients	with	arterial	hypertension	
and/or hypokalemia)
Exclusion of a phaeochromocytoma
•	 Exclusion	of	a	phaeochromocytoma
•	 Catecholamine	or	metanephrine	excretion	(24h	urine)
•	 meta-	and	normetanephrines	(plasma)
imaging  
•	 CT	or	MRI	of	abdomen	and	CT	thorax
•	 Bone	scintigraphy	(when	suspecting	skeletal	metastases)
•	 FDG-PET	(optional)
staging during follow-up  
•	 	CT	or	MRI	of	abdomen	and	CT	thorax	every	2	-	3	months	(depending	
on treatment)
The upper panel of the table shows the preoperative laboratory workup that ENSAT suggests to perform in 
all patients with a suspicion of ACC, the middle panel indicates the imaging procedure suggested by ENSAT 
in all patients with a suspicion of ACC at time of the diagnosis of the tumor and the lowest panel indicates 
the imaging procedure suggested by ENSAT during the follow-up of patients with ACCs.
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selected cases or are experimental such as [11C]Metomidate PET or [123I]Iodometomidate 
scan.7, 13, 62, 64, 65
On the basis of the ENSAT classification,66 advanced ACC is defined by locoregional 
spread (stage III) or the presence of distant metastases (stage IV). At the time of diag-
nosis about 18-26% and 21-46% of ACC patients have stage III and stage IV disease, 
respectively.11, 66-68
Prognostic factors
ACC is one of the most aggressive solid tumors in humans, as evidenced by a 5-year 
survival rate below 15% at the metastatic stage.11, 12 In the absence of local invasion 
and/or metastasis, the differential diagnosis between benign ACT [or adrenocortical 
adenoma (ACA)] and ACC is challenging and is based on the use of pathological scores 
evaluating the presence or absence of particular features.13 The most widely used score 
is the Weiss’s score (WS), which includes 9 parameters: mitosis, atypical mitosis, necrosis, 
venous invasion, sinusal invasion, capsular invasion, nuclear atypia, diffuse architecture, 
and clear cell.69-71 ACTs having at least 3 of the 9 parameters indicated in the WS can more 
often behave as malignant tumors and they are therefore classified as ACC, although this 
distinction still has some limitations.7, 13, 71 The status of tumor margin after resection12 
and the TNM according with the ENSAT classification66 are well established prognostic 
factors. Other prognostic factors include the mitotic count (which is also included in 
the WS),72 proliferative index (Ki67),73 number of organs involved72 and cortisol excess.74 
Recently, some molecular markers like IGF2, and β-catenin have also been suggested to 
have a prognostic role75, 76 but these require a further validation.7, 13
Therapy
Surgery remains the only curative treatment in patients diagnosed at an early stage 
and should be performed in centers with consolidated experience (more than 10 ACCs/
years).7, 11-14 In patients with ACC, open surgery is the standard surgical approach for 
stage I-III. The role of laparoscopy, which can be considered as the standard surgical 
approach for benign adrenal masses and which can be performed safely by a skilled 
surgeon, also in case of small localized ACC, is still matter of debate.7, 13 The aim of 
surgery in locally advanced ACC is to obtain a margin-free complete resection, which 
might require resection of parts of some other adjacent organs.7 Adjuvant therapies 
can include radiotherapy and/or mitotane as shown in figure 2. These therapies aim to 
decrease the chance of recurrence, particularly in case in which surgery failed to obtain 
microscopic margin-free resection or in case of tumors with high risk of recurrence as 
defined by the presence of a stage III disease or a Ki67 higher than 10%.7
All therapies of unresectable or metastatic ACC must be considered palliative.13 In the 
case of inoperable local infiltrating or metastatic ACC, surgical excision of the primary 
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tumor and/or metastasis should be considered in the case of an objective response 
after neoadjuvant chemotherapy, when a radical resection seems to be feasible.7, 67 Ad-
ditionally, surgery can be considered in patients with tumor recurrence after an initial 
resection, in case of patients with a time to first recurrence longer than 12 months, and 
when radical resection seems to be feasible.7
Mitotane, a derivate of the DDT pesticide, is currently the only drug approved in 
Europe and in the United States for the treatment of advanced ACC.7 As monoche-
motherapy, mitotane induces an objective tumor response in 13-35% of patients.7, 11 
Several retrospective studies reported a higher objective response rate (up to 66%) 
and improved survival when the patients presented plasma mitotane level above 14 
mg/L.11, 14, 77 Response rates ranging between 14 and 55% were reported when mitotane 
was combined with cytotoxic chemotherapy in retrospective or phase II trials.11, 14, 77 
Recently the FIRMACT study, the first phase III trial ever performed in ACC compared the 
two polychemotherapy regimens believed to be the most active in ACC, mitotane plus 
etoposide, doxorubicin and cisplatin (M-EDP) versus mitotane plus streptozocin (M-S). 
M-EDP yielded a significantly higher response rate (23% vs 9%), but overall survival was 
not significantly different compared to M-S (14.8 months vs 12 months).78 These results 
have been interpreted as a superiority of M-EDP, which is currently considered the first 
line regimen in ACC patients requiring cytotoxic therapy.7 Unfortunately, no new treat-
ment options have emerged in the last four decades underlining the urgent need for 
new therapeutic options.11, 14, 77, 78
figure 2. Algorithm of the management of adrenocortical carcinoma (ACC) according to stage, risk factors, 
and disease characteristics. *Low-risk ACC is defined stage I–II and Ki67 expression in ≤10% of neoplastic 
cells; high-risk ACC: stage III or Ki67 expression in >10% of neoplastic cells. Reproduced with permission 
from reference n 6.
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Pheochromocytomas (PCCs)
Epidemiology
PCCs and paragangliomas (PGLs) are neuronal crest-derived neuroendocrine tumors 
arising from the chromaffin cells of the adrenal medulla or the extra-adrenal para-
ganglia.3, 7, 79 The incidence of PCCs/PGLs is about 2-8 new cases/million/year.3, 7, 80 
Malignancy is defined by the presence of metastasis in non-chromaffin tissues and it is 
rare representing about 10-17% of all PCCs/PGLs, with an overall incidence below 1 new 
cases/million/year.7, 80, 81
Genetic aspects
During the last 20 years important progress has been made in discovering genetic 
alterations that can lead to development of PCCs and PGLs in the context of familial 
syndromes and in some sporadic cases.82, 83 About 40% of the PCC/PGL patients harbor 
a germline mutation in one of the susceptibility genes identified, which include kinase 
receptor and signalling regulators [such as RET and neurofibromin 1 (NF1)], transcription 
factors [such as MYC-associated factor X (MAX)], energy metabolism components [such 
as succinate dehydrogenase (SDH) subunits SDHA, SDHB, SDHC, SDHD and cofactor 
SDHAF2], constituents of the cellular response to hypoxia [such as von Hippel–Lindau 
(VHL) and hypoxia-inducible factor 2A (HIF2A)], as well as endosomal signaling [such as 
transmembrane protein 127 (TMEM127)].83
An additional 25-30% of the remaining apparently sporadic cases harbor a somatic 
mutation in one of the above-mentioned genes.82, 83
Based on their transcriptional profiles, PCCs/PGLs have been classified in two different 
clusters: cluster 1 includes tumors with an increased expression of genes related to the 
hypoxic response, whereas cluster 2 includes tumors with an increased expression of 
genes related to kinase pathways.83-85 PCCs/PGLs harboring mutations in VHL, SDHA, 
SDHB, SDHC, SDHD, SDHAF2 and HIF2A belong to cluster 1, whereas tumors harboring 
mutations in RET, NF1, TMEM127 and MAX belong to cluster 2.83, 85
Clinical presentation and diagnosis
In most patients, the clinical presentation of PCCs/PGLs is related to catecholamine 
excess which can cause acutely a variety of clinical symptoms (hypertension, tachycar-
dia, pallor, headache, anxiety, hyperglycemia, weight loss, nausea, constipation, fever, 
flushing etc.). As such, this type of tumor is often referred to as the great mimic.10, 80 
The catecholamine hypersecretion causes in these patients an increased cardiovascular 
morbidity and mortality. Symptoms related to tumor growth are less common, but 
they can be the first clinical presentation of some tumors that are unable to secrete 
catecholamines.80 In the case of patients affected by a familial syndrome, the presence 
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of other clinical manifestation associated with the syndrome or the periodic radiological 
screening can lead to the diagnosis of PCCs/PGLs. About 25% of all PCCs are discovered 
incidentally and about 5% of all incidentalomas are PCCs.10, 86, 87
When a PCCs/PGLs is clinically suspected the measurement of plasma free (nor)
methanephrine (catecholamine metabolites) or urinary fractionated (nor)methaneph-
rine is recommended.80 In patients with a clear biochemical evidence of a PCCs/PGLs, 
localization of the tumor is performed with CT of the thorax, abdomen and pelvis with 
nonionic contrast as first-choice imaging modality, while MRI is preferred in case of 
head/neck paragangliomas PGLs.80 In all patients with metastatic disease and in some 
patients with increased risk of metastatic disease functional imaging using 18F-FDG PET/
CT and 123I-metaiodobenzylguanidine (MIBG) and/or somatostatin receptor imaging 
with 111In-Pentetreotide and/or 18F-DOPA can be required for a better definition of tumor 
burden, but also to guide treatment.80
Prognostic factors
The overall 5 years survival rate in malignant PCCs/PGLs ranges between 34-60%.7, 10, 88 
As above mentioned, most PCCs/PGLs are benign, but in absence of proven metastasis, 
it is difficult to predict whether a tumor behaves as benign or malignant. Some prog-
nostic factors, such as the presence of a SDHB mutation, a tumor diameter larger than 5 
cm and an extra-adrenal localization, can help to identify patients that require a closer 
follow-up.10, 88-92 However, since metastasis can be discovered even a long time after the 
resection of the primary tumor a long term follow-up (at least 10 years) is required in all 
patients.7, 10, 80, 81, 93
Therapy
Different from the important progress made in discovering genetic alterations that can 
lead to development of PCCs and PGLs, only scant progress has been made in treating 
patients with malignant PCCs/PGLs. In all patients with resectable tumors, surgery is the 
first treatment approach.7 The treatment with anti-adrenergic agents (i.e. α-adrenergic 
blockers) can help to manage symptoms and is recommended in all hormonally active 
PCCs/PGLs to reduce perioperative cardiovascular complications.80 In patients with met-
astatic PCCs/PGLs, treatment is palliative and it aims to control excessive catecholamine 
secretion and tumor burden.7 According with the recently published European Society 
for Medical Oncology (ESMO) clinical practice guidelines, in patients with unresectable/
metastatic disease, when non progressive and with low tumor burden a wait and see ap-
proach and/or a loco-regional approach is feasible, while in patients with an apparently 
more aggressive disease treatment should be recommended.7
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In progressive PCCs, treatment with meta-iodobenzylguanidine (131I-MIBG) or certain 
types of systemic chemotherapy are used, but a low rate of response and frequent recur-
rences underline the need of new treatment approaches.7, 94
The ROle Of The mTOR PAThwAy in nORMAl AnD TuMORAl ADRenAl 
Cells
introduction
The limited efficacy of conventional antineoplastic treatment in malignant ATs increases 
the need for novel and more effective treatment options. In recent years, progress in 
the understanding of the pathogenesis of tumors is encouraging and has initiated the 
development of so called “targeted drugs”, compounds that specifically interfere with 
molecular mechanisms involved in tumor cell growth and/or tumor vascular supply. 
This category of drugs includes compounds interfering with growth factor receptors 
(including pro-angiogenesis factors) and their related signaling pathways. Alterations in 
expression of growth factors and their cognate receptors are considered to be involved 
in the pathogenesis of both ACCs and PCCs.95-97 Moreover, tumor angiogenesis is es-
sential for the growth and progression of solid tumors, including ATs.95, 96, 98, 99 Therefore, 
compounds interfering with tumor angiogenesis and growth factor signaling pathways 
represent a potential novel treatment opportunity for the management of malignant 
ATs.
The mTOR pathway
The mammalian target of rapamycin (mTOR) is a protein kinase of the phosphoinositide 
3 kinase (PI3Ks)/protein kinase B (PKB or AKT) signaling pathway, that forms multimolec-
ular intracellular complexes and functions as a gatekeeper of metabolism, as well as cell 
growth. mTOR receives signals from sensors of cell stress, intracellular nutrients levels 
and several growth factors, including vascular endothelial growth factor (VEGF), insulin-
like growth factors (IGFs), epidermal growth factor (EGF) and platelet-derived growth 
factor (PDGF).100-103 The complexes formed by mTOR are named mTORC1 and mTORC2, 
and are sensitive or insensitive to rapamycin respectively, the oldest compound among 
the mTOR inhibitors.104, 105 The binding of many growth factors to their cognate receptor 
tyrosine kinases (RTKs), leads to the recruitment of PI3K to the membrane, where this 
enzyme converts phosphatidylinositol-bisphosphate (PIP2) to phosphatidylinositol-
trisphosphate (PIP3), providing docking sites for signaling proteins, including 3-phos-
phoinositide-dependent protein kinase 1 (PDK1) and serine-threonine kinases AKT. 
These events are antagonized by PTEN (phosphatase and tensin-homologue) that limits 
the growth factors signaling by dephosphorylating PIP3. Figure  3 shows a simplified 
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scheme of growth factor induced activation of the mTOR pathway and the sites of action 
of compounds acting as mTOR inhibitors.
PDK1 is a serine-threonine kinase that phosphorylates and activates AKT, which elicits 
many downstream signaling events including the activation of mTORC1. AKT promotes 
mTORC1 activity mainly by phosphorylating tuberosus-sclerosis-complex (TSC1/2).104, 106 
This phosphorylation leads to the inactivation of TSC2 that is an indirect inhibitor of 
mTORC1 and results in the activation of this complex.104 mTOR as part of mTORC1 com-
plex can be also directly phosphorylated by AKT, forming phospho-mTOR (p-mTOR) that 
is often studied as marker of mTOR activation. However, whether this phosphorylation 
is crucial or not in the activation of mTORC1 complex is still matter of discussion.104, 106 
The activation of the mTORC1 complex leads to the phosphorylation and activation 
of downstream effectors of the pathway: the protein kinase p70 ribosomal protein 
S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E binding proteins 
(4EBP1).104, 105 S6K1 and 4E-BP1 are both regulators of mRNA translation and stimulate 
the synthesis of several oncogenic proteins such as c-Myc, hypoxia-inducible factor-1α 
(HIF-1α), VEGF, IGF-II and cyclin D.101 mTORC2 regulates the cytoskeleton function and 
it has been proposed to be an important activator of the AKT function. Growth factors 
stimulate mTORC2, activity and some components of mTORC2 complex are phosphory-
lated as consequences of growth factor stimulation, but the responsible kinases are 
uncertain.104, 105 Therefore, there are evidences that mTOR, as part of both complexes 
(mTORC1 and mTORC2), mediates the intracellular signaling induced by growth factor 
receptor activation (Figure 3). However, mTORC1 is downstream to AKT and mTORC2 is 
to be upstream to AKT.101, 104
It is noteworthy that mTOR is an intracellular mediator of IGFII and VEGF activity and, 
in turn, it is able to control the synthesis of these growth factors.101 VEGF is one of the 
most important mediators of angiogenesis in solid tumors including adrenal tumors. 
Moreover, growth factors such as IGFs and VEGF are autocrine/paracrine regulators of 
tumoral cell growth in many different types of tumors, including ATs (Figure 4).95, 97-99, 107
Dysregulation of the mTOR pathway has been found in many human tumors, includ-
ing neuroendocrine tumors.101, 102, 108, 109 Therefore, the mTOR pathway is as an important 
target for antineoplastic therapies and it is conceivable that this pathway could also 
play a role in the pathogenesis of ATs. mTOR inhibitors may exert their antitumor effects 
indirectly, by inhibiting tumor angiogenesis, and directly by inhibiting cell growth and 
proliferation.104 As such, a role for mTOR inhibitors in inhibiting ATs growth, particularly 
because of central role of mTOR pathway as mediator of several mitogenic and angio-
genic factors, may be suggested.
A clinical role for an mTOR inhibitor as anticancer treatment was first demonstrated in 
a large phase III study that showed an improved overall survival in patients with renal cell 
carcinoma treated with temsirolimus (CCI-779), as compared with other treatments.110 
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Subsequently, many clinical trials have been conducted and others are still ongoing, to 
investigate the antineoplastic effects of mTOR inhibitors, alone or in combination with 
other compounds, in several kinds of solid tumors and hematological malignancies.111 
This has led to the approval of some of these compounds for the treatment of some 
type of cancer including particular categories of renal cancer, neuroendocrine tumors 
and breast cancer.110-113 Most of the evaluated compounds such as sirolimus (rapamy-
cin), temsirolimus, everolimus (RAD001) and deforolimus (AP23573), mainly target the 
mTORC1 complex (shown in Figure 3 as “traditional” mTOR inhibitors),.101, 102, 106, 108, 111
The activity of mTORC2 is not directly inhibited by the above listened compounds, but 
it has been reported that long-term treatment with rapamycin can inhibit the activity of 
mTORC2 by the sequestering of mTOR as part of the mTORC1 complex.101, 105 However, 
new compounds, able to inhibit directly both mTORC complexes, such as AZD8055 and 
OSI-027 (reported in figure 3 as “new” mTOR inhibitors), are currently being evaluated for 
their efficacy in preclinical and clinical studies.106, 111 The results of these studies should 
answer the question whether the use of compounds blocking both mTORC complexes 
could have an additional advantage over the use of traditional mTOR inhibitors in the 
treatment of tumors.
At the time the studies presented in this thesis were initiated, there were no preclinical 
or clinical studies evaluating the effects of mTOR inhibitor drugs in ACTs and only very 
limited data in PCCs.109, 114, 115
Therefore, the overall aim of this thesis is to explore the role of the mTOR pathway as a poten-
tial target for new treatment option in ATs.
Role of the mTOR pathway in the normal adrenal gland
There are only limited studies that addressed the mTOR pathway in normal adrenal 
gland. The expression of mTOR, p-mTOR, AKT and phospho-AKT (p-AKT) in the normal 
adrenal gland was initially evaluated only as a control for ATs.109, 116 In 3 out of 3 normal 
adrenals no staining for p-mTOR and p-AKT, evaluated by immunohistochemistry, was 
reported in normal adrenal-medullas.116 Fassnacht et al. evaluated the expression of 
total-AKT and p-AKT in 4 normal adrenal glands by immunohistochemistry.109 These in-
vestigators described a notable staining for total-AKT and p-AKT in the reticularis layer, 
whereas a weaker expression of total-AKT and p-AKT was found in the zona fasciculata 
and zona glomerulosa and only a faint staining for total-AKT in the normal medulla. 
These preliminary observations already suggested a layer-specific pattern of activation 
of the PI3Ks/AKT/mTOR pathway in the normal adrenal gland, which appeared to be 
predominantly inactive in the normal adrenal medulla and active in the reticularis layer 
of the adrenal cortex. IGFs have been reported to stimulate the adrenal steroidogenesis, 
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particularly the androgen production.107 The activation of PI3K/AKT/mTOR-pathway in 
the reticularis of normal adrenals suggests a potential role of this pathway in the control 
of androgen production, probably as an intracellular mediator of the IGFs.
On the basis of the scarce existing information on the mTOR pathway in the adrenal gland, 
the fi rst aim of this thesis is to evaluate the expression of the main components of the mTOR 
pathway in normal adrenals (chapter 3).
Potential role of the mTOR pathway in adrenal tumors
At the time the studies presented in this thesis were initiated, the role and function 
of mTOR and its pathway in adrenal tumors were not extensively clarifi ed. Total-AKT is 
found to be overexpressed both in ACCs and in PCCs, compared to normal adrenals or 
adenomas.109 The corresponding activated form, p-AKT, has also been reported to be 
overexpressed in PCCs.109, 117 Equivocal data exist with respect to p-AKT expression in 
ACC.25, 109 Indeed, some authors reported overexpression of p-AKT in ACC,25 while others 
did not.109 Mice with a heterozygous deletion of the PTEN gene are known to have an 
increased tendency to develop PCCs.118 However, PTEN mutations appear to be rare in 
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human PCCs,119, 120 which has recently been confi rmed by an integrated genetic analy-
sis.121 Conversely, other type of mutations such as RET and NF1 described in PCCs/PGLs 
appear to be associated with an activation of the mTOR pathway in humans83
In H295 and SW13, two diff erent human ACC cell lines25, 122 and in PC12, a rat PCC cell 
line,123 IGF-I stimulation has been correlated with increased AKT phosphorylation, sug-
gesting that AKT acts as an intracellular mediator of IGF signaling in ATs. In PC12 cells, 
the eff ects of some growth factors on downstream components of mTOR pathway have 
also been evaluated. EGF and nerve growth factor (NGF) were reported to stimulate the 
phosphorylation of 4EBP1124 and EGF was shown also to increase the phosphorylation of 
S6K1.125 These eff ects were prevented by the administration of rapamycin.125
As indicated above, it has been shown that mTOR can stimulate the translation of 
IGF-II and VEGF. In turn, this stimulation can be induced by the same growth factors.101 
Therefore, mTOR may act as an intracellular mediator of growth factors in ATs as well, 
and could be an intracellular component of the pro-growth autocrine loops considered 
to be involved in the pathogenesis of ATs (particularly the IGFs), as shown in Figure 4.
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figure 4. Potential role of the mTOR pathway in adrenal tumors
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To better clarify the role of the mTOR pathway in ATs, the second aim of this thesis is to 
describe the expression of the main components of the mTOR pathway in different types 
of ATs (chapters 2, 3 and 7), as well as to describe the potential relationship between these 
components and the main components of the IGF pathways in these tumors (chapters 2, 4 
and 7).
The role mTOR as a drug target in the treatment of adrenal tumors
At the time the studies presented in this thesis were initiated there were no clinical or 
preclinical published data evaluating the effects of mTOR inhibitors in ACCs. However, 
compounds blocking IGF-I receptor activity were found to inhibit the proliferation of 
H295 cells.25, 28 These effects were correlated with a reduction of p-AKT,25 suggesting that 
AKT itself and/or mTOR could be a potential target for the treatment of ACCs. Inhibition 
of the IGF-I-receptor in preclinical models of human ACCs has been associated with a 
reduction of VEGF production.25 According with the described role of mTOR in VEGF 
production,101 it is conceivable that the inhibition of VEGF induced by the IGF-I receptor 
inhibitors is related to the inhibition of mTOR pathway. LY294002, an AKT inhibitor, has 
been shown to inhibit proliferation of PC12 PCC cells in a time- and dose-dependent 
manner.117 In neuroblastoma cell lines (a tumor closely related to PCC), rapamycin inhib-
its cell proliferation by inducing cell cycle arrest.126 Rapamycin, evaluated with a single 
dosage, significantly inhibits cell growth in the normal chromaffin rat cells, but not in 
PC12 cell line.115 In a study evaluating the effects of glucacon-like-peptide-1 (GLP-1) in 
PC12 cells, used as model for neuronal cells, the authors show that GLP-1, through the 
activation of PI3K /AKT/mTOR pathway, was able to protect these cells from oxidative 
stress-induced cell apoptosis.127 These protective effects were inhibited by the treatment 
with rapamycin. In an animal model for PCC, temsirolimus was found to inhibit tumor 
progression.118 This effect could either be attributed to a direct effect of the mTOR inhibi-
tor on tumoral cell proliferation or to the inhibitory effects of temsirolimus on vascular 
growth. Therefore, further preclinical studies should be performed to clarify whether 
these compounds might have a direct effect on PCC cells, whether these effects could 
depend on the presence of growth factors, such as IGFs, in the cell environment, and 
whether the combination treatment using mTOR inhibitors and other compounds, such 
as IGF-I receptor antagonists, could have stronger antineoplastic effects than the mono-
therapy. The promising effects of mTOR inhibitors in the treatment of neuroendocrine 
tumors128, 129 have encouraged the use of mTOR inhibitors in the treatment of some pa-
tients with advanced malignant pheochromocytomas.114 Unfortunately, in these 4 cases 
the treatment did not produce promising results. However, all these patients started 
treatment in a very late stage of disease, therefore, this early negative clinical experience 
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cannot exclude that the use of mTOR inhibitors in an earlier stage of disease may have 
more beneficial effects.
Overall, the efficacy of mTOR inhibitors in AT has not been extensively evaluated. In 
addition, the effects of this class of drugs in combination with other compounds, such as 
drugs targeting the IGF pathway or drugs frequently used in the treatment of this type 
of tumors (e.g. mitotane in ACC), warrants investigation.
Therefore, the third aim of this thesis is to evaluate the effects of mTOR inhibitors, alone 
or in combination with mitotane in ACC cell models (chapters 2, 3 and 5), and alone or in 
combination with drugs targeting the IGF pathway in ACC and PCCs cell models (chapters 
2, 3 and 7).
Finally, since the results of the studies presented in chapters 2, 3, 4 and 5 of this thesis, 
as well as novel data from the literature, suggest that the role IGF in adult ACC may 
have been over-estimated, and because it became apparent that mTOR inhibitors alone 
may not fully fulfill the requirement of an effective treatment option for patients with 
advanced ACC, novel targets for ACC still need to be explored.
As such, the fourth aim of this thesis is to explore the presence of a large number of molecu-
lar events that can be targetable with mTOR inhibitors or other types of targeted drugs. This 
issue was investigated in a large series of advanced ACCs (chapter 6).
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AbsTRACT
Patients with adrenocortical carcinoma (ACC) need new treatment options. The aim of 
this study was to evaluate the effects of the mTOR-inhibitors sirolimus and temsirolimus 
on human-ACC cell growth and cortisol production.
In H295, HAC15 and SW13 cells we evaluated mTOR, IGF2 and IGF1-receptor expres-
sion; the effects of sirolimus and temsirolimus on cell growth; the effects of sirolimus 
on apoptosis, cellcycle and cortisol production. Moreover, the effects of sirolimus on 
basal- and IGF2-stimulated H295 cell-colony-growth and on basal- and IGF1-stimulated 
phospho-AKT, phospho-S6K1 and phospho-ERK in H295 and SW13 were studied. Finally, 
we evaluated the effects of combination treatment of sirolimus with an IGF2-neutralizing 
antibody.
We have found that H295 and HAC15 expressed IGF2 at a >1800-fold higher level than 
SW13. mTOR-inhibitors suppressed cell growth in a dose/time-dependent manner in 
all cell lines. SW13 were the most sensitive to these effects. Sirolimus inhibited H295 
colony-surviving-fraction and size. These effects were not antagonized by IGF2, suggest-
ing the involvement of other autocrine regulators of mTOR-pathways. In H295, sirolimus 
activated escape-pathways. The blocking of endogenously produced IGF2 increased the 
antiproliferative effects of sirolimus on H295. Cortisol production by H295 and HAC15 
was inhibited by sirolimus.
The current study demonstrates that mTOR-inhibitors inhibit the proliferation and 
cortisol production in ACC cells. Different ACC cells have different sensitivity to the 
mTOR-inhibitors. mTOR could be a target for the treatment of human ACCs, but variable 
responses might be expected. In selected cases of ACC the combined targeting of mTOR 
and IGF2 could have greater effects than mTOR-inhibitors alone.
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inTRODuCTiOn
Adrenocortical carcinomas (ACC) are uncommon malignancies with an incidence of 1-2 
new cases/million/year.1, 2 ACCs are highly aggressive tumors, associated with a 5-years 
survival ranging between 37 and 47%, for which novel treatment options are required.1-3
The insulin-like growth factor (IGF) system seems a major actor in the pathogenesis 
of ACC and is presently considered an attractive target for new treatments in these 
cancers.4-6
mTOR is a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/Akt signalling 
pathway, functions as a gatekeeper of cell growth, metabolism and proliferation, receiv-
ing signals from sensors of cell stress, intracellular nutrients levels and several growth 
factors receptors including IGFs and vascular-endothelial-growth-factors receptors.7-9 
mTOR exists as part of two complexes: mTORC1 and mTORC2, respectively sensitive or in-
sensitive to rapamycin (sirolimus).10 The binding of growth factors to their receptor leads 
to the phosphorylation and activation of AKT, which elicits many downstream signaling 
events including the activation of mTOR as part of the mTORC1 complex. Activation of 
the mTORC1 complex leads to the phosphorylation and activation of downstream ef-
fectors of the pathway: the protein-70-ribosomal-protein-S6-kinase-1 (S6K1 (RPS6KB1)) 
and eukaryotic-translation-initiation-factor-4E-binding-proteins (4EBP1 (EIF4EBP1)).10 
Both S6K1 and 4EBP1 are regulators of mRNA translation and stimulate the synthesis of 
several proteins involved in cell proliferation.10
Alterations in the mTOR pathway have been found in many human tumours, regard-
less of deregulation of IGF system.8, 9, 11 Therefore, the mTOR pathway is considered a 
target for antineoplastic therapy in several malignancies and it has very recently been 
proposed as target for ACC treatment.12, 13 mTOR inhibitors may exert their antitumor 
effects directly by inhibiting cell growth and proliferation and indirectly, by inhibiting 
tumor angiogenesis.10, 11
Presently, many clinical trials are investigating the effects of compounds inhibiting 
mTORC1 activity (traditional mTOR inhibitors), such as sirolimus, temsirolimus, and 
everolimus, alone or in combination with other compounds, in several types of malig-
nancy.8, 9, 11, 14
The role and function of mTOR and its pathway in ACC have not been clarified yet.12 
Recently, Doghman et al. showed that mTOR is activated in childhood ACCs and that 
everolimus is able to inhibit in vitro cell proliferation in ACC cell lines and growth of ACC 
xenografts in immunodeficient mice.13
The aims of this study were: 1) to evaluate the expression of mTOR, IGF2 and IGF-
1receptor (IGF1R) in different human ACC cell lines, 2) to test the in vitro effects of the 
mTOR inhibitors sirolimus and temsirolimus on ACC cell lines in order to understand 
the mechanism of mTOR inhibitor-induced cell growth inhibition, 3) to explore the role 
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of the IGF2 autocrine loop in the effects of mTOR inhibitors, 4) to evaluate the effect of 
mTOR inhibitors on cortisol secretion.
MATeRiAls AnD MeThODs
Study methodology
In this study we characterized the expression of the mTOR and IGF2 in three different 
human ACC cell lines: NCI-H295R (H295), HAC15 and SW13. In H295 and SW13 we 
also evaluated the expression of IGF1R. In all these cell lines we tested the dose- and 
time-dependent effects of sirolimus and temsirolimus on cell growth and the effects 
of sirolimus on induction of apoptosis and cell cycle. In H295, we tested the effects of 
sirolimus in the presence and absence of IGF2 stimulation on colony formation and 
determined the effect of blocking of endogenously produced IGF2 by an IGF2-specific 
neutralizing antibody on sirolimus-induced cell growth inhibition. In H295 and SW13 
we explored the effects of sirolimus on basal- and IGF1 induced AKT, ERK1/2 and S6K1 
phosphorylation. In the hormonally active ACC cells (H295 and HAC15), the effect of 
sirolimus on cortisol production was evaluated.
Cell lines and culture conditions
The human hormonally active ACC cell line H295, its clone HAC15, and the hormonally 
inactive ACC cell line SW13 were obtained from the American Type Culture Collection 
(Manassas, VA), from Dr. W. Rainey (as gift) and from ECACC (Salisbury, Wiltshire, UK), 
respectively.15
The cells were cultured in 75-cm2 culture flasks at 37°C in a humidified incubator at 
5% CO2. For all cell lines, the culture medium consisted of DMEM/F12K medium, supple-
mented with 5% fetal calf serum (FCS), penicillin (1x105 U/liter), and l-glutamine (2 
mmol/liter). Cells were harvested with trypsin (0.05%)-EDTA (0.53 mM) and resuspended 
in culture medium. Cell viability always exceeded 95%. Media and supplements were 
obtained from Invitrogen (Breda, The Netherlands).
Drugs and reagents
mTOR inhibitors sirolimus and temsirolimus were purchased from LC Laboratories (Inc. 
Woburn, MA, USA). They were dissolved in dimethylsulfoxide (DMSO) as concentrated 
(10-3M) stock solutions (stored at -20°C) and diluted in DMSO before use. IGF1 and IGF2 
were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands) and from Biosource 
(Tilburg, The Netherlands) respectively; both IGFs were diluted in 0.01M acetic acid solu-
tion as concentrated (10-5M) stock solutions (stored at -20°C) and diluted in medium 
before use.
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Anti-IGF2 neutralizing antibody (m610 human monoclonal antibody to IGF2) was 
kindly provided by Dr. Dimiter Dimitrov and Dr. Yang Feng.16
Quantitative RT-PCR
The expression of mTOR and IGF-II mRNA in human ACC cells was evaluated by quantita-
tive RT-PCR.
From human ACC cell lines, total-RNA was isolated using a commercially available kit 
(High Pure RNA Tissue kit; Roche, Almere, The Netherlands). cDNA was synthesized us-
ing 500 ng of total-RNA in a Super Reverse Transcriptase (RT) buffer (HT Biotechnology 
Ltd., Cambrige, UK), together with 40 nmol of each deoxynucleotide-triphosphate, 15 
ng oligo-dT primer, 20 U RNAse inhibitor, and 4 U AMV/Super RT (HT Biotechnology) 
in a final volume of 40 µl. This mixture was incubated for 1 hour at 40°C and thereafter 
5 times diluted in bidest. A quantitative PCR was performed by TaqMan Gold nuclease 
assay (Perkin Elmer Corporation, Foster City, CA, USA) and the ABI-PRISM-7900 sequence 
Detection System (Perkin Elmer, Groningen, The Netherlands) for real-time amplifica-
tions, according to manufacturer’s protocol. The assay was performed using 7,5 µl Taq-
Man Universal PCR Master Mix (Applied Biosystems, Alphen a/d Ryn, The Netherlands), 
primers and probes amount as reported in supplementary materials 1 and 5 µl cDNA 
template, in a total reaction volume of 12,5 µl. After an initial heating at 50°C for 2 min 
and 95°C for 10 min, samples were subjected to 40 cycles of denaturation at 95°C for 15 
s and annealing for 1 min at 60°C. The primers and probes were purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). The sequence of the primers primers and probes 
used are reported in the supplementary material 1. Samples were normalized against 
the expression of the housekeeping gene hypoxanthine-phospho-ribosyl-transferase-1 
(HPRT (HPRT1)). PCR efficiencies (E) were calculated for the primer-probe combinations 
used (supplementary material 1).17 The relative expression of genes were calculated us-
ing the comparative threshold method, 2-∆Ct18 after efficiency correction19 of target and 
reference gene transcripts (HPRT).
Immunohistochemistry (IHC): AgarCyto cell-block
The expression of mTOR and IGF2 proteins in human ACC cell lines was evaluated by 
IHC using AgarCyto cell-blocks. H295, HAC15 and SW13 cell pellets were fixed in 4% 
formaldehyde solution in PBS, embedded in 2% agarose and afterwards in paraffin.20 
AgarCyto cell-blocks were cut in 5μm sections, deparaffinized and dehydrated. Antigen-
retrieval was performed by microwave treatment in Tris–EDTA Buffer (pH 9.0). The slides 
were cooled for 1 hour at +4˚C and later incubated for 1 hour at room temperature (RT) 
with the anti-mTOR primary antibodies or over-night at +4˚C with the anti-IGF2 primary 
antibodies. The slides incubated with anti-IGF2-antibodies were subsequently washed 
and incubated for 30’ at RT with Poly-Rabbit anti-Goat IgG. The slides were further 
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washed and incubated for 30 min  at RT with Poly-AP-Goat anti-Mouse/Rabbit IgG. After 
washing, staining was visualized by 30 min incubation in new fuchsin solution. Slides 
were counterstained with hematoxylin and coverslipped. The antibody and the controls 
used are listened in supplementary material 2.
Immunocytochemistry : chamber slides
Cells were plated on poly-L-lysine-coated culture chamber slides (NUNC A/S, Roskilde, 
Denmark). After 48h, medium was removed and cells were fixed with 4% paraformalde-
hyde and 0.2% picric acid in phosphate buffer, pH 6.9, for 40 min. at RT. After washing, 
the cells were treated for 3 min with 50% methanol and for 3 min with 100% methanol. 
After another washing, the cells were treated with a 3% H2O2-PBS solution for 15 min 
at RT in the dark, to quench endogenous peroxidase. After washing, the cells were 
incubated for 1 hour at RT with an IGFIR monoclonal antibody (supplementary mate-
rial 2). Finally, the cells were incubated for 30 min at RT with HRP/anti-Rabbit/Mouse 
(Dako Detection System). Bound antibodies were visualized by incubation with freshly 
prepared DAB (Dako Detection System). Slides were counterstained with haematoxylin 
and cover slipped. For negative controls, the primary antibody was omitted.
Cell proliferation assay
Measurement of total DNA content. Cells were plated in 1 ml of medium in 24-well plates 
at the density necessary to obtain a 65-70% cell confluence in the control groups at the 
end of the experiment. Twenty-four hours later, sirolimus or temsirolimus were added 
to wells in quadruplicate. The concentrations of compounds tested in H295 and HAC15 
ranged between 10-9M and 10-5M. In the SW13, a maximal effect of compounds was 
observed already at 10-8M. Therefore, we tested concentrations of compounds ranged 
between 10-12M and 10-8M. Controls were vehicle-treated. The cells inoculated for 6 and 
9 days were refreshed every 3 days by adding fresh compounds. After 24 hours, 3, 6 and 
9 days of treatment, the cells were harvested for DNA measurement, as a measure of cell 
number. Measurement of total DNA content was previously described in detail.21
Cell Proliferation Reagent WST-1 (WST). In H295 cells, the effect IGF2-specific neutral-
izing antibody on sirolimus-induced inhibition of cell proliferation was determined by 
WST-1 assay (Cell Proliferation Reagent WST-1 (Roche, UK)), according to the protocol 
provided by the manufacturer. Cells were plated in 100µl of medium+5%FCS (standard 
medium) in 96 well-plates (20.000 cells/well). After 24h, the medium was changed with 
medium+1%FCS and the following reagents were added: vehicle, sirolimus (10-9M), 
anti-IGF2 (4*10-8M), sirolimus+anti-IGF2. After 72h cell proliferation was measured by 
WST-1 assay. The experiment was repeated twice and each experiment was performed 
in quadruplicate.
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DNA fragmentation assay
DNA fragmentation assay was used to determine the effects of the compounds on 
apoptosis. The cells were plated in 24-well plates and treated as above described for 
the cell proliferation assay. After 24 hours and 3 days of incubation, DNA fragmenta-
tion was determined using a commercially available ELISA kit (Roche Diagnostic GmbH, 
Penzberg, Germany). The standard protocol supplied by the manufacturer was used. The 
same plates were also analyzed for the measurement of total DNA content. The amount 
of DNA-fragmentation (apoptosis) was corrected for the total DNA content in each well.
Cortisol secretion assay
In H295 and HAC15, we evaluated the effects of sirolimus on cortisol production. The 
cells were plated in 24-well plates and treated for 6 days as above described for the 
cell proliferation assay. We tested the effects of the sirolimus on cortisol production in 
concentrations corresponding to the EC50 on cell proliferation after 6 days of treatment. 
The culture supernatants from experiment performed in H295 and HAC15 cells were 
collected and stored at –20oC until determination of the cortisol concentration.
The cortisol concentration was determined by a non-isotopic, automated chemilu-
minescence immunoassay system (Siemens Medical Solutions Diagnostics, Breda, The 
Netherlands). Cortisol levels were expressed as percentage of control and were corrected 
for the total DNA content in each well, thereby reflecting cortisol production per cell.
Cell cycle analysis
Cells were plated in 12-well plates at the density necessary to obtain a 65-70% cell 
confluence in the control groups at the end of the experiment. Twenty-four hours later 
sirolimus was added to wells in triplicate. In each cell line the effects of sirolimus on cell 
cycle were tested in concentrations corresponding to the EC50 on cell proliferation after 
6 days of treatment. In addition, the effects of the compounds at concentrations of 10-6M 
in H295 and HAC15 and 10-8M in SW13 were tested. Control groups were vehicle-treated. 
We evaluated the effects of the compounds on cell cycle after 24 hours of treatment in 
SW13, and in H295 and HAC15 cell lines after 72 hours of treatment according to the 
different growth rates of these cells. Following treatment, cells were harvested by gentle 
trypsinization, washed with ice-cold PBS and collected by centrifugation. Cells were 
resuspended in 200μl PBS and fixed in 70% ice-cold ethanol, followed by an overnight 
incubation at -20°C. After centrifugation, the cells were washed once with PBS and in-
cubated for 30 min at 37°C in PBS containing 40μg/ml propidium iodide (Sigma Aldrich, 
Zwijndrecht, The Netherlands) and 10μg/ml of DNase-free RNase (Sigma Aldrich, Zwijn-
drecht, The Netherlands). For each tube, 20,000 cells were immediately measured on a 
FACScalibur flow cytometer (Becton Dickinson, Erembodegem, Belgium) and analyzed 
using CellQuest Pro Software.
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Colony forming assay
Cells were plated in poly-L-lysine (10 µg/ml; Sigma-Aldrich, Zwijndrecht, The Nether-
lands) coated 12-well plates (2500 cells/well) and cultured in complete medium for three 
weeks.
Cells were allowed to attach for 24 hours before to be treated with the vehicle, siro-
limus (5*10-9M), IGF2 (10-8M) or the combination of the two compounds. The experi-
ment has been performed two times in triplicate. Cells were treated continuously and 
medium plus the compounds were refreshed every three or four days. After 3 weeks the 
formed colonies were fixed with 100% ethanol and stained with hematoxylin to allow 
calculation of the average colony forming efficiency. Colonies containing more than 50 
cells were automatically counted with a Multi Image Light Cabinet from Alpha Innotech 
Corporation (Cell Biosciences, San Leandro).
Plating efficiency was defined as the mean number of colonies formed divided by the 
number of plated cells for control cultures expose to the vehicle express as percentage. 
The surviving fraction (SF) was calculated as (mean number of colonies)/(number of 
plated cells x plating efficiency).22
Protein Extraction
H295 and SW13 cells were plated in 3 ml of medium in 6-well plates at the density 
required to obtain 65-70% cell confluence at the end of the experiment. Seventy-two 
hours later cells were starved for 12 hours and then incubated for 1 hour with sirolimus 
or vehicle. The final concentrations of sirolimus tested were 10-6M and 5x10-9M in H295 
and 10-8M and 10-10M in SW13. Thirty minutes prior to collection of cells, IGF1 (10-8M) 
was added to selected wells. Cells were washed with ice-cold PBS.Whole-cell lysates 
were prepared by adding 200µl of ice-cold RIPA lysis buffer (Pierce Biotechnology,Inc., 
Rockford, USA) with the addition of 1% Halt Phosphatase Inhibitor Cocktail (Pierce 
Biotechnology, Inc., Rockford, USA) to each well. After 1 minute of incubation on ice 
the cell lysates were transferred to the labelled tubes. After 15 minutes incubation on 
ice (mixing every 5 minutes), the samples were spun down at 13000 rpm at 4°C. The 
supernatants were stored at -80°C.
The total amount of proteins was calculated with dye-binding assay (Bio-Rad Protein 
Assay), using bovine serum albumin as standard curve and a spectrophotometer set to 
595nm as reader.
Western Blotting 
Total protein solution (30 µg) diluted in a water solution containing 20% SDS sample 
buffer were denatured (5 minutes in a bath at 95°C) and separated by electrophoresis 
on 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes 
were first incubated for 2 hours with blocking buffer (0.1%Tween20-PBS/5% bovine 
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serum albumin for membranes for AKT mesurement and 0.1%Tween20 PBS/3% non-fat 
dry milk for the remaining membranes) and subsequently incubated overnight at 4°C 
with the primary antibody (supplementary material 3). After 1 hour of washing in 0.1% 
Tween20-PBS, the membranes were incubated for 1 hour with the secondary antibody 
at room temperature, followed by 1 hour wash in 0.1% Tween20-PBS. Starting from the 
incubation with the secondary antibodies the membranes were preserved in dark con-
dition. Immunodetection was performed using the Odyssey infrared imaging system (LI-
COR Biosciences, Cambridge, UK). The optical density of the appropriately sized bands 
was measured using the Odyssey molecular imaging software (LI-COR Biosciences). The 
relative expression of total-Akt, total-S6K, or total-ERK was calculated as a ratio to the 
expression of actin. The relative expression of phospho-Akt, phospho-S6K, or phospho-
ERK was calculated as a ratio to total Akt, S6K, or ERK respectively.
Statistical analysis
All the experiments were carried out at least three times, with the exception of colony 
forming assay and the western blot that were performed twice. The repeated experi-
ments gave comparable results. For the statistical analysis statistical software of SPSS 
(SPSS 15.0; SPSS Inc., Chicago,IL) and GraphPad Prism 5.0 (GraphPhad Software, San 
Diego, CA) were used.
We used non-parametric tests to evaluate the differences among groups (Mann-
Whitney test and Kruskall-Wallis).
The comparative statistical evaluations among treatment groups were performed by 
ANOVA, followed by a multiple comparative test (Newman-Keuls or Dunnett’s test).
ResulTs
Expression of mTOR IGFII and IGFIR in ACC cell lines
The IGF2 mRNA levels in H295 and HAC15 (H295=59.3±31; HAC15=50.6±9; ration 
over HPRT, mean±SD) cells were more than 1800-fold higher (p<0.001) than in SW13 
in which IGF2 mRNA was just detectable (0.03±0.03; mean±SD), whereas the mRNA 
expression levels of mTOR were comparable between the cell lines (H295=0.12±0.05; 
HAC15=0.12±0.08; SW13=0.14±0.06). The higher expression levels of IGF2 in H295 and 
HAC15 compared to SW13 were also confirmed at protein level by the immunostaining 
(figure 1). In addition, the mTOR immunostaining showed a strong positivity in all cell 
lines (figure  1). A positive immuno-reactivity for IGF1R was shown in both H295 and 
SW13 cell lines (figure 2).
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figure 1. Immunocytochemical detection of mTOR (middle panel) and IGF2 (right panel) in human ACC cell 
lines. Left panel shows the absence of staining in the negative controls. Magnification, X100.
figure 2. Immunocytochemical detection of IGF1R (right panel) in the human ACC cell lines H295 and 
SW13. Left panel shows the absence of staining in the negative controls. Magnification, X200.
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Effects of mTOR inhibitors on cell growth and apoptosis in ACC cell lines
In ACC cell lines, sirolimus and temsirolimus significantly suppressed the cell growth in a 
dose and time-dependent manner (figure 3 shows the effects in H295 and SW13; effects 
in HAC15 are shown in supplementary figure 1). In H295, both compounds were able to 
significantly inhibit the cell growth with a comparable potency after 9 days of treatment 
(EC50: 4.8x10-9M vs 1.9x10-8M). The effects of sirolimus ranged between 61.7% inhibition 
(p<0.001) at the maximal dose (10-5M) and 16.7% (p<0.01) at the minimal dose tested 
(10-9M). The effects of temsirolimus ranged between 57.1% inhibition (p<0.001) at the 
maximal dose (10-5M) and 16% (p<0.05) at the minimal dose tested (10-9M). 
In HAC15, both compounds were able to significantly inhibit the cell growth with a 
comparable potency after 9 days of treatment (EC50: 1.4x10-8M vs 4.3x10-7M). The effects 
figure 3. Dose-/time-dependent effect of sirolimus (S; panels A and C) and temsirolimus (T, panels B and 
D) treatment on cell proliferation, expressed as DNA content/well after 24 h (closed square), 3 days (closed 
triangle), 6 days (closed down triangle), and 9 days (closed diamond) treatment in H295 (left panels) and 
SW13 (right panels) cells. Data are expressed as the percentage of control and represent the meanGS.D. 
Control is set as 100%.
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of sirolimus ranged between 79.9% inhibition (p<0.001) at the maximal dose (10-5M) 
and 24.4% (p<0.05) at the minimal dose tested (10-9M). The effects of temsirolimus 
were ranged between 81% inhibition (p<0.001) at the maximal dose (10-5M) and 24.6% 
(p<0.05) at the minimal dose tested (10-9M). 
Nine days of treatment with sirolimus (figure 3C) and temsirolimus 10-10M were already 
able to significantly inhibit the cell growth of SW13 cells. Sirolimus was significantly 
more potent than temsirolimus in terms of EC50 (EC50: 3.3x10-11 M vs 1.7x10-10 M; p=0.02), 
but not with respect to the maximal and the minimal effective concentration of the two 
compounds. The effects of sirolimus ranged between 91.7% inhibition (p<0.001) at the 
maximal dose (10-8M) and 49.3% (p<0.05) at the dose of 10-10M. The effects of temsiroli-
mus were ranged between 91.5% inhibition (p<0.001) at the maximal dose (10-8M) and 
34.9% (p<0.05) at the dose of 10-10M. 
In H295 sirolimus was able to significantly induce DNA fragmentation only at the 
highest dose used (10-5M) (figure 4). Sirolimus 10-5M was able to induce apoptosis also 
in HAC15. These effects were more pronounced after 24 hours than after 3 days of treat-
ment. At the doses tested (10-8M to 10-12M), 24 hours and 3 days of treatment, sirolimus 
was not able to significantly induce apoptosis in SW13 (not shown).
Effects of sirolimus on cortisol secretion in ACC cell lines
Sirolimus induced a significant inhibition of cortisol secretion in H295 and HAC15. These 
effects were still present after the correction for the estimated cell number in each well, 
suggesting a direct effect of sirolimus on hormonal secretion in ACC cells (figure 5). Cortisol 
secretion was inhibited by 21.7% in the in H295 sirolimus (5x10-9M) treated cells (P<0.01) 
(figure 5A) and by 41.3% in sirolimus (10-8M) treated HAC15 cells (P<0.001) (figure 5B).
figure 4. Twenty-four hour treatment with sirolimus at high dose (10-5 M) was able to induce cell apoptosis, 
as measured by the induction of DNA fragmentation, in H295 (A) and HAC15 (B) cells. Data are expressed as 
percentage of control and represent the mean±S.D. Control is set as 100%. **P<0.01;***P<0.001 vs control.
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Effects of sirolimus on cell cycle progression and colony formation in ACC cell lines
To explore the mechanisms involved in mTOR inhibitor induced inhibition of cell prolif-
eration we performed FACS analysis and colony forming assay. At FACS analysis siroli-
mus 10-6M induced a significant G1-phase arrest in H295 and HAC15 (table 1). In SW13 
we observed a significant G1-phase arrest by sirolimus at 10-8 and 10-10M (table 1). This 
effect at the highest concentration of compound used was accompanied by a decrease 
in S-phase and G2-phase (table 1).
The plating efficiency for H295 in colony forming was 8.6%. Three weeks of treatment 
with sirolimus 5x10-9M, significantly inhibited the formation and growth of colonies 
as measured by a reduced surviving fraction (69.9% vs control; p<0.001) and average 
colony size (56.6%; p<0.001) (figure  6). IGF2 10-8M was able to significantly increase 
the colony growth by increasing their size (62.7%; p<0.001) and the surviving fraction 
(29%; p<0.05). At the condition tested, the effects of sirolimus on surviving fraction and 
colony size were not reverted by the coadministration of IGF2. Similar results were also 
obtained when we repeated the experiment using IGFII 5x10-8 M (results not shown).
figure 5. Six-day treatment with sirolimus inhibits cortisol production in ACC cells H295 (A) and HAC15 
(B) independently of the inhibition of cell proliferation. The graphs showin parallel the effects of sirolimus 
on the cell proliferation (total DNA content) and on cortisol production for both cell types. The dose of 
sirolimus used (5x10-9 M in H295 and 10-8 M in HAC15) corresponded at the EC50 of cell growth inhibition 
in each cell type. The cortisol levels measured were normalized for the total number of cells present in each 
well (Cortisol/total DNA content). Data are expressed as percentage of control and represent the mean±S.D. 
Control is set as 100%.
Chris - Interior v8.indd   47 04-06-15   15:03
48 Chapter 2
Table 1: Effects of sirolimus on cell cycle distribution in human adrenocortical cancer cell lines (H295, 
HAC15 and SW13 cells)
Phase sub g0 Phase g0/1 Phase s Phase g2/M
(mean±SD) (mean±SD) (mean±SD) (mean±SD)
h295
Control 2.9±0.6 55.8±5.1 12.4±2.8 27.8±3.7
Sirolimus 10-6Ma 2.8±0.7 59.4±3.8* 11.3±2.9 26.4±3.8
Sirolimus 5x10-9 Ma 3.9±1.8 55.9±4 11.6±1.4 28.6±4.2
hAC15
Control 7.8±2.9 60.7±1.5 15.7±0.9 15.8±3.4
Sirolimus 10-6 Ma 6.8±1.5 63.8±2.3* 14.2±1.6 15.3±2
Sirolimus 10-8 Ma 8±2.2 61.6±1.9 15.6±1.3 14.8±1.2
sw13
Control 1.8±0.3 56.7±5 15.9±0.9 25.7±5.2
Sirolimus 10-8 Mb 1.9±0.6 72.9±5.7** 11.2±2.4 ** 14±3.6 **
Sirolimus 10-10 Mb 1.8±0.3 67±6.2 ** 14.4±1.7 16.8±4.7**
SD: standard deviation; acell cycle distribution measured after 72 hours of incubation; bcell cycle distribu-
tion measured after 24 hours of incubation; *p<0.05 vs control; ** p<0.001 vs control.
figure 6. Effects of 3-week treatment with IGF2 (10-8 M) and/or sirolimus (5x10-9 M) on colony formation and 
growth of the human ACC cell line H295. Left panel: IGF2 stimulates H295 cell proliferation by increasing 
the average size of colonies (A) as well as the surviving fraction (B). Both these effects are efficiently antago-
nized by the coadministration of sirolimus. Data are expressed as percentage of control and represent the 
mean±S.D. Control is set as 100%. The right panel (C) shows a representative photograph of the wells contain-
ing treated and untreated cells as used to perform colony-forming experiments.***P<0.001 vs control.
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effects of sirolimus on the igf activated intracellular pathways in ACC cells
To further understand the mechanisms responsible for the effects of the mTOR inhibitor 
in ACC cell lines, we studied the effects of sirolimus and/or IGF1 on some key intracel-
lular components of the IGF pathway in H295 and SW13 (Figure 7). Thirty minutes IGF1 
(10-8M) stimulation significantly increased the phosphorylation of S6K1 and AKT in both 
cell lines. IGF1 stimulation increased the phosphorylation of ERK1/2 in H295. H295 cells 
treated with sirolimus 10-6M and 5x10-9M had significant lower phospho/total-S6K1 
than control and IGF1-stimulated cells, as expected by a successful inhibition of the 
mTORC1 complex activity. Sirolimus 10-8 and 10-10M reduces phospho/total-S6K1 also 
figure 7. Western blotting results. In H295 ACC cell line (left panel): effects of sirolimus (10-6 and 5x10-9 
M) with/without IGF1 (10-8 M) administration on phospho-S6K/total S6K (A), phospho-ERK/total ERK (B), 
and phospho-AKT/total AKT (C). In SW13 ACC cell line (right panel): effects of sirolimus (10-8 and 5x10-10 M) 
with/without IGF1 (10-8 M) administration on phospho-S6K/total S6K (D), phospho-ERK/total ERK (E), and 
phospho-AKT/total AKT (F). In the two ACC cell lines, the administration of sirolimus±IGF1 induced differ-
ent effects on IGF-activated intercellular pathways (explanation in the text). Protein activation is measured 
as the ratio of phosphoprotein band density/total protein band density. Values are expressed as percent-
age of the control, mean±S.D.*P<0.05; **P<0.01; ***P<0.001 vs control.
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in SW13, but this reduction resulted statistically significant only when compared to the 
IGF1-stimulated cells and not when compared to the control (12 hours starved cells). 
In both cell lines the sirolimus induced inhibition of S6K1 phosphorylation was not 
reverted by the IGF1 stimulation. In H295 the treatment with sirolimus was associated 
with an increased AKT-phosphorylation and this AKT stimulation was enhanced by the 
IGF1 stimulation. In SW13 the treatment with sirolimus alone did not increase the AKT-
phosphorylation. However, an increased phospho/total-AKT was observed in all IGF1 
stimulated cells despite the sirolimus treatment. In SW13 the ERK1/2 phosphorylation 
was not affected by the IGF1 and/or sirolimus treatment.
Effect of IGFII neutralization on sirolimus-induced H295 cell growth inhibition
To better address the potential influence of the IGF2 autocrine loop on ACC cell sen-
sitivity to the mTOR inhibitors, we tested effects of sirolimus (10-9M) on cell growth in 
presence or absence of anti-IGF2 neutralizing antibodies (4x10-8M). This concentration 
of anti-IGF2 was previously shown to completely block IGF2 (10-8M) –induced cell pro-
liferation.16 FCS medium (1%) was used to minimize the presence of exogenous growth 
factors. In these conditions a 72h treatment with sirolimus combined with anti-IGF2Abs 
was able to almost totally block H295 cell proliferation (90% inhibition compared to 
controls). Sirolimus or anti-IGF2 antibody alone induced an inhibition in H295 cell prolif-
eration of 64% and 42%, respectively (figure 8).
figure 8. Effect of 72 h combination treatment with anti-IGF2 neutralizing antibodies (anti-IGF2 Abs) at 
a concentration of 4x10-8 M and sirolimus (S, 10-9 M) oncell proliferation (WST-1) of H295 cells. Data are 
expressed as the percentage of control and represent the mean±S.D. Control is set as 100%. ***P<0.001.
Chris - Interior v8.indd   50 04-06-15   15:03
mTOR and adrenocortical carcinoma 51
DisCussiOn
In the present study, we describe the expression of mTOR, IGF2 and IGF1R and the in 
vitro anti-proliferative and anti-secretive effects of the mTOR inhibitors in the currently 
available human ACC cell lines. All ACC cell lines expressed comparable mRNA and pro-
tein mTOR levels. Both H295 and SW13 showed a significant IGF1R protein expression. 
Conversely, the expression levels of IGF2 were considerably higher in H295 and its clone 
HAC15 than those in SW13. These results show that mTOR is expressed in human ACC 
cell lines and its expression appears to be unrelated to IGF1R expression or IGF2 over-
expression.
The mTOR inhibitors caused a significant inhibition of cell growth in vitro and sirolimus 
induced a significant reduction of hormonal production in the hormonally active cells, 
independent of the effect on cell growth. Sirolimus appeared to be more potent than 
temsirolimus in inhibiting cell proliferation in SW13. Temsirolimus acts as direct inhibitor 
of mTOR, but in vivo temsirolimus is also converted in sirolimus.23 After having proven 
that temsirolimus inhibits the in vitro cell-growth in ACC cell lines also in a direct way, 
we continued the experiments using sirolimus only. Cell cycle arrest appeared the pre-
dominant mechanism responsible for the observed antiproliferative effects of sirolimus, 
as already reported in other cancer cell lines.24
In H295 and SW13, IGF1 stimulation has been correlated with increased AKT-phos-
phorylation.6, 25 In this study we describe an IGF1 induced AKT and S6K1 phosphoryla-
tion in both ACC cell lines confirming the role of the AKT/mTOR pathway as intracellular 
mediator of the IGF signalling in ACCs. Moreover, we prove that long term exposure to 
IGF2promotes colony growth in H295 and these effects are antagonized by mTOR in-
hibitors. It has been reported that everolimus can produce anti-vascular effects in in vivo 
model ACCs.13 Therefore, mTOR plays a role as intracellular mediator of the autocrine/
paracrine loops considered to be involved in the pathogenesis of ACCs.12, 26
In the present manuscript we found that the different ACC cell lines display a differ-
ential sensitivity to the anti-growth effects of the mTOR inhibitors. The antiproliferative 
effects of the drugs were observed at concentrations of sirolimus and temsirolimus that 
can be reached in vivo in humans.23 Moreover, cell growth inhibition at these concentra-
tions was considerably higher in SW13 than in H295 (and its clone HAC15). Many factors 
can contribute to this difference. SW13 cells differ from H295 because they harbour TP53 
mutation,27 they are less differentiated, they do not over-produce IGF2 and steroids and 
they present a higher growth rate. Cells with TP53 mutation have been suggested to 
be more sensitive to mTOR inhibitors.14, 28 The absence of the IGF2 overproduction can 
contribute to the higher sensitivity of SW13 cells, compared to other two cell lines. The 
overstimulation of the growth-factor-receptors can determine the over-activation of 
the mTOR pathway upstream to mTOR (i.e. increased phosphorylation of AKT), or can 
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over-activate other pro-growth pathways such us the Ras/Raf/MEK/ERK pathway (i.e. 
increased phosphorylation of ERK1/2), determining resistance or escape to the effects 
of traditional mTOR inhibitors.14, 29-31 We performed all our experiments using the same 
culture medium in all cell lines. In such a setting, the endogenus production of growth 
factor by the cells may determine differential sensitivity to mTOR inhibitors. The pro-
liferation of H295 is stimulated by an autocrine/paracrine IGF2/IGF1-receptor-loop.32 
The over-activation of this loop can negatively influence the sensitivity of H295 to 
the mTOR inhibitors. This hypothesis is supported by the results obtained in WB, the 
experiments using anti-IGF2 neutralizing Abs and the colony-forming experiments. Us-
ing WB we demonstrated that the effects of sirolimus on the IGF activated intracellular 
pathways are different in H295 and SW13 cells. At the condition tested, IGF1 induced the 
activation of the AKT/mTOR pathway in both cell lines and ERK activation only in H295. 
Sirolimus suppressed the mTORC1 activity in both cell lines. However, in H295, but not 
in SW13, the inhibition of mTORC1 activity was associated with a significant increased 
phosphorylation of AKT, supporting an over-activation of the mTOR pathway upstream 
to mTORC1 in H295, likely representing an escape pathway. This activation could result 
by the IGF2 endogenous production that persistently stimulates the IGF1-receptor (au-
tocrine IGF loop) even in starved H295 cells. The effects of sirolimus on AKT were even 
enhanced by IGF1 administration which also induced ERK stimulation in the sirolimus 
treated H295, despite the fact that both basal and IGF1 S6K phosphorylation was fully 
blocked by sirolimus. These results show that in H295 cells treated with sirolimus, IGF 
can stimulate two pathways potentially associated with traditional mTOR inhibitors 
treatment escape: AKT and ERK pathways.14, 28 To further provide evidence that in H295 
the endogenous overproduction of IGFII has a negative interference with the effects 
of mTOR inhibitors, we explored the effects of sirolimus alone or in presence of anti-
IGF2 neutralizing antibodies (at concentration predicted to effectively neutralize the 
endogenous IGF2production). These experiments demonstrated for the first time that 
IGF2 neutralization increases the anti-proliferative effects of mTOR inhibitors in an ACC 
model. This raises the question whether the cotreatment of traditional mTOR inhibitors 
and IGF1 receptor antagonists should be considered for patients with ACCs, known to 
have a strong IGF autocrine loop.
In colony forming assay, H295 cells were more sensitive to sirolimus than observed 
with the DNA measurement. Possible mechanisms that could explain this higher 
sensitivity include: the disruption of the growth factor paracrine/autocrine loops; the 
selection of “aggressive clones” and the mTORC2 complex inhibition. In colony form-
ing experiments the cell density is very low leading to the disruption of growth factor 
paracrine/autocrine loops and reducing the growth factor induced activation of escape 
pathways. However, in the colony experiments IGF2 (used at a dose comparable to the 
concentration reached in the medium of H295 in DNA-measurement experiments) stim-
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ulated cell proliferation, but did not revert the effects of sirolimus, suggesting that IGF2 
is not the only autocrine/paracrine regulator of the mTOR pathway activity in H295. By 
disrupting the autocrine/paracrine loops we forced the cells to grow in a less favourable 
condition and this could lead to the selection of “more aggressive clones”. H295 cells 
showed a low plating efficacy suggesting that only a small percentage of cells are able 
to adapt and grow under these conditions. These cells could be less dependent by the 
autocrine/paracrine loops, less sensitive to the IGF2 and consequentially less exposed 
to the growth factor-induced activation of the escape pathways. This hypothesis could 
also contribute to explain the observed incapability of the IGF2 to revert the sirolimus 
induced inhibition on H295 colony growth. Three weeks of continuous treatment of 
H295 cells with sirolimus induced a significant reduction of the cell surviving fraction 
compared to controls. These results can suggest that long time treatment with mTOR 
inhibitor does not only block the cell growth, but also induces cell death. Traditional 
mTOR inhibitors as sirolimus and temsirolimus have the mTORC1 complex as target. 
The presence of activated mTORC2 can stimulate the AKT activation representing a 
potential mechanism of escape to the effects of traditional mTOR inhibitors for cancer 
cells. However, it has been suggested that long term treatment with traditional mTOR 
inhibitors can also indirectly inhibit the TORC2 complex by sequestering mTOR as part of 
the TORC1 complex.7, 33 This double block is considered one of the potential mechanisms 
of mTOR inhibitor induced tumor cell death.14 Moreover, mTORC2, as well as mTORC1, 
is activated by growth factors. Therefore, in colony experiments the disruption of the 
autocrine/paracrine loops may also contribute to the mTORC2 inhibition.34, 35 This raises 
the question whether the use of drugs simultaneously blocking mTORC1 and mTORC2 
or mTORC1 and PI3K could have a place in the treatment of selected patients with ACCs.
For the first time we show an anti-secretive effect (inhibition of cortisol production) of 
mTOR inhibitors in ACC cell lines. The mechanisms responsible for this effect still need 
to be clarified. mTOR inhibitors are already used in the clinical setting and no signs or 
symptoms of hypo-adrenalism have been described.36 Therefore, it is probable that 
mTOR inhibitors are not able to suppress the physiological adrenal steroid production. 
The IGFs are able to stimulate adrenal steroid production. It is thus possible that mTOR 
could play a role as intracellular mediator of the effects of IGFs and that mTOR inhibition 
could antagonize this pro-secretive effect of IGFs in ACC cells.
Conclusions, translational aspects and future directions
The results of the current study suggest that ACCs may be considered for treatment with 
traditional mTOR inhibitors. The effects of these compounds in vitro at concentration 
potentially reachable in vivo are predominantly cytostatic, although it is shown that long 
time treatment with traditional mTOR inhibitors (in conditions disrupting the autocrine 
loops) can lead to cell death. Additional clinical benefit in patients with hypersecretive 
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ACCs could be an inhibitory effect of these compounds on cortisol secretion. However, 
several factors such as cell type, cell differentiation, the presence of an autocrine growth 
factor loop, as well as the cell environment could largely influence the sensitivity of ACCs 
to these drugs. These differences point out the importance to investigate the presence 
of biomarkers predictive of potential clinical benefit and to eventually proceed in the 
clinical investigation of these compounds only in selected patients with higher chance 
to respond to this treatment. This study also suggest to investigate the role of TP53 
mutations, cell differentiation, proliferative index, the presence of activated autocrine 
loops as potential marker predictive of mTOR inhibitor effects in ACCs and the activation 
of AKT and ERK during the treatment as potential markers of escape. Lastly, it is sus-
pected that in some cases of ACCs, combined treatment with mTOR inhibitors and other 
compounds should be considered to overcome possible mechanisms of resistance to 
mTOR inhibitors used as mono-therapy.
Particularly the effects of treatment targeting the IGF2 autocrine loop, in combination 
with mTOR inhibitors, warrants further investigation in ACC.
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suPPleMenTARy MATeRiAl
supplementary material 1: Primers probes and relative amount in PCR mixtures.

 
1 
 
 
 
 
 
  Amount (nmol/l) added in the 
total reaction volume (12,5 l) 
used for each sample 
E factor for 
primersprobe 
mixture used 
IGFII    1,98 
 forward 5’CCAAGTCCGAGAGGGACGT3’ 300  
 reverse 5’TTGGAAGAACTTGCCCACG3’ 300  
 probe 5’FAMACCGTGCTTCCGGACAACTTCCCTAMRA3’ 200  
mTOR    1,91 
 forward 5’TGCTGCGTGTCTTCATGCAT3’ 300  
 reverse 5’GGATTGCAGCCAGTAACTTGATAG3’ 300  
 probe 5’FAMACAGCCCAGGCCGCATTGTCTAMRA3’ 100  
HPRT    1,98 
 forward 5’CACTGGCAAAACAATGCAGACT3’ 500  
 reverse 5’GTCTGGCTTATATCCAACACTTCGT3’ 500  
 probe 5’FAMCAAGCTTGCGACCTTGACCATCTTTGGATAMRA3’ 100  
 
 
 

     

antimTOR primary 
antibodies 
monoRabbit  Cell Signaling Technology 1:25 breast 
cancer 
antiIGFII primary 
antibodies 
polyGoat  Santa Cruz Biotechnology 1:500 human 
ACC  
antiIGFIR primary 
antibodies 
monoMouse Novus Biologicals 1:500 human 
pancreas 
antiGoat IgG secondary 
antibodies 
polyRabbit DakoCytomation 1:200  
antiMouse/RabbitIgG secondary 
antibodies 
polyAPGoat PowerVision+ (ImmunoVision Technologies) as provided by the 
manufacturer 
 
 
Negative controls included omission of the primary antibodies and the incubation with secondary antibodies (Poly
APGoat anti Mouse/Rabbit IgG for mTOR and PolyAPRabbit anti Goat IgG and PolyAPGoat anti 
Mouse/Rabbit IgG for IGFII) 
 
 

     
antiphosphoS6K(Thr389) 70 kDa primary antibodies monoRabbit  Cell Signaling Technology 1:1000 
antitotalS6K 70 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:1000 
antiphosphoAKT(Ser473)  60 kDa primary antibodies polyRabbit Cell Signaling Technology 1:1000 
antitotalAKT 60 kDa primary antibodies polyRabbit Cell Signaling Technology 1:1000 
antiphosphoERK1/2 (Tyr 204)  42,44 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:200 
antitotal ERK 42 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:500 
antiactin 42 kDa primary antibodies monoMouse SigmaAldrich 1:1000 
 
Precision Plus Protein Standard from BioRad aboratories, Inc, was used as protein marker 
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supplementary material 2: Antibodies used for IHC. Protein detected use type and source purcha
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  Amount (nmol/l) added in the 
total reaction volume (12,5 l) 
used for each sample 
E factor for 
primersprobe 
mixture used 
IGFII    1,98 
 forward 5’CCAAGTCCGAGAGGGACGT3’ 300  
 reverse 5’TTGGAAGAACTTGCCCACG3’ 300  
 probe 5’FAMACCGTGCTTCCGGACAACTTCCCTAMRA3’ 200  
mTOR    1,91 
 forward 5’TGCTGCGTGTCTTCATGCAT3’ 300  
 reverse 5’GGATTGCAGCCAGTAACTTGATAG3’ 300  
 probe 5’FAMACAGCCCAGGCCGCATTGTCTAMRA3’ 100  
HPRT    1,98 
 forward 5’CACTGGCAAAACAATGCAGACT3’ 500  
 reverse 5’GTCTGGCTTATATCCAACACTTCGT3’ 500  
 probe 5’FAMCAAGCTTGCGACCTTGACCATCTTTGGATAMRA3’ 100  
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
antimTOR primary 
antibodies 
monoRabbit  Cell Signaling Technology 1:25 breast 
cancer 
antiIGFII primary 
antibodies 
polyGoat  Santa Cruz Biotechnology 1:500 human 
ACC  
antiIGFIR primary 
antibodies 
monoMouse Novus Biologicals 1:500 human 
pancreas 
antiGoat IgG secondary 
antibodies 
polyRabbit DakoCytomation 1:200  
antiMouse/RabbitIgG secondary 
antibodies 
polyAPGoat PowerVision+ (ImmunoVision Technologies) as provided by the 
manufacturer 
 
 
Negative controls included omission of the primary antibodies and the incubation with secondary antibodies (Poly
APGoat anti Mouse/Rabbit IgG for mTOR and PolyAPRabbit anti Goat IgG and PolyAPGoat anti 
Mouse/Rabbit IgG for IGFII) 
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antiphosphoS6K(Thr389) 70 kDa primary antibodies monoRabbit  Cell Signaling Technology 1:1000 
antitotalS6K 70 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:1000 
antiphosphoAKT(Ser473)  60 kDa primary antibodies polyRabbit Cell Signaling Technology 1:1000 
antitotalAKT 60 kDa primary antibodies polyRabbit Cell Signaling Technology 1:1000 
antiphosphoERK1/2 (Tyr 204)  42,44 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:200 
antitotal ERK 42 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:500 
antiactin 42 kDa primary antibodies monoMouse SigmaAldrich 1:1000 
 
Precision Plus Protein Standard from BioRad aboratories, Inc, was used as protein marker 
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Negative controls included omission of the primary antibodies and the incubation with secondary antibod-
ies (PolyAPGoat anti Mouse/Rabbit IgG for mTOR and PolyA
supplementary material 3: Antibodies used for WB.

 
1 
 
  
 
 
 
  Amount (nmol/l) added in the 
total reaction volume (12,5 l) 
used for each sample 
E factor for 
primersprobe 
mixture used 
IGFII  1,98
forward 5’CCAAGTCCGAGAGGGACGT3’ 300  
reverse 5’TTGGAAGAACTTGCCCACG3’ 300  
 probe 5’FAMACCGTGCTTCCGGACAACTTCCCTAMRA3’ 200  
mTOR    1,91 
 for ard ’ GCT C T TC T ATG A 3’   
 reverse ’GGATTGC CA TAACTTGA AG3’ 3   
 probe 5’F  A CC AGGCC CATTG CTAMRA3’ 100  
HPRT    1,98 
 for ard ’CA AAACAATG AGAC 3’ 5   
 reverse ’ TC G TTATATC AA C TCGT3’ 5   
 probe 5’F CA TTGC A CTTGACCATCTTTGGATAMRA3’ 100  
 
 
 

     

antimTOR primary 
antibodies 
monoRabbit  Cell Signaling Technology 1:25 breast 
cancer 
antiIGFII primary 
antibodies 
polyGoat  Santa Cruz Biotechnology 1:500 human 
ACC  
antiIGFIR primary 
antibodies 
monoMouse Novus Biologicals 1:500 human 
pancreas 
antiGoat IgG secondary 
antibodies 
polyRabbit DakoCytomation 1:200  
antiMouse/RabbitIgG secondary 
antibodies 
polyAPGoat PowerVision+ (ImmunoVision Technologies) as provided by the 
manufacturer 
 
 
Negative controls included omission of the primary antibodies and the ncubation with secondary antibodies (Poly
APGoat anti Mouse/Rabbit IgG for mTOR and PolyAPRabbit anti Goat IgG and PolyAPGoat anti 
Mouse/Rabbit IgG for IGFII) 
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antiphosphoS6K(Thr389) 70 kDa primary antibodies monoRabbit  Cell Signaling Technology 1:1000 
antitotalS6K 70 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:1000 
antiphosphoAKT(Ser473)  60 kDa primary antibodies polyRabbit Cell Signaling Technology 1:1000 
antitotalAKT 60 kDa primary antibodies polyRabbit Cell Signaling Technology 1:1000 
antiphosphoERK1/2 (Tyr 204)  42,44 kDa primary antibodies monoMouse Santa Cruz Biotechnology 1:200 
a titotal ERK 42 a ri ar  a ti i s Mouse Santa Cruz Biot l  :5  
a tiactin 42 a ri ar  a ti i s  s  igmaAldrich :  
 
Precision Plus Protein Standard from BioRad aboratories, Inc, was used as protein marke  
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Precisio  l s Protein Standard from BioRad L boratories, Inc, was used as p otein marker.
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Supplementary figure 1. 
Sirlimus A) and temsirlimus ) significantly suppressed te cell grt in a dse and time
dependent manner in HAC15 cells). 
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
 
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supplementary figure 1. Sirolimus (A) and temsirolimus (T) significantly suppressed the cell growth in a 
dose and timedependent manner in HAC15 cells).
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Supplementary figure 2. 
Exemplary figure of the blotting gels corresponding to the results presented in figure 7 
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supplementary figure 2. Exemplary figure of the blotting gels corresponding to the results presented in 
figure 7
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AbsTRACT
mTOR-pathway has been recently suggested as a new potential target for therapy in 
adrenocortical carcinomas (ACCs).
The aim of the current study is to describe the expression of the mTOR-pathway in normal 
(NAs) and pathological adrenals and to explore whether there are correlation between 
the expression of these proteins and the in vitro response to sirolimus. At this purpose, 
the MTOR, S6K1 (RPS6KB1), and 4EBP1 (EIF4EBP1) mRNA expression was evaluated in 10 
NAs, 10 hyperplasia (AHs), 17 adenomas (ACAs) and 17 ACCs by qPCR whereas total(t)/
phospho(p)-mTOR, t/p-S6K and t/p-4EBP1 protein expression was assessed in three NAs, 
three AHs, six ACAs and 20 ACCs by immunohistochemistry. The effects of sirolimus on 
cell survival and/or cortisol secretion in 12 human primary cultures of adrenocortical 
tumors (ATs) were also evaluated.
In the NAs and AHs a layer-specific expression of evaluated proteins was observed. S6K1 
mRNA levels were lower in ACCs compared with NAs, AHs and ACAs (p<0.01). A subset 
of ATs presented a moderate-high staining of the evaluated proteins. Median t-S6K1 
protein expression in ACCs was lower than ACAs (p<0.01). Moderate to high staining of 
p-S6K1 and/or p-4EBP1 was observed in most ATs. A subset of ACCs not having mod-
erate to high staining had higher Weiss than others (p<0.029). In primary AT cultures 
sirolumus significantly reduced cell survival or cortisol secretion only in sporadic cases.
In conclusion these data suggest the presence of an activated mTOR-pathway in a subset 
of ATs and a possible response to sirolimus only in certain ACC cases.
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inTRODuCTiOn
Adrenocortical cancer (ACC) is a rare and aggressive cancer with a 5-year survival at 
the metastatic stage below 15%.1-3 The insulin-like growth factor (IGF) system has been 
considered a major actor in the pathogenesis of ACCs and an attractive target for new 
treatments in patients affected by this malignancy.4-6 Another important factor may 
be mTOR, which is a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/Akt 
signalling pathway, playing a pivotal role in cell growth, metabolism and proliferation.7 
Activation of the mTOR pathway leads to the phosphorylation and activation of down-
stream effectors such as the protein-70-ribosomal-protein-S6-kinase-1 (S6K1)(RPS6KB1) 
and eukaryotic-translation-initiation-factor-4E-binding-proteins (4EBP1)(EIF4EBP1).7 
S6K1 and 4EBP1 are both regulators of mRNA translation and stimulate the synthesis 
of several proteins involved in cell proliferation and survival.7 Alterations in the mTOR 
pathway have been found in many human tumours.8-10 Therefore, the mTOR pathway is 
considered a target for antineoplastic therapy in several malignancies and it has recently 
been proposed as target for ACC treatment.11-13
MATeRiAls AnD MeThODs
Subjects
A total of 65 adrenal samples (26 ACC, 19 adrenocortical adenomas [ACAs], ten adrenal 
hyperplasia [HAs] and ten normal adrenals [NAs]) were selected from the tissue bank 
(from 1992 and July 1, 2010) of the Erasmus Medical Centre, Rotterdam (The Nether-
lands). HAs were obtained from adult patients undergoing bilateral adrenal removal for 
Cushing’s syndrome. All tissues were frozen within 60 minutes after surgical removal. 
NAs were obtained from adult donors or adult patients undergoing normal adrenal 
removal during surgery for kidney cancer.
An additional 12 adrenal samples (seven ACC, five ACA) were collected during surgery 
and they were processed immediately to obtain primary adrenal tumor cell cultures.
This study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center.
The Weiss score, assessed by an expert pathologist in adrenal disease (RRdK), was used 
to make the distinction between adenomas and carcinomas.14
The following clinical parameters were recorded in all patients: date of diagnosis, age, 
gender, ENSAT stage,15 Weiss score, mitotic count (as defined by the presence number of 
mitoses equal or higher than five in 50 high-power fields), hormonal status, and type of 
hormonal secretion (cortisol and/or androgens and/or estrogens and/or mineralocorti-
coids).3
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Total RNA isolation and quantitative RT-PCR (qRT-PCR)
From snap frozen adrenal tissues, total-RNA was isolated using a commercially available 
kit (High Pure RNA Tissue kit; Roche, Almere, The Netherlands).
Total RNA from the human ACC cell line NCI-H295R was used as a positive control.
The cDNA synthesis from total-RNA and quantitative PCR were performed as described 
previously.11
The mRNA expression of MTOR, 4EBP1, S6K1 and of the housekeeping gene hypoxan-
thine phosphoribosyltransferase (HPRT (HPRT1) were evaluated by quantitative RT-PCR 
in human adrenocortical tissue samples depending on the availability of frozen tissues.
The primers and probes were purchased from Sigma-Aldrich. The sequence of the 
primers and probes used are reported in the Supplementary table  1, see section on 
supplementary data given at the end of this article. Samples were normalized against 
the expression of HPRT. PCR efficiencies (E) were calculated for the primer-probe combi-
nations used (Supplementary table 1).16 The relative expression of genes was calculated 
using the comparative threshold method, 2-∆Ct,17 after efficiency correction18 of target 
and reference gene transcripts (HPRT).
Immunohistochemistry (IHC)
The expression of total/phospho-mTOR, total/phospho-4EBP1 and total/phospho-S6K1 
in adrenal samples were evaluated.
Paraffin-embedded tissue specimens were cut in 5 μm sections, deparaffinized and 
dehydrated. Antigen-retrieval was performed by microwave treatment in Tris–EDTA 
Buffer (pH 9.0). The slides were cooled for 1 hour at +4˚C and incubated for 1 hour at 
room temperature (RT) with the primary antibodies. The primary monoclonal antibod-
ies (MABs) to detect mTOR, phospho-mTOR, 4EBP1, phospho-4EBP1 and phospho-S6K1 
were purchased from Cell Signaling Technology (Inc.-3 Trask Lane-Danvers, MA 01923, 
USA, dilution: 1:25, 1:50, 1:1200; 1:25 and 1:100 respectively). The primary MAB to detect 
S6K1 was purchased from Santa Cruz Biotechnology, Inc. (dilution 1:25). The slides were 
washed and incubated for 30 min at RT with secondary antibodies (Poly-AP-Goat anti-
Mouse/Rabbit IgG PowerVision+; ImmunoVision Technologies, Duiven, the Netherlands) 
at the concentration provided by the manufacturer. After washing, staining was visual-
ized by incubation for 30 min with new fuchsin solution.19 Only phospho-S6K1 staining 
was performed and visualized with a Dako Detection System, following a different 
protocol described previously.11 All slides were counterstained with hematoxylin and 
coverslipped. Positive controls included cases of breast cancer with previously proven 
positivity at immunohistochemistry (IHC) for the protein evaluated. Negative controls 
included omission of the primary antibody and the incubation with secondary antibod-
ies.
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The staining was evaluated independently by two investigators and any discrepancy 
was resolved by a consensus review. In tumor specimens (ACAs and ACCs) the results 
were interpreted in a semiquantitative manner by using an intensity-proportion scoring 
system as described previously.20 The score was calculated by the sum of the intensity 
score and the proportion of the stained cells; this provided a score between 0 and 6. The 
proportion score was as follows: 0 = no positivity (or less than 10%); +1 = less than 1/3 
tumor cell positivity; +2 = 1/3 to 2/3 tumor cell positivity; and +3 = more than 2/3 tumor 
cell positivity. The intensity score was as follows: +1 = weak staining; +2 = intermediate 
staining; +3 = strong staining. The score 0 was considered as negative; 2-3 as low; 4-5 
as intermediate and 6 as high. Finally, adrenocortical tumors (ATs) were dichotomously 
grouped as having intermediate to high expression of the evaluated protein and phos-
phoproteins (IHC score equal-higher than 4) or not (IHC score lower than 4).
In AHs and in NAs, we used only the intensity score as indicated above.
To evaluate the correlation between the in vitro response to sirolimus (rapamycin) and 
the protein expression of the main components of the mTOR pathway, the expression of 
total/phospho-mTOR, total/phospho-4EBP1 and total/phospho-S6K1 were evaluated in 
12 additional AT samples used to perform AT primary cell cultures. In this additional se-
ries, the staining was performed and visualized with a Dako Detection System, following 
a different protocol described previously (De Martino, van Koetsveld et al. 2012). In this 
system, dilution of total/phospho-mTOR, total/phospho-4EBP1 and total/phospho-S6K1 
antibodies were: 1:50, 1:100, 1:2400; 1:50; 1:50 and 1:100 respectively.
Drugs and reagents
The mTOR inhibitor sirolimus was purchased from LC Laboratories Inc. (Woburn, MA, 
USA), dissolved in dimethylsulfoxide (DMSO) as concentrated (10-3M) stock solution 
(stored at -20°C) and diluted in 40% DMSO before use. IGF1 was purchased from Sigma-
Aldrich, diluted in 0.01M acetic acid as concentrated (5x10-6M) stock solution (stored at 
-20°C) and diluted in culture medium before use.
Cell lines and culture conditions
The human ACC cell lines H295 and SW13 were obtained from the American Type Culture 
Collection (Manassas, VA, USA) and from ECACC (Salisbury, Wiltshire, UK), respectively. 
Cells were cultured, as described previously in detail.11
Immunocytochemistry: chamber slides
To evaluate the expression of total/phospho-4EBP1 and total/phospho-S6K1 in ACC cell 
lines, H295 and SW13 cells were plated on poly-L-lysine-coated culture chamber slides 
(NUNC A/S, Roskilde, Denmark), for 48h in full medium. Subsequently, medium was 
refreshed and cells were incubated for 16h in a complete medium or starved in serum-
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free medium containing 0.1% human serum albumin (medium-HSA), according with the 
different treatment group assigned. Finally, media were refreshed again and cells were 
incubated for 30 min in complete medium or medium containing HSA with or without 
IGF1 (10-8M), according with the different treatment group assigned (Figure 1). Immuno-
cytochemistry in chamber slides was performed, as described previously in detail.11 The 
figure 1. Immunocytochemical detection of total 4EBP1, phospho-4EBP1, total S6K1, and phospho-S6K1 
in two human adrenocortical carcinoma cell lines H295 and SW13 plated in different medium conditions 
(details in the text). Panel A medium conditions include a complete continuous medium. Panel B medium 
conditions include 48 h in a complete medium followed by16 h in a serum-free medium containing 0.1% 
human serum albumin (medium-HSA), thus an additional 30 min in medium-HSA. Panel C medium condi-
tions include 48 h in a complete medium followed by 16 h in medium-HSA and thus 30 min in a complete 
medium. Panel D medium conditions include 48 h in a complete medium followed by 16 h in medium-HSA 
and thus 30 min in medium-HSA with IGF1 (10-8 M). The two pictures at the bottom show the absence of 
staining in the negative controls. Magnification, x200.
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dilution of total/phospho-mTOR, total/phospho-4EBP1 and total/phospho-S6K1 antibod-
ies were: 1:2400; 1:50; 1:50 and 1:100 respectively.
Primary cell culture of human adrenocortical tumors
Immediately after surgery, the adrenal specimens were minced into small pieces and 
dissociated with collagenase type I (2 mg/ml; Sigma-Aldrich). Cell viability, after Ficoll 
density gradient separation, was determined by trypan blue exclusion and always ex-
ceeded 90%. Cells were cultured in DMEM/F12K medium (Invitrogen), supplemented 
with 5% FCS, penicillin (1x105 U/l; Bristol-Meyers Squibb, Woerden, The Netherlands) 
and L-glutamine (2 mmol/l; GIBCO). Cells were plated at a density of 100.000 cells per 
well in 24-well plates (Corning Costar, Schiphol, The Netherlands). After 3-4 days of incu-
bation at 37°C in a humidified incubator containing 5% CO2, the medium was changed 
and incubations without or with sirolimus were performed for 7 days in quadruplicate. 
Controls were treated with the vehicle. The medium and test substances were washed 
every 3 days. On day 7, media were collected, cells were washed twice with saline, fol-
lowed by lysis for DNA analysis as described previously in detail (Hofland, et al. 1990). 
Owing to a limitation in the cell yield obtained per tissue, and the absence of cortisol 
secretion in some cases, not all experiments could be carried out in each individual case.
Cortisol secretion assay
In cortisol-secreting adrenal tumor primary cultures, we evaluated the effects of siroli-
mus on cortisol production. The culture supernatants from primary culture experiments, 
performed as above described, were collected and stored at -20°C until determination 
of the cortisol concentration.
The cortisol concentration was determined by a non-isotopic, automated chemilu-
minescence immunoassay system (Siemens Medical Solutions Diagnostics, Breda, The 
Netherlands). Cortisol levels were expressed as percentage of control and were corrected 
for the total DNA content in each well, thereby reflecting cortisol production per cell.
Statistical analysis
Statistical analysis was performed using the statistical software of SPSS (SPSS 15.0; SPSS 
Inc.). Quantitative data were expressed using means and standard deviations (SD) and 
medians and range. Qualitative data are expressed as percentage. Mann-Whitney U test 
and Kruskall-Wallis test were used to compare two or more groups. The comparative 
statistical evaluations among treatment groups in primary culture experiments were 
performed by ANOVA, followed by a multiple comparative test (Newman-Keuls). Spear-
man’s rank correlation coefficient was used to test correlation.
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ResulTs
Study population
This study included samples from 65 adrenal patients. Only two of the included ACC 
patients were children (9.5 and 4.2 years old respectively).
To describe the mTOR pathway, the mRNA expression levels of MTOR, 4EBP1, and S6K1, 
were evaluated by qRT-PCR in 54 human adrenocortical tissue samples (17 ACC, 17 
ACAs, ten AHs and ten NAs) and the protein expression levels of mTOR, phospho-mTOR, 
4EBP1, phospho-4EBP1 total-S6K1 and phospho-S6K1 were evaluated by IHC in 32 hu-
man adrenocortical tissue (20 ACCs, six ACAs, three AHs, and three NAs). For 20 cases 
(11 ACC including the two children, and three ACA, three AH, and three NA patients we 
had adequate material to perform the analysis of the mTOR pathway by both qRT-PCR 
and IHC.
mRNA expression of mTOR pathway components in human adrenal samples
The mRNA expression of MTOR, 4EBP1, and S6K1were  evaluated by quantitative RT-PCR 
in 54 adrenocortical tissue samples. In the samples, no statistically signifi cant diff er-
ences between the expression levels of MTOR (ACCs: 0.16±0.29; ACAs: 0.35±0.21; AHs: 
0.29±0.07; NAs: 0.27±0.19, median±SD) and 4EBP1 (ACCs: 0.36±0.60; ACAs: 0.41±0.64; 
AHs: 0.36±0.42; NAs: 0.33±0.08) were found, while the mRNA expression levels of 
S6K1 were signifi cantly lower in ACCs than in other groups (ACCs: 0.10±0.08 vs ACAs: 
0.20±0.11; AHs: 0.29±0.07; NAs: 0.23±0.08; p<0.01) (fi gure 2A, B and C). In the group of 
ACCs, a signifi cant correlation was found between the mRNA levels of MTOR and 4EBP1 
(p=0.043),  (p=0.003); S6K1 and 4EBP1 (p=0.011), but no relationships were observed 
figure 2. Box plot representation of the relative (A) mTOR, (B) 4EBP1, and (C) S6K1 mRNA expression ob-
served in normal and pathological human adrenal samples. A signifi cantly lower (P<0.01) relative mRNA 
expression of S6K1 was observed in adrenocortical carcinomas (ACCs) compared with all the other groups 
(C). (aP<0.01; bP<0.001; ooutliers; *extreme outliers).
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with the Weiss score, mitotic index and TNM. The correlations were also present when 
whole series of samples was considered.
Protein expression of mTOR pathway components in human normal adrenal and 
adrenal hyperplasia.
All the evaluated components of the mTOR pathway were expressed in cortex of the 
evaluated NA and AH specimens. However, a layer-specific expression of the evaluated 
proteins was observed. The intensity of staining for the majority of the evaluated pro-
teins was moderate to strong in glomerulosa and reticularis layers, weak to moderate in 
fasciculata and faint to weak in NA medulla, with the exception of phospho-S6K1 which 
showed moderate to strong staining in normal medulla.
Representative pictures of the staining observed in NAs are reported in Figure 3.
Protein expression of mTOR pathway components in human adrenocortical 
tumors
In 26 ATs (20 ACCs and six ACAs), the protein expression of the total and phospho-mTOR, 
total and phospho-4EBP1, total and phospho-S6K1 were evaluated by IHC. Table 1 sum-
marizes the results of the IHC and the main clinical features of the evaluated patients. 
Figure 4 shows 2 exemplary cases of immunostaining in ATs (a case of ACC [left panel] 
and a case of ACA [right panel]).
All ACCs, except one case (19/20; 95%), and all ACAs evaluated showed a positive 
staining for total-mTOR. This expression was intermediate to high in 12 ACCs (60%) and 
in all ACA samples. The staining of phospho-mTOR was present in a lower number of 
cases (5/20 ACCs and 3/6 ACAs) and only in some of these it was intermediate to high 
(two ACCs and two ACAs). A positive staining for total 4EBP1 was observed in all tumor 
samples evaluated with the exception of one ACC. This staining was intermediate to 
high in 15 ACCs (75%) and in all ACAs evaluated. The staining for phospho-4EBP1 was 
positive in 19 ACCs (95%) and in all ACAs. This staining was intermediate to high in 12 
ACCs (60%) and in all ACAs. A positive total S6K1 staining was observed in 15 (75%) 
ACCs and all ACAs. This staining was intermediate to high in five ACCs (25%) and four 
ACAs (67%). The staining for phospho-S6K1 was positive in eight (40%) ACCs and four 
ACAs (67%). This staining was intermediate to high in six ACCs (30%) and three ACAs 
(50%) respectively. The overall total-S6K1 score observed in ACAs was higher than ACCs 
(p=0.009) (Figure 5 A).
Considering together the staining score of phospho-S6K1 and phospho-4EBP1, an in-
termediate to high staining of at least one of the two components of the mTOR pathway 
was found in 16 ACCs (80%) and in all ACAs. An intermediate to high staining of both 
components was described in two ACCs (10%) and in three ACAs (50%). Interestingly, all 
ATs (six ACAs and 20 ACCs), which did not present any intermediate to high staining of 
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the two above-mentioned phosphoproteins had signifi cantly higher Weiss scores than 
others (p=0.009) (Figure  5 B). This diff erence was still present considering only ACCs 
(p=0.029) (Figure 5 C).
In ACC group a higher total-S6K1 (5±2 vs 2±2; p=0.04) and phospho-4EBP1 (5±1 vs 
3±2; p=0.04) protein expression was observed in tumors having a mitotic count lower 
than 5.
Several positive correlations between the staining score of diff erent components of 
the mTOR pathway in adrenocortical tumors were observed (Supplementary table 2 see 
section on supplementary data given at the end of this article), potentially suggesting 
common regulators.
In the 14 ATs, for which adequate material was available to perform both IHC and 
qRT-PCR, none of the evaluated components showed a signifi cant correlation between 
mRNA expression levels and protein expression levels.
figure 3. Exemplary pictures of the immunocytochemical detection of total mTOR, phospho-mTOR, total 
4EBP1, phospho-4EBP1, total S6K1, and phospho-S6K1 in normal adrenals. Large pictures represent all the 
normal adrenal ayers (magnifi cation, x40) and smaller pictures represent the higher magnifi cation (100x) of 
each adrenal layers (from the outer to the inner: glomerulosa (g); fasciculata (f ); reticularis (r); and medulla 
(m)).
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figure 5. (A) Box plot representation of total S6K1 protein expression observed in malignant (ACCs) and be-
nign (ACAs) adrenocortical tumors. The expression of S6K1 (total score; explanation in the text) in ACCs was 
significantly lower than that in ACAs. (B) Box plot representation of the Weiss score values in adrenocortical 
tumors (including six ACAs and 20 ACCs) divided into two groups according to the presence (yes) or ab-
sence (no) of an intermediate to high IHC score for phospho-4EBP1 and/or phospho-S6K1 (explanation in 
the text). (C) Box plot representation of the Weiss score values in the malignant subgroup of adrenocortical 
cancer (ACC) divided into two groups according to the presence (yes) or absence (no) of an intermediate to 
high IHC score for phospho-4EBP1 and/or phospho-S6K1. Tumors not having an intermediate to high IHC 
score for phospho-4EBP1 and/or phospho-S6K1 had a significantly higherWeiss score than other tumors 
(B); this difference was still present considering only ACCs (C).
figure 4. Immunocytochemical detection of total mTOR (A), phospho-mTOR (B), total 4EBP1 (C), phospho-
4EBP1 (D), total S6K1 (E), and phospho-S6K1 (F) in a case of human adrenocortical carcinoma (ACC (left 
panel)) and a case of human adrenocortical adenoma (ACA (right panel)). Picture ‘G’ shows the absence of 
staining in the negative controls, and picture ‘H’ the HE staining in both panels. Magnification, X200.
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ACCs associated with a hormonal production did not present any significant differ-
ence in the mRNA and protein expression levels of the evaluated components when 
compared with the non-secreting ACCs.
Protein expression of mTOR pathway components and in vitro response to 
sirolimus in preclinical models of human ATs
In order to explore whether the protein expression of the main components of the mTOR 
pathway are predictive for the effects of mTOR inhibitors in in vitro models of human ATs, 
we performed experiments in human ACC cell lines and in primary cell cultures of ACCs 
and ACAs.
Human ACC cell lines. To define whether total/phospho-4EBP1 and total/phospho-S6K1 
protein expression are correlated with the in vitro response of ACC cell lines to mTOR 
inhibitors, immunocytochemistry was performed in H295 and SW13. We had previously 
described the effects of sirolimus in these cell lines11 and demonstrated that SW13 are 
more sensitive to sirolimus treatment than H295 cell line. All the evaluated proteins 
were well expressed in both cell lines, either in basal or in serum/IGF1-stimulated condi-
tions (Figure 1). No major differences were observed in total/phospho-4EBP1 and total/
phospho-S6K1 protein expression between the cell lines.
Primary human ACC and ACA cell cultures. To determine whether the protein expres-
sion of all evaluated components of the mTOR pathway were correlated with the in vitro 
response of primary human AT cell cultures to mTOR inhibitors, immunocytochemistry 
was performed in tissue of seven ACC and five ACA from which primary cultures were 
performed. In these cell cultures, the response to sirolimus (10-10 and 10-6M) was defined 
based on the presence or absence of a significant inhibition in cell number (as evalu-
ated by DNA measurement) and/or cortisol secretion (in the cortisol-secreting tumors). 
Supplementary table  3, see section on supplementary data given at the end of this 
article shows the results of the effect of sirolimus in primary cultures. Only one ACC 
primary culture showed a significant cell number reduction after sirolimus treatment 
(figure 6 A). In a different case which was a cortisol-secreting ACC, sirolimus treatment 
significantly inhibited cortisol secretion (figure  6 C), but it did not affect cell number 
(figure 6 B). There were no clear differences in the expression of the evaluated proteins 
between the two responder cases and the others. These results suggest that only a small 
subset of ACC show a response to mTOR inhibitors and that there is not a clear correla-
tion between response to sirolimus and protein expression of the main components of 
the mTOR pathway.
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DisCussiOn
This study demonstrates a layer-specific protein expression pattern of the major com-
ponents of the mTOR pathway in normal adrenals and suggests the presence of an 
activated mTOR pathway in a subset of adrenal tumors.
Generally, malignant adrenal tumors (ACCs) showed variable protein expression of the 
evaluated components of the mTOR pathway and lower S6K1 mRNA and protein levels 
than adrenal benign tumors, suggesting a possible deregulation of the mTOR pathway 
figure 6. Effects of sirolimus in primary cultures of adrenocortical cancer: two responder cases. (A) A case 
with a significant reduction in cell survival as measured by the total DNA content. (B and C) A case with a 
significant reduction in cortisol secretion normalized for the total DNA content (C). Values are expressed as 
the percentage of the control and are described as mean±S.D. of four repeated measurements. *P<0.05; 
**P<0.01;***P<0.001.
Chris - Interior v8.indd   74 04-06-15   15:03
mTOR pathway and adrenal 75
in ACCs. However, it is difficult to establish whether these downregulations could be 
related to an abnormal mTOR pathway activity. Phospho-S6K1 and/or phospho-4EBP1 
have been considered as potential markers of mTOR pathway activation in human 
cancers.21, 22 Although a higher percentage of benign tumors presented an intermedi-
ate to high staining of these phospho-proteins compared to the ACCs, the total scores 
of phospho-S6K1 or phospho-4EBP1 were not significantly higher in ACAs compared 
with ACCs. Interestingly, tumors not having an intermediate to high staining of these 
phosphoproteins had a significantly higher Weiss score than tumors presenting an 
intermediate to high staining of at least one phosphoprotein. These data suggest that 
the mTOR pathway activity was downregulated in a subgroup of tumors with a more 
aggressive pathological phenotype (although not in all cases with aggressive pathologi-
cal phenotype), thus indicating that a subset of less differentiated ACCs could be less 
dependent on activation of the mTOR pathway.
The different expression of the evaluated proteins in the different layers of the adrenal 
cortex suggests a specific role of the mTOR pathway in particular adrenal functions. For 
example the stronger expression of several components of the mTOR pathway in the re-
ticularis could suggest a role of this pathway in the androgen production and the stron-
ger expression of these components in the glomerulosa may be related to angiotensin 
II induced activation of the mTOR pathway.23 We did not perform a real comparison 
between the staining observed in NAs and that observed in ATs because the presence of 
different layers in NAs, expressing the evaluated proteins at different intensities, made 
it difficult to attribute a semiquantitative IHC score as done for tumors. However, if we 
consider as reference, for example, the most representative layer of the adrenal cortex, 
which is the fasciculata, some tumors over-express and others have lower expression 
of the evaluated proteins. This observation reinforces the suggested heterogeneity of 
adrenocortical tumors, particularly in ACCs, in the expression of the mTOR pathway.
Several positive correlations between the mRNA levels of the different evaluated com-
ponents of the mTOR pathway were observed. Similarly, correlations were also observed 
among the different protein expression levels, suggesting that different components 
of the mTOR pathway could have common regulators of transcription and/or protein 
translation. Conversely, we did not find correlations between the expression observed at 
mRNA levels and the expression observed at protein levels. This absence of correlation 
between protein and mRNA expression could suggest different mechanisms of regu-
lation in protein and mRNA expressions, such as the presence of post-transcriptional 
regulators or could simply be explained by the small sample size.
The PI3-K/AKT/mTOR pathway is an intracellular pathway that mediates the effects of 
many growth factors including the IGFs.12, 24 Preclinical studies demonstrated that mTOR 
inhibitors inhibit in vitro cell proliferation in ACC cell lines11 and used at high dose; they 
also inhibit growth of ACC xenografts in immunodeficient mice.13 Moreover, mTOR path-
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way has been found to be activated in childhood ACCs.13 However, genomic abnormality 
associated with the potential PI3-K/AKT/mTOR pathway activation such as the loss of the 
tumor suppressor gene PTEN or PI3KCA mutations are not common events in ACCs.25, 26
Nakamura et al., evaluating the presence of potential surrogate markers of targeted 
drugs in ACCs by IHC, failed to demonstrate a significant overexpression of phospho-
S6K1 and phospho-4EBP1 in 41 ACCs as compared with 54 ACAs and 5 NAs. Conversely 
their results suggest a trend to a down-regulation of expression of these proteins in 
ACCs. This study demonstrates the expression of these proteins for each individual 
tumor and the percentage of positive/negative cases as established considering only 
intermediate to high staining. Adopting this approach we could define different subsets 
of ACC patients: 10% with an intermediate to high staining of both phospho-S6K1 and 
phospho-4EBP1; 30 or 60% expressing respectively phospho-S6K1 or phospho-4EBP1 
and 80% expressing at least one of these proteins. Based on these results it can be 
hypothesized that a subset of patients with ACCs could potentially be candidate for 
treatment with mTOR inhibitors. However, it must be considered that tissue biomarkers 
capable of defining the sensitivity of patients to the mTOR inhibitors have not been yet 
been validated in the clinical setting. To explore the role of the main components of the 
mTOR pathway as predictor of response in in vitro models of ATs, we performed experi-
ments in human ACC cell lines and in primary cell cultures of human ACCs and ACAs. 
Our previous study had demonstrated that sirolimus inhibits cell proliferation in H295 
and SW13 human ACC cell lines although with a different potency, SW13 cell lines being 
more sensitive than H295 cell lines.11 These two cell lines express total/phospho-4EBP1 
and total/phospho-S6K1 at a comparable level, suggesting that the expression of these 
proteins is not useful to predict the different sensitivity to sirolimus observed in these 
cell lines. We further investigated the role of mTOR, phospho-mTOR, 4EBP1, phospho-
4EBP1 total-S6K1 and phospho-S6K1 as predictor of response to sirolumus treatment in 
human ACC and ACA cell primary cultures. Also in this context protein expression was 
found to be unable to predict a differential sensitivity to sirolimus. In primary cultures 
experiments sirolimus significantly inhibited total DNA content only in one case of ACC 
with sarcomatoid features.27 These results suggest that only a small subset of ACCs 
might respond to treatment with mTOR inhibitors. Additionally, they might indicate that 
ACCs with this particular phenotype could be more sensitive to this treatment. While 
both ACC cell lines showed a significant response to sirolimus in terms of DNA,11 only 
one of the seven evaluated ACCs showed a response in this type of experiments. In this 
regard, it should be considered that primary cultures are in fact unable to proliferate, 
and therefore, DNA analysis in this context represents cell survival rather than a cell 
proliferation. For this reason the effects of sirolimus on total DNA content in primary 
cultures could be underestimated.
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IGF2 is known to be overexpressed in ACC compared to ACA or non-pathological ad-
renals and this explains why the IGF pathway has been historically considered an attrac-
tive target for ACCs. The absence of an overactivation of the PI3-K/AKT/mTOR pathway 
raises the question whether there is dissociation between the known over expression of 
the IGF2 in ACC and the activation of the classical IGF stimulated intracellular pathway. 
The variable expression of the evaluated components of the mTOR pathway suggests 
that mTOR inhibitors must be used with caution in unselected patients with ACC. Few 
patients with advanced ACCs who received everolimus, as salvage treatment, did not 
receive any major benefit.28 Few ACC patients have been treated in registered clinical 
trials.29-31 These studies failed to prove the hoped efficacy of these compounds, but 
they suffer of limitations. As mitotane can interfere with the metabolism of other drugs 
including mTOR inhibitors, it became necessary to determine mitotane levels in these 
patients. However, these early clinical experiences suggest that a subset of patients 
could benefit (more than 6 month tumor stabilization) from combined treatment includ-
ing mTOR inhibitors and IGF1R antagonists.30, 31 In a previous study, we demonstrated 
that in H295 ACC cells, IGFs can activate mechanisms of escape from mTOR inhibitors 
which could be responsible for a reduced sensitivity to the treatment with these drugs.11 
The blocking of endogenously produced IGF2 increased the antiproliferative effects of 
sirolimus.11 These preclinical studies support the rational to combine IGF1R antagonist 
and mTOR inhibitor treatment in a subset of patients with ACCs.
In conclusion, despite the well-known IGF2 overexpression and the potential role of 
the mTOR pathway in ACCs, presently there is no evidence that clearly supports a key 
role of this pathway in the pathogenesis of ACCs. However, this study suggests that a 
subset of ACCs have an activated mTOR pathway. Presently, there is not a strong proven 
rationale for the use of the mTOR inhibitors alone in ACCs. Therefore, further studies are 
warranted to investigate the potential role of mTOR inhibitors, alone or in association 
with other drugs, in ACC patients. The association between the Weiss score and the 
expression of the mTOR pathway components should be confirmed in larger series. 
Moreover, the role of the expression of the mTOR pathway components as prognostic 
parameters and as predictive biomarker for treatment with mTOR inhibitors in ACC war-
rants further investigation.
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supplementary table  1. Primers/probes used, relative amount in PCR mixtures and relative efficiency-
factor (E-factor).
 
 
 
Supplementary table 1. Primers/probes used, relative amount in PCR mixtures 
and rela ive efficiency-factor (E-factor). 
   
Amount (nmol/l) added in the 
total reaction volume (12,5 µl) 
used for each sample 
E factor for 
primers-probe 
mixture used 
mTOR    1,91 
 forward 5’-TGCTGCGTGTCTTCATGCAT-3’ 300  
 reverse 5’-GGATTGCAGCCAGTAACTTGATAG-3’ 300  
 probe 5’-FAM-ACAGCCCAGGCCGCATTGTC-TAMRA-3’ 100  
     
4EBP1    1,94 
 forward 5’-GGCGGCACGCTCTTCA-3’ 300  
 reverse 5’-TCAGGAATTTCCGGTCATAGATG-3’ 300  
 probe 5’- FAM-ACCACCCCGGGAGGTACCAGGA-TAMRA-3’ 100  
     
S6K1    1,86 
 forward 5’-TGGAAGACACTGCCTGCTTTT-3’ 300  
 reverse 5’-TGATCCCCTTTTGATGTAAATGC-3’ 300  
 probe 5’- FAM-CTTGGCAGAAATCTCCATGGCTTTGG-TAMRA-3’ 200  
     
HPRT    1,98 
 forward 5’-CACTGGCAAAACAATGCAGACT-3’ 500  
 reverse 5’-GTCTGGCTTATATCCAACACTTCGT-3’ 500  
 probe 5’-FAM-CAAGCTTGCGACCTTGACCATCTTTGGA-TAMRA-3’ 100  
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supplementary table 3. Effects of siroluimus on primary cultures of adrenocortical tumors.
 
 
 
Supplementary table 3. Effects of siroluimus on primary cultures of adrenocortical 
tumors. 
Patient ID Tumor 
Type
Responders
Control 10 nM 1000M Control 10 nM 1000M
A ACC 100±7.4 99,8±3.6 96±9.6 - - - no
B ACC 100±9.4 55.6±13.4*** 66.7±7.2** - - - yes
C ACC 100±12 99.9±9.7 110.5±14.7 - - - no
D ACC 100±4.3 ND 94.3±10.8 - - - no
E ACC 100±13.4 116.2±18 113.4±19.4 100±16.4 91.4±16.7 94.5±13.8 no
F ACC 100±11.9 94.1±2.5 95.4±9.1 100±1.3 88.4±8.2* 69.8±3.8*** yes
G ACC 100±20.8 98.6±19.2 96.9±19.6 100±17.4 86.3±10.4 74±23 no
H ACA 100±3.6 75.7±37.2 69.6±3.5 - - - no
I ACA 100±6 90.1±14.4 98.2±7.6 - - - no
J ACA 100±70.7 76.6±14.4 98.6±33.3 - - - no
K ACA 100±7.2 97.7±8.8 86.7±8 - - - no
L ACA 100±4.4 84.9±34.4 94±1 100±6.8 108.2±17.8 96±17.1 no
*p<0,05; **p<0,01; ***p<0,001
Effects of sirolimus on total DNA 
content
Effects of sirolimus on total cortisol 
secretion adjested for DNA content
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Effects of the dual 
IGF1-/Insulin-Receptor 
inhibitor OSI-906 and 
mTOR inhibitors in an in 
vitro model of human 
adrenocortical carcinoma
Maria Cristina De Martino, Peter M. van Koetsveld, Richard A. Feelders, 
Wouter W. de Herder, Fadime Dogan, Joseph A.M.J.L. Janssen, Davine 
Hofste Op Bruinink, Claudia Pivonello, A. Marlijn Waaijers, Annamaria 
Colao, Ronald R de Krijger, Rosario Pivonello & Leo J. Hofland.
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AbsTRACT
The IGF and mTOR-pathways are considered as potential targets for therapy in patients 
with adrenocortical carcinoma (ACC).
This study aims to describe the IGF pathway in ACC and to explore the in vitro response 
to the combined treatment with the dual IGF1-/Insulin-Receptor inhibitor OSI-906, 
(linsitinib) and mTOR inhibitors (sirolimus and everolimus) in an in vitro model of ACC. At 
this purpose, the protein expression level of IGF2, IGF1-Receptor [IGF1R] and IGF2R was 
evaluated by immunohistochemistry in 17 human ACC samples and the mRNA expres-
sion level of IGF1, IGF2, IGF1R, Insulin-Receptor[IR]A, IRB, IGF2R, IGF-Binding-Proteins 
[IGF-BP] 1, 2, 3 and 6 was evaluated by qRT-PCR in 12 samples. In H295 and HAC15 ACC 
cell lines the combined effects of OSI-906 and sirolimus or everolimus on cell survival 
were evaluated.
A high protein expression of IGF2, IGF1R and IGF2R was observed in 14 (82%), 11 (65%) 
and 17 (100%) of the samples, respectively. A high relative expression of IGF2 mRNA was 
found in the majority of samples. The mRNA levels of the IRA were higher than that of 
IRB and IGF1R in the majority of samples (75%). OSI-906 inhibits cell growth in the H295 
and HAC15 cell lines and, combined with sirolimus or everolimus, OSI-906 showed a 
significant additive inhibitory effect.
In conclusion, in addition to IGF2 and IGF1R, ACC express IGF2R, IRA and several IGF-
binding proteins, suggesting that the interplay between the different components of 
the IGF pathway in ACC could be more complex than previously considered. The ad-
dition of mTOR inhibitors to OSI-906 may have stronger antiproliferative effects than 
OSI-906 alone.
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inTRODuCTiOn
Malignant tumors of the adrenal cortex, defined as adrenocortical carcinoma (ACC), are 
rare but aggressive cancers for which new treatment options are required.1-3 Although 
most ACC are sporadic, rarely ACC develop in the context of certain genetic syndromes 
such as the Beckwith–Wiedemann syndrome (BWS), Li-Fraumeni syndrome and  familial 
colorectal polyposis. The study of these syndromes has supported the potential role 
of some molecular pathways in ACC pathogenesis.4 Particularly the BWS is a genetic 
syndrome associated with childhood ACC, other childhood tumors and a somatic over-
growth syndrome in which deregulation of imprinted genes on chromosomal locus 
11p15 leads to a biallelic expression of IGF2.4, 5 Although the estimated prevalence of BWS 
in patients with ACC is very low and restricted to childhood,4, 6 IGF2 has been reported to 
be over-expressed in about 70-90% of sporadic ACCs as compared to normal adrenals or 
benign adrenocortical tumors.7-16 Therefore, the insulin-like growth factor (IGF) system 
is considered as a promising target for new medical treatment options in ACC.10, 13, 17 
The IGF system participates in the regulation of growth, lifespan and metabolism and 
includes circulating ligands, exerting their effects as endocrine and/or paracrine factors 
[insulin, IGF1 and IGF2 (IGFs)]; binding proteins (IGF-BP1-6 that modulate the bioavail-
ability of IGFs) and multiple receptors.18 Among the receptors, the IGF1 receptor (IGF1R) 
and the insulin receptor isoforms A and B (IRA and IRB) are tyrosine-kinase receptors. 
The mannose 6-phosphate/insulin-like growth factor2 receptor (IGF2R) is a scavenger 
receptor involved in the internalization and degradation of IGF2. In adult humans, 
insulin predominantly exerts metabolic effects through the activation of IRB, whereas 
IGFs, particularly IGF1, mainly exerts growth-stimulating effects through the activation 
of IGF1R receptors. IRA is predominantly expressed during fetal development when it 
is an important mediator of pro-growth effects of insulin and IGFs. IRA expression in 
malignant tumor tissue has been suggested to be involved in cancer development.18 
Currently, the efficacy of several IGF1R and IGF1R/IR inhibitors is evaluated in clinical 
trials, alone or in combination with other agents for the treatment of several malignant 
disorders.19, 20 mTOR is a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/Akt/
mTOR signalling pathway and plays a pivotal role in cell growth, metabolism and pro-
liferation, by mediating the effects of various growth factors, including the IGFs.21 The 
mTOR pathway is considered a target for antineoplastic therapy in several malignancies 
and it has recently been proposed as a target for ACC treatment.22-24
This study aims at describing the IGF pathway in ACC and to explore the in vitro re-
sponse to the combined treatment with a dual IGF1-R/INS-R inhibitor (OSI-906) and the 
mTOR inhibitor (sirolimus) in an in vitro model of ACC using ACC cell lines and primary 
human ACC cell cultures.
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MATeRiAls AnD MeThODs
Subjects
Seventeen ACC and 6 normal adrenal tissue samples (NA) samples were used for this 
study. Fresh tissue was snap frozen within 60 minutes after surgical removal. NA samples 
were collected for in vitro studies from adrenalectomy (NA) due to renal cell carcinoma. 
This study was approved by the Medical Ethics Committee of the Erasmus MC and all 
patients gave written informed consent.
The following clinical parameters were recorded in all patients: date of diagnosis, 
age, gender, ENSAT stage,25 Weiss score (assessed by an expert pathologist in adrenal 
disease [RRdK]),26 mitotic count (as defined by the presence number of mitoses equal or 
higher than 5 in 50 high-power fields), hormonal status and type of hormonal secretion 
(cortisol and/or androgens and/or estrogens and/or mineralocorticoids).27
Total RNA isolation and quantitative RT-PCR (qRT-PCR)
From snap frozen adrenal tissues (available for 12 ACC cases and 6 NA cases), total RNA 
was isolated using a commercially available kit (High Pure RNA Tissue kit; Roche, Almere, 
The Netherlands).
Total RNA from the human ACC cell line NCI-H295R (H295) was used as a positive 
control.
The cDNA synthesis from total RNA and quantitative PCR were performed as previously 
described.22 mRNA expression of IGF1, IGF2, IGF1-Receptor [IGF1-R], Insulin-Receptor[IR]
A, IRB, IGF2R, IGF-Binding-Proteins [BP] 1, 2, 3 and 6 and of the housekeeping gene hy-
poxanthine phosphoribosyltransferase (HPRT) was evaluated by RT-qPCR in human ACC 
tissue samples, depending on the availability of frozen tissues.
The primers and probes were purchased from Sigma-Aldrich (Zwijndrecht, The Neth-
erlands) and they were previously reported ( Supplementary material table 1). Samples 
were normalized to the expression of HPRT. PCR efficiencies (E) were calculated for 
the primer-probe combinations used (Supplementary material table  1).28 The relative 
expression of genes was calculated using the comparative threshold method, 2-∆Ct,29 
after efficiency correction30 of target and reference gene transcripts (HPRT).
Immunohistochemistry (IHC)
The expression of IGF2, IGF1-R and IGF2R in adrenal samples was evaluated. Paraffin 
embedded tissue specimens were cut in 5 μm sections, deparaffinized and dehydrated. 
Antigen-retrieval was performed by microwave treatment in Tris–EDTA Buffer (pH 9.0). 
The slides were cooled for 1 hour at +4˚C and incubated for 1 hour at room temperature 
(RT) with the primary monoclonal antibodies and incubated overnight at +4˚C with the 
primary polyclonal antibodies. The primary monoclonal antibodies to detect IGF1-R 
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were purchased from Novus Biologicals (NB110-87052; dilution: 1:500) and the primary 
polyclonal antibodies to detect IGF2 and IGF2R were purchased from R&D Systems (AF-
292-NA; dilution: 1:500) and Santa Cruz Biotech (SC-25462; dilution: 1:50) respectively. 
The slides were washed and incubated for 30 min at RT with secondary antibodies (Poly-
AP-Goat anti-Mouse/Rabbit IgG PowerVision+; ImmunoVision Technologies) at the 
concentration provided by the manufacturer. After washing, staining was visualized 
by a 30 min incubation in new fuchsin solution. Only IGF1-R staining was performed 
and visualized with a Dako Detection System, following a different protocol previously 
described.22 All slides were counterstained with hematoxylin and coverslipped. Positive 
controls included cases of adrenocortical cancer and normal human pancreas with 
previously proven positivity at IHC for the protein evaluated. Negative controls included 
omission of the primary antibody and the incubation with secondary antibodies.
The staining was evaluated independently by two investigators and any discrepancy 
was resolved by a consensus review. The results were interpreted in a semiquantitative 
manner by using an intensity-proportion scoring system previously described.31 The 
score was calculated by the sum of the intensity score and the proportion of the stained 
cells; this provided a score between 0 and 6. The proportion score was as follows: 0 = no 
positivity (or less than 10%); +1  =  less than 1/3 tumor cell positivity; +2  =  1/3 to 2/3 
tumor cell positivity; and +3 = more than 2/3 tumor cell positivity. The intensity score 
was as follows: +1  =  weak staining; +2  =  intermediate staining; +3  =  strong staining. 
The score 0 was regarded as negative; 2-3 as low; 4-5 as intermediate and 6 as high. 
Finally adrenocortical tumors were dichotomously grouped as having intermediate to 
high expression of the evaluated protein and phospho-proteins (IHC score equal-higher 
than 4) or not (IHC score lower than 4).
Drugs and reagents
The dual IGF1-R/IR inhibitor OSI-906 and the mTOR inhibitors sirolimus and everolimus 
were purchased from LC Laboratories (Inc. Woburn, MA, USA) and prepared as a 10-3M 
stock solution in dimethylsulfoxide (DMSO). Compounds were stored at -20°C and 
further diluted in 40% DMSO before the use. Final DMSO concentration, also added as 
vehicle to controls, was 0.4%.
Cell lines and culture conditions
The human ACC cell lines H295 and HAC15 were obtained from the American Type Cul-
ture Collection (Manassas, VA) and from Dr. W. Rainey (as gift), respectively.32 The cells 
were cultured as previously described in detail.22
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Measurement of total DNA content assay
Measurement of total DNA content per well was used to determine the effects of the 
compounds on cell proliferation. Cells were plated in 1 ml of medium in 24-well plates at 
the density required to obtain a 65-70% cell confluence in the control groups at the end 
of the experiment. The experiments were performed using medium containing high (5% 
FCS) or low serum (1% FCS). Twenty-four hours later compounds were added to wells 
in quadruplicate, medium was refreshed at day 3 and fresh compounds were added 
again. After 3 or 6 days of treatment with the selected compounds, cells were harvested 
for DNA measurement, as a measure of cell number. All controls were vehicle treated. 
Measurement of total DNA content was previously described in detail.33
Apoptosis assay
Apoptosis has been studied using two methods: “DNA fragmentation assay” and “Mu-
seTM Annexin V & Dead Cell Kit”.
DNA fragmentation assay. The cells were plated in 24-well plates and treated as above 
described for the cell proliferation assay. After 24 hours compounds were or vehicle 
were added and after 3 days of incubation, DNA fragmentation was determined using 
a commercially available ELISA kit (Roche Diagnostic GmbH, Penzberg, Germany). The 
standard protocol supplied by the manufacturer was used. The same plates were also 
analyzed for the measurement of total DNA content. The amount of DNA-fragmentation 
(apoptosis) was corrected for the total DNA content in each well.
MuseTM Annexin V & Dead Cell Kit (Millipore, Germany). Cells were plated in 12-well plates 
at the density necessary to obtain a 65-70% cell confluence in the control groups at the 
end of the experiment. Twenty-four hours later sirolimus was added to wells in duplicate. 
Control groups were vehicle-treated. After seventy-two hours of treatment, cells were 
harvested by gentle trypsinization and processed for staining according to the protocol 
provided by the supplier of the assay. The experiments were repeated twice.
Cell cycle assay
The effects of compounds on cell cycle progression were evaluated using the “MuseTM 
Cell Cycle Assay” (Millipore, Germany). Cells were plated in.12-well plates at the density 
necessary to obtain a 65-70% cell confluence in the control groups at the end of the 
experiment. Twenty-four hours later sirolimus was added to wells in duplicate. Control 
groups were vehicle-treated. After seventy-two hours of treatment, cells were harvested 
by gentle trypsinization and processed for fixation and staining according to the proto-
col provided by the supplier of the assay. The experiments were repeated twice.
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Statistical analysis
All the experiments were carried out at least three times, with the exception of the apop-
tosis assays and cell cycle assay that were performed twice. The repeated experiments 
gave comparable results. For the statistical analysis statistical software of SPSS (SPSS 
15.0; SPSS Inc., Chicago,IL) and GraphPad Prism 5.0 (GraphPhad Software, San Diego, CA) 
was used. The Spearman’s rank coefficient (rho) was used to test correlation.
We used non-parametric tests to evaluate the differences among groups (Mann-
Whitney test and Kruskall-Wallis). The comparative statistical evaluations among 
treatment groups were performed by ANOVA, followed by a multiple comparison test 
(Newman-Keuls).
ResulTs
Study population
This study included samples from seventeen patients with ACC (main clinical charac-
teristics reported in table  1). Only two of the included ACC patients were children in 
which the presence of a genetic cause was not known (case 6 and 8; 9.5 and 4.2 years 
old respectively).
To describe the IGF pathway, the protein expression levels of IGF2, IGF1-R and IGF2R 
were evaluated by IHC in the ACC samples. In twelve of these samples, the mRNA expres-
sion levels of IGF1, IGF2, IGF1-R, IRA, IRB, IGF2R, IGF-BP 1, 2, 3 and 6 were evaluated by 
RT-qPCR.
Table 1: IGF2, IGF1R and IGF2R protein expression in 17 adrenocortical cancer samples
Patient 
number
Sex Weiss Hormonal 
secretion
Score Considerable 
expression
Score Considerable 
expression
Score Considerable 
expression
1 F 3 C 4 yes 5 yes 4 yes
2 F 5 C and A 6 yes 4 yes 5 yes
3 F 9 A 6 yes 3 no 4 yes
4 M 6 C and A 3 no 6 yes 5 yes
5 F 6 A 5 yes 5 yes 5 yes
6 F 7 C and A 6 yes 6 yes 5 yes
7 M 8 none 4 yes 5 yes 6 yes
8 F 4 A 6 yes 3 no 5 yes
9 F 7 none 4 yes 3 no 5 yes
10 F 3 none 3 no 4 yes 5 yes
11 F 7 C and A 6 yes 4 yes 5 yes
12 F 5 A 5 yes 6 yes 6 yes
13 F 7 none 4 yes 3 no 4 yes
14 F 8 none 6 yes 3 no 5 yes
15 M 4 A 6 yes 4 yes 6 yes
16 F 6 none 6 yes 2 no 5 yes
17 M 6 C 3 no 5 yes 6 yes
Median 6; 
Range 3-9
Median 5; 
Range 3-6
Frequency 
14/17 (82%)
Median 4; 
Range 2-6
Frequency 
11/17 (65%)
Median 5; 
Range 4-5
Frequency 
17/17 (100%)
 IGFII protein expression IGFIR protein 
expression
IGFIIR protein 
expression
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mRNA expression of the components of the IGF pathway in human ACC and NA 
samples
The mRNA expression of several components of the IGF pathway was evaluated by RT-
qPCR in 12 ACC samples and in 6 NA samples. As shown in Figure 1, the expression levels 
of most of these IGF pathway components is quite variable in the different samples 
evaluated, although a high relative expression of IGF2 was found in the majority of 
samples observed (mean 66,8±106,4; median levels 24.82; range 0.01-289.68). As com-
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figure 1. mRNA expression levels of the main components of the IGFs and mTOR pathways (expressed as 
relative mRNA expression as normalized to the house-keeping gene HPRT) in a series of 17 human ACC 
samples (panel A) and in a series of 6 normal adrenals (panel B).
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pared with other receptors evaluated, the receptor expressed at highest levels within 
tumors was IRA in 7 of 12 samples (58.3%); IGF2R in 3 (25%); IGF1R in one (8.3%) and IRB 
in the remaining one (8.3%). Considering only the tyrosine-kinase receptors, IRA was the 
receptor expressed at highest levels in the majority of samples (83%). Mean levels of IRA 
were significantly higher than mean levels of IGF1R (0.25±0.26 vs 0.07±0.09; p<0.05). 
In all the evaluated samples, excepted for three cases, IRA/IRB ratio was higher than 1 
(2.19±1.59). As compared with other IGFBPs evaluated, the IGFBP expressed at highest 
levels within tumors was IGFBP2 in 7 of 12 samples (58.3%); IGFBP3 in 4 (33.3%) and 
IGFBP6 in only one case (8.3%). Mean levels of IGFBP2 were significantly higher than 
the mean level of IGFBP1 and IGFBP6 (1.16±1.9 vs 0.04±0.1; p<0.01 and vs 0.18±0.07; 
p<0.05, respectively). A negative correlation was found between IGF2 and IGFBP6 (rho: 
-0.8; p<0.003), whereas a positive correlation was found between IGF1R and IGF2R (rho: 
0.7; p<0.009); IGF1R and IRB (rho: 0.8; p<0.003); IGF1R and IGFBP1 (rho: 0.8; p<0.001) and 
IRA and IGFBP2 (rho: 0.8; p<0.003). No relationship was observed between the mRNA 
levels of the IGF components and any clinical parameters evaluated including hormone 
production, Weiss score, mitotic index and TNM.
Mean levels of IGF1 and IGFBP6 were significantly lower in ACC as compared with 
NA (0.3±0.4 vs 0.5±0.3; p<0.05 and 0.2±0.2 vs 2.0±1.6 p<0.01, respectively). Mean levels 
of IGF2 were considerably higher in ACC as compared with NA (66.8±103.6 vs 1.9±2.3; 
p<0.05), but this difference did not reach statistical significance, probably as a conse-
quence of the small sample size and the high variation of IGF2 levels within the tumor 
samples. Comparing the expression of the evaluated components of the IGF pathway in 
the 12 ACC evaluated to the median value of each component in the NA, we observed an 
over expression of: IRA in 7 cases (58%); IRB in 4 (33,3%); IGF1 in 2 (17%); IGF2 in 9 (75%); 
IGF1R in 5 (41.6%); IGF2R in 5 (41.6%); IGFBP1 in 10 (83.3%); IGFBP2 in 3 (25%); IGFBP3 in 
9 (75%) and IGFBP6 in none. In addition, 9 ACC samples showed an IRA-IRB ratio higher 
than the median value observed in normal adrenals.
Protein expression of the components of the IGF pathway in human ACC samples
The protein expression of IGF2, IGF1R and IGF2R was evaluated by IHC in 17 human ACC. 
Table 1 summarizes the results of the IHC and the main clinical features of the evaluated 
patients. An intermediate to high staining for IGF2 (82%; median score 5; range 3-6) 
and IGF1R (65%; median score 4; range 2-6) was observed in most tumor tissues and for 
IGF2R (median score 5; range 4-6) in all ACC. No correlations were observed between 
the expression of the different proteins that were evaluated and between these proteins 
and the main clinical-pathological characteristics of the corresponding patients. No 
correlations were observed between the protein and mRNA expression of IGF2, IGF1R 
and IGF2R although a trend to positive correlation was found between IGF2 protein and 
mRNA expression. Figure 2 shows an exemplary case of immunostaining in ACC.
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Effects of dual IGF1-R/INS-R inhibitor in human adrenocortical cell lines
In both H295 and HAC15 cell lines OSI-906 inhibited cell proliferation in a dose- and 
time-dependent manner (figure  3A and 3D). OSI-906 was slightly, but significantly, 
more potent in inhibiting cell proliferation in HAC15 compared to H295. HAC15 cells 
were slightly more sensitive to OSI906 than H295 cells. After 6 days of treatment in full 
medium the IC50 of OSI-906 in H295 was 1.5x10-7M and in HAC15 2.9x10-8M (p<0.01). The 
maximal inhibition observed In H295 and HAC15 was 90% and 95%, respectively (not 
statistically significant; p=0.3). In both H295 and HAC15 cells the potency of OSI-906 
and the maximal inhibition observed were similar in cell cultured in medium with high 
serum compared with cells cultured in medium with low serum (figure 3B and 3E). At the 
condition tested, OSI-906 induced DNA-fragmentation in a dose-dependent manner in 
both H295 and HAC15 (figure 3C and 3F).
A B
C D
figure 2. Immunohistochemical detection of IGF2 (A), IGF1R (B) and IGF2R (C) in a case of human adreno-
cortical carcinoma. Pictures “D” shows the absence of staining in the negative control for panel B. Magnifica-
tion, X200.
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Effects of the dual IGF1R/INS-R inhibitor OSI-906 in combination with mTOR 
inhibitors on human ACC cells
Sirolumus and everolimus inhibited cell proliferation in H295 and HAC15 cells in a 
dose-dependent manner in both experimental conditions tested (high vs low serum 
concentration medium) data not shown. Sirolimus was slightly, but not significantly, 
more potent than everolimus. The potency of both compounds was similar in me-
dium containing either high or low serum concentration. Selected doses of sirolimus or 
everolimus combined with OSI-906 5x10-8M had statistically significant additive effect 
on cell proliferation (figure  4). Particularly both concentrations used of sirolimus and 
everolimus showed additivity with OSI-906 in inhibiting H295 and HAC cell proliferation 
when tested in medium containing low serum concentration (figure 4B, 4D, 4F and 4H). 
Only the highest concentrations used of mTOR inhibitors (10-6M) showed some additiv-
ity with OSI-906 in inhibiting H295 and HAC cell proliferation when tested in medium 
containing high serum concentration (figure 4A, 4C, 4E and 4G).
At the condition tested only the highest concentrations used of sirolimus (10-6M) 
showed significant additivity with OSI-906 in increasing annexin V, used as measure of 
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figure 3. Dose and time-dependent effect of OSI-906 treatment on H295 (A-B) and HAC15 (D-E) cell prolif-
eration, expressed as DNA content/well after 3 days and 6 days (panels A and D) and after 6 days in medium 
with high or low serum (panels B and E). Dose-dependent effects of 3-day treatment with OSI-906 on apop-
tosis of H295 (C) and HAC15 (F) cells, expressed as DNA fragmentation (normalized to the DNA content of 
each well). Data are expressed as the percentage of control and represent the mean± SEM. Control is set as 
100%. *** p<0.001.
Chris - Interior v8.indd   95 04-06-15   15:03
96 Chapter 4
apoptosis, in H295 (figure 5A). Everolimus did not show a statistically significant additiv-
ity in increasing annexin V in H295 (figure 5B).
OSI-906 (10-7M) alone or in combination with sirolimus 10-6M or 5x10-9M significantly 
increased the proportion of cells in G0/G1 phase of the cell cycle (p<0.05, p<0.05 and 
p<0.01 respectively). OSI-906 in combination with sirolimus 10-6M or 5x10-9M signifi-
cantly reduced the proportion of G2/M (p<0.05) (figure 5C). Additionally the combined 
treatment with OSI-906 and sirolimus showed a trend to have additive effects in 
inducing G1-cell cycle block. Statistically significant additive effects in increasing the 
proportion of cells in G0/G1 phase (p<0.05) and reducing the proportion of cells in G2/M 
phase (p<0.05) were observed when combining OSI-906 10-7M and sirolimus 5x10-9M as 
compared with sirolimus alone (figure 5C).
OSI-906 (10-7M) alone or in combination with everolimus 10-6M or 5x10-9M signifi-
cantly increased the proportion of cells in G0/G1 phase of the cell cycle (p<0.01). OSI-906 
alone or in combination with everolimus 10-6M or 5x10-9M significantly reduced the 
proportion of cells in G2/M phase (p<0.01) (figure  5D). Additionally, the combined 
treatment with OSI-906 and everolimus showed significant additive effects in inducing 
G1-cell cycle block. Particularly, when combining OSI-906 10-7M and everolimus 10-6M 
or 5x10-9M, statistically significant additive effects in increasing the proportion of cells 
in G0/G1 phase (p<0.05 and p<0.01, respectively) and in reducing the proportion of G2/M 
(p<0.05) as compared with everolimus alone were observed (figure 5D).
Figure 4. Effect of OSI-906 (Osi), alone or in combination with the mTOR inhibitors sirolimus (S) or everoli-
mus (E), on H295 (A-D) and HAC15 (E- H) cell proliferation. Results are expressed as DNA content/well. Two 
different conditions have been tested: medium with high (panels: A, C, E and G) or low serum (panels: B, D, 
F and H). Data are expressed as the percentage of control and represent the mean± SEM. Control is set as 
100%. *p<0.05; **p<0.01; *** p<0.001; x p<0.05 vs control; xx p<0.01 vs control; xxx p<0.001 vs control.
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DisCussiOn
The results of this study show that the majority of ACC express IGF2, IGF1R and IGF2R 
mRNA and protein and demonstrate IRA mRNA expression in these tumors, suggesting 
that factors such as IGF2R and IRA, not well described before, could interact with IGF2, 
potentially modulating the role of IGF2 in adrenocortical tumorigenesis. Mean levels 
of IGF1 and IGFBP6 were significantly lower in ACC as compared with NA. Additionally, 
this study demonstrates that treatment of human ACC cells with OSI-906, a dual IGF1R/
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figure 5. Panels A and B: Effect of OSI-906 (Osi), alone or in combination with the mTOR inhibitors sirolimus 
[(S); panel A] or everolimus [(E); panel B], on Annexin V as a measure of induction of apoptosis in H295 cell 
line. Data are expressed as the percentage of control and represent the mean± SEM. Control is set as 100%. 
*p<0.05 vs Osi alone; xxx p<0.001 vs control. Panels C and D: Effect of OSI-906 (Osi), alone or in combination 
with the mTOR inhibitors sirolimus (panel C) or everolimus (panel D), on cell cycle in H295 cell line. Data are 
expressed as mean± SEM. *p<0.05 and **p<0.01 vs S (panel C) or E (panel D) alone; x p<0.05 and xx p<0.01 
vs control.
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IR inhibitor, reduces cell proliferation and that combined treatment with OSI-906 and 
mTOR inhibitors can have additive antiproliferative effects.
A high mRNA and protein expression of IGF2 is found in most evaluated samples, 
in agreement with the already well known IGF2 overexpression in 70-90% of ACC.7-16 
IGF1R protein expression was demonstrated in all the evaluated ACC samples and an 
intermediate to high staining was observed in more than 50% of cases. These data are 
in agreement with previous studies describing IGF1R expression in most ACC.10, 13, 34 The 
protein expression of IR in most ACCs has been previously described as well,34 however, 
to the best of our knowledge, the differential expression of IRA and IRB isoforms of the 
IR in ACCs, has never been explored. Unfortunately, to the best of our knowledge, there 
are currently no antibodies available to distinguish between the IR isoforms. We could 
therefore only evaluate IR isoform expression at mRNA level. While IRB is considered 
as the main mediator of metabolic effects of insulin and IGFs in adult tissue, IRA is an 
isoform of the IR, predominantly expressed during fetal development and is considered 
as an important mediator of growth-promoting effects of insulin and IGFs.18 IRA has a 
higher affinity for IGF2 compared with the IGF1R and its expression in malignant tumor 
tissue has been suggested to be involved in cancer development.18 To our knowledge 
this is the first study demonstrating the presence of IRA in ACCs and showing that in 
these cancers, IRA is often expressed at higher level compared with IGF1R and IRB. 
The expression of IGF2 and the IGF1R has suggested a potential role of an IGF2-IGF1R 
autocrine loop in adrenocortical tumorigenesis.35 The current study suggests a role of 
IRA as potential additional mediator of the IGF2 effects in ACC. However, in addition to 
the tyrosine kinase receptors involved in the IGF pathway, also IGF2R and IGFBPs could 
play a role in modulating the IGF effects. The IGF2R serves a function in the degradation 
of IGF2, intracellular trafficking of lysosomal enzymes and activation of transforming 
growth factor beta. Down-regulation of IGF2R has been found in some type of cancers 
and it has been suggested that IGF2R could play a role as a tumor suppressor gene 
in some malignancies.36, 37 Loss of heterozygosis at the locus of IGF2R gene has been 
reported to be a frequent event in ACC, supporting a potential role of IGF2R as a tumor 
suppressor gene also in ACC development.38 However, a low protein expression of IGF2R 
in ACC has never been described. Conversely, the current study demonstrates the pres-
ence of a high IGF2R protein expression in most ACCs, suggesting that a high level of 
IGF2R protein might counteract the growth-stimulating effects of IGF2 in adrenocortical 
tumorigenesis. In line with previously published data, in the current study a variable 
expression of IGFBPs was found in ACCs.9, 39 Several correlations between the different 
components of the IGF pathway were found suggesting the existence of common 
mechanisms of regulation. However no correlations with clinical-pathological param-
eters were found. This lack of correlation might be related to the small sample size and 
to the complexity of the IGF pathway. Among the IGFBPs evaluated, the IGFBP expressed 
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at higher levels was IGFBP2, whereas IGFBP6 was expressed at lowest level. Addition-
ally the expression of IGFBP6 was significantly lower in ACC than in normal adrenals. 
Therefore, whether high IGFBP2 and/or low IGFBP6 could play a role in the regulation of 
IGF pathway in adrenocortical tumorigenesis deserves further investigation.
The IGF pathway is considered as one of the most promising targets for a novel medi-
cal treatment modality in patients with ACC.10, 13, 23, 40 In preclinical models of ACC, two 
types of drugs targeting the IGF1R, i.e. NVP-AEW541, a selective IGF1R kinase inhibitor 
and IMC-12, an IGF1R antibody, have been reported to have antiproliferative effects,10, 13 
thus encouraging the development of clinical trials in ACC patients using drugs target-
ing the IGF pathway. The current study confirms that OSI-906 (linsitinib), an IGF1R/IR 
inhibitor, inhibits the proliferation of the human ACC cell lines H295 and HAC15 in vitro 
already at a concentration lower than the concentrations reached in vivo in humans 
(about 5x10-6M). OSI-906 has been recently tested in ACC patients in a phase III clinical 
trial (NCT00924989). The results of this study have been presented at ASCO meeting 
in 201441 showing that a small subgroup of patients seems to benefit from treatment 
with this drug, although improvements in overall or progression-free survival were not 
observed. These apparently  controversial results between preclinical and clinical stud-
ies, could be explained in several ways. First, it might indicate that our preclinical models 
are not representative enough for the population of patients with ACC, because these 
tumors are heterogeneous. The role of the IGF pathway as a potential target for treat-
ment in ACC might have been overestimated, as suggested by the fact that up-to-date 
in vivo experiments demonstrated that isolated IGF2 overexpression has no oncogenic 
potential.42 Since disappointing results emerged in clinical trials adopting different 
types of drugs targeting the IGF pathway in different types of malignancies, despite 
apparently promising preclinical data,43 it could be hypothesized that current strategies 
adopted to target this pathway might still be inadequate. Indeed, biomarkers that can 
predict tumor response to IGF-targeting drugs, that might drive the selection of patient 
candidates to these drugs, have not been identified yet. Additionally, the complexity 
of the system could have been underestimated (such as the expression of potential 
regulators of the IGF pathway, as IGF2R in ACC) and the existence of interfering factors 
may not have been characterized yet. For example, in case of ACC patients the potential 
pharmacokinetic interactions between mitotane and drugs acting on the IGF pathway 
should be better investigated. Mitotane is strong a inducer of CYP3A4 and was shown 
to decrease bioavailability of sunitinib in patients with ACC.44 Finally, targeting only the 
IGF pathway might not be sufficient to suppress cell growth because other pathways, 
that in part also interact with the IGF pathway (e.g. the mTOR pathway) are still activated. 
As such, before to finally declare a “game over”42 for the role of IGF2 in adrenocortical 
tumorigenesis and as potential target for novel treatment in ACC patients, it could prob-
ably be useful to return to the bench and try to better explore the IGF pathway in its 
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whole complexity. In line with this, the results of the current study point out that ACC 
express components of the IGF pathway, such as IRA and IGF2R, that have not been 
considered before.
In a previous study from our group it was demonstrated that mTOR inhibitors in-
hibit cell proliferation in H295 and SW13 human ACC cell lines, but in H295, probably 
as consequence of the IGF2 overexpression, this treatment could activate two potential 
pathways of escape to treatment with traditional mTOR inhibitors, i.e. the AKT and ERK 
pathways.45 These data provide the rational for experiments combining mTOR inhibitors 
and drugs targeting the IGF pathway in ACC. In the current study the effects of OSI-906 
in combination with mTOR inhibitors were evaluated and the results of these experi-
ments demonstrated that these compounds can have additive antiproliferative effects 
in some of the tested conditions. Particularly additive antiproliferative effects were more 
pronounced when the experiments were performed using medium with low serum, 
suggesting that cell environment and the presence of growth factors different from IGF2 
could influence the effects of these combination of compounds. These results are in line 
with a recently published phase I study demonstrating that a subgroup (about 40%) of 
ACC patients treated with cixutumumab (IGF1R inhibitor) and temsirolimus experienced 
a long term disease stabilization.46 These results suggest that treatment strategies com-
bining mTOR inhibitors and OSI-906 warrant further investigation, although considering 
the heterogeneous expression of the main components of the IGF pathway in the dif-
ferent ACC samples, the apparently modest antiproliferative effects observed at a low 
concentration of these compounds as well as the potential limits of the used human cell 
lines as model of human ACC, caution is recommended before moving from the bench 
to the bedside.
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supplementary table 1
Supplemental material 
Table 1 
Oligo 
Name 
               Forward                 Reverse                      Probe 
IGF1R CCAAAACTGAAGCCGAGAAG GGGTCGGTGATGTTGTAGGT AAGCAGGAACACCACGGCCG 
IGF2R ACCGACCCCTCCACGC CCTCCAAGGCCACCTTCAG AGCAGTACGACCTCTCCAGTCTGGCAAA 
IGF1 TTGTGATTTCTTGAAGGTGAAGATG CGTGGCAGAGCTGGTGAAG TACCTGGCGCTGTGCCTGCTCA 
IGF2 CCAAGTCCGAGAGGGACGT TTGGAAGAACTTGGCCACG ACCGTGCTTCCGGACAACTTCCC 
IRA CGTTTGAGGATTACCTGCACAA GCCAAGGGACCTGCGTTT TGGTTTTCGTCCCCAGGCCATC 
IRB CCCAGAAAAACCTCTTCAGGC GGACCTGCGTTTCCGAGA CTGGTGCCGAGGACCCTAGGCC 
mTOR TGCTGCGTGTCTTCATGCAT GGATTGCAGCCAGTAACTTGATAG ACAGCCCAGGCCGCATTGTC 
p70S6K TGGAAGACACTGCCTGCTTTT TGATCCCCTTTTGATGTAAATGC CTTGGCAGAAATCTCCATGGCTTTGG 
4EBP1 GGCGGCACGCTCTTCA TCAGGAATTTCCGGTCATAGATG ACCACCCCGGGAGGTACCAGGA 
HPRT TGCTTTCCTTGGTCAGGCAGTAT AAATCCAACAAAGTCTGGCTTATATC CAAGCTTGCGACCTTGACCATCTTTGGA 
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AbsTRACT
Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment 
options. Mitotane alone, or in combination with cytotoxic chemotherapy, represents 
the current referral treatment for patients with unresectable ACC. Recent studies have 
shown that mTOR inhibitors suppress growth of ACC cells. The current study aimed at 
evaluating the effects of mitotane in combination with the mTOR inhibitor sirolimus.
In human H295 and SW13 ACC cells the effects of a 6-day treatment with increasing 
doses of mitotane in the presence or absence of selected doses of sirolimus has been 
tested on cell proliferation, as measured by the total DNA content. The tested doses of 
mitotane ranged between 10-7 and 10-5M in both cell lines, whereas those of sirolimus 
were 5x10-9 and 10-6M in H295 and 5x10-11M and 10-10 M in SW13.
In H295, mitotane significantly inhibited cell proliferation at all concentrations tested, 
with an IC50 of 4.5x10-6M and a maximal inhibition of 87% as compared with vehicle-
treated controls (p<0.001). In SW13, mitotane significantly inhibited cell proliferation at 
concentrations higher than 2.5x10-6M, with an IC50 of 1.6x10-5M and a maximal inhibition 
of 81% as compared with vehicle-treated controls (p<0.001). In both H295 and SW13 
sirolimus significantly inhibited cell proliferation at both concentrations tested and 
when combined with mitotane, it showed significant additive effects. This additivity was 
observed only with low mitotane doses (between 10-7 and 5x10-6M). Using mitotane 
doses higher than 5x10-6M the cell proliferation inhibition was already nearly maximal 
and no significant additive effects could be observed.
The current study demonstrates that sirolimus has additive antiproliferative effects when 
combined with low doses of mitotane. These doses correspond to concentrations lower 
than the therapeutic range of mitotane. If this effect can also be achieved in vivo, our 
data suggest that the addition of sirolimus to mitotane might be useful in ACC patients 
when the therapeutic range of mitotane range is not reached.
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inTRODuCTiOn
ACC is a rare but aggressive solid cancer with and incidence of about 1-2 new cases/
million/year and a 5-year survival rate of below 15% at the metastatic stage.1, 2 Surgery 
remains the only curative treatment in patients diagnosed at an early stage.1-3
Mitotane, is currently the only drug approved in Europe and in the United States for 
the treatment of advanced ACC.4 As monochemotherapy, a response rate of mitotane 
between 13 and 35% has been reported.1, 4 However, in patients achieving plasma mito-
tane level above 14 mg/L a higher response rate (up to 66%) and an improved survival 
have been reported.1, 3, 4 In combination with chemotherapy response rates of mitotane 
range between 14 and 55%.,1, 3, 4, 5 No novel treatment option has emerged in the last 
four decades,1, 3-5 underling the urgent need of new therapeutic options for patients 
affected by this malignancy.
The mTOR pathway is considered a target for antineoplastic therapy in several malig-
nancies and it has recently been proposed as target for ACC treatment.6-8 In preclinical 
models of ACC, mTOR inhibitors such as sirolimus, temsirolimus and everolimus inhibit 
cell proliferation in a dose- and time-dependent manner.6-8 However, the human ACC 
cell line SW13 was found to be more sensitive to mTOR inhibition than the H295 cell line, 
which is considered as the most representative model of ACC.9 These preclinical data, 
together with the expected heterogeneity of ACC, suggest that caution is required be-
fore using this class of drugs in unselected ACC patients9, 10 and caution is also supported 
by preliminary clinical experience with the use of everolimus in some ACC patients with 
a late stage of disease.11 Unfortunately, due to the absence of a clear predictor of the 
effectiveness of mTOR inhibitors in this malignancy, it is difficult to define selection cri-
teria for patients, who are candidates for this class of drugs.12 Therefore, combination of 
mTOR inhibitors with different drugs, potentially active in ACC, could be a more prudent 
clinical approach than the use of these inhibitors as monotherapy in unselected ACC 
patients. Among the possible combination treatment options, there is a rationale to use 
mTOR inhibitors in association with drugs targeting the IGF pathway.9 This combina-
tion treatment has recently been evaluated in an early-phase clinical trial suggesting a 
potential clinical effect in a subset of ACC patients that experienced prolonged disease 
stabilizations.13 To our knowledge, there are no studies evaluating the effects of mTOR 
inhibitors combined with mitotane in ACC. Therefore, this study aimed at evaluating the 
effects of mitotane in combination with sirolimus in two ACC cell lines the H295 and the 
SW13.
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MATeRiAls AnD MeThODs
Cell lines and culture conditions
Two human ACC cell lines the NCI-H295R (H295) and the SW13, were obtained from the 
American Type Culture Collection (Manassas, VA) and from ECACC (Salisbury, Wiltshire, 
UK), respectively.14
The cells were cultured in 75-cm2 culture flasks at 37°C in a humidified incubator 
at 5% CO2. For all cell lines, the culture medium consisted of DMEM/F12K medium, 
supplemented with 5% fetal calf serum (FCS), penicillin (1x105 U/liter), and l-glutamine 
(2 mmol/liter). Cells were harvested with trypsin (0.05%)-EDTA (0.53 mM) solution and 
resuspended in culture medium. Cell viability always exceeded 95%. Media and supple-
ments were obtained from Invitrogen (Breda, The Netherlands).
Drugs and reagents
Mitotane was purchased from Sigma-Aldrich and dissolved in ethanol as a concentrated 
(10-2M) stock solution (stored at -20°C) and diluted in ethanol prior to use. The mTOR 
inhibitor sirolimus (rapamycin) was purchased from LC Laboratories (Inc. Woburn, MA, 
USA) and dissolved in dimethylsulfoxide (DMSO) as a concentrated (10-3M) stock solu-
tion (stored at -20°C) and diluted in 40% DMSO prior to use.
Measurement of total DNA content.
Cells were plated in 1 ml of culture medium in 24-well plates at the density required 
to obtain a 65-70% cell confluence in the control groups at the end of the experiment. 
Twenty-four hours later mitotane and/or sirolimus were added to the wells in triplicate, 
medium and compounds were refreshed after three days of treatment and controls 
were vehicle-treated. The tested doses of mitotane ranged between 10-7 and 10-5M in 
both cell lines, sirolimus was tested at concentrations of 5x10-9 and 10-6M in H295 and 
5x10-11M and 10-10M in SW13. The different doses of sirolimus used were selected on 
the bases of the previously reported dose-response curves of sirolimus in the used cell 
lines.9 After 6 days of treatment, the cells were harvested for DNA measurement, as a 
measure of cell number. Measurement of total DNA content was previously described 
in detail.15
Statistical analysis
All the experiments were carried out at least three times. The repeated experiments gave 
comparable results. For the statistical analysis statistical software of GraphPad Prism 
(GraphPhad Software, San Diego, CA) was used. The comparative statistical evaluations 
among treatment groups were performed by ANOVA, followed by a multiple compara-
tive test (Newman-Keuls). The half maximal inhibitory concentration (IC50) was calculated 
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assuming that log(inhibitor) vs. response curves follow a symmetrical sigmoidal shape 
with a standard slope of of -1.0. Results are expressed as means±standard-errors.
ResulTs
Effects of Mitotane plus sirolimus on cell growth in ACC cell lines
In both H295 and SW13, mitotane significantly inhibits cell proliferation in a dose-de-
pendent manner as shown in Figure 1. In H295 the antiproliferative effects of mitotane 
were observed already at the lowest concentration tested (10-7M); these effects ranged 
between 10% (p<0.05) and 87% (p<0.001), as compared with vehicle-treated control. 
In SW13 antiproliferative effects of mitotane were observed at concentrations between 
2.5x10-6M and 10-5M. These effects ranged between 30% (p<0.01) and 81% (p<0.001) as 
compared with vehicle-treated controls. Mitotane was slightly, but significantly more 
potent in H295 (IC50 4.5x10-6M) than in SW13 (IC501.6x10-5M) (p<0.01).
In both H295 and SW13, the selected concentrations of sirolimus significantly inhibited 
cell proliferation. In H295, sirolimus at concentrations of 5x10-9M and 10-6M reduced cell 
proliferation by 24% (p<0.001) and 45% (p<0.001), as compared with vehicle-treated 
controls, respectively. In SW13 cells, sirolimus at concentrations of 5x10-11M and 10-10M, 
reduced cell proliferation by 57% (p<0.001) and 70% (p<0.001) as compared with 
vehicle-treated controls, respectively.
When mitotane was used at low concentrations (between 10-7 and 5x10-6M), siroli-
mus had additive effects, when compared with mitotane alone. In H295, this additivity 
was 9-15% and 14-30% when using 5x10-9M or 10-6M of sirolimus, respectively, and the 
maximal additive effects were observed at the lowest mitotane concentration tested 
(Figure 1 A). In SW13, the additivity was 19-58% and 25-66% when using 5x10-11M or 
10-10M of sirolimus, respectively, and the maximal additive effects were observed at 
the lowest mitotane concentration tested (Figure 1 B). Of note, mitotane alone used at 
concentration of 10-7 and 10-6M, was unable to inhibit cell proliferation in this cell line, 
while an inhibition of cell proliferation was observed when these low concentrations of 
mitotane where combined with sirolimus alone, even at very low concentrations. The 
addition of sirolimus to mitotane did not significantly interfere with the dose-response 
curves of mitotane in the tested cell lines (Figure 2). In H295, as compared with sirolimus 
alone, mitotane at a concentration higher than 10-7M had significant additive effects 
when combined with both the concentrations of sirolimus tested (p<0.01 or p<0.001; 
Figure 1A). In SW13, as compared with sirolimus alone, mitotane had significant additive 
effects only when the highest concentration of mitotane (10-5M) was combined with 
the lowest concentration of sirolimus (5x10-11M) (p<0.05; Figure 1B).
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figure 1. Combined effects of a 6-day treatment with increasing concentrations of mitotane (Mito) and 
selected concentrations of sirolimus (S) in two human ACC cell lines: H295 (panel A) and SW13 (panel B). At 
some of the combinations tested significant additive inhibitory effects on cell growth are observed in both 
cell lines. *p< 0.05, ** p<0.01 and ***p< 0.001; xp< 0.05, xxp< 0.01 and xxxp< 0.001 vs control.
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DisCussiOn
The current study demonstrates that in human ACC cell lines, sirolimus has additive 
antiproliferative effects when combined with low mitotane doses.
Mitotane is considered as a referral drug in the treatment of patients with advanced 
ACC, but unfortunately there are patients who do not respond and/or tolerate the drug, 
raising the requirement of new treatment options.1, 4
The monitoring of mitotane plasma levels during treatment is very important, 
because a response rate up to 66% has been reported in patients achieving mitotane 
plasma level above 14 mg/L, but a higher rate of adverse effects is reported when the 
plasma mitotane level exceeds 20 mg/L, making the therapeutic window of this drug 
very narrow. A rapid achievement and long-term maintenance of these therapeutic 
range (14-20 mg/L) has been suggested as predictor of mitotane response in patients 
with ACC.1, 4, 16, 17 However, this clinical goal is sometimes difficult to be reached because 
mitotane has a complex pharmacokinetical profile that causes large variation in indi-
vidual drug availability and in some patients the onset of adverse events can preclude a 
fast drug escalation or the use of a full dose of the drug. Treatment strategies combining 
mitotane with other drugs could increase the response rate of patients, as compared 
with monotherapy, for several reasons. The combination could have additive antiprolif-
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figure 2. Dose-response curve of 6-days treatment with increasing mitotane M) concentrations, alone or 
in combination with two selected concentrations of sirolimus (S), in two ACC cell lines: H295 (panel A) 
and SW13. The addition of sirolimus to mitotane did not significantly change the dose response curve of 
mitotane. Data are expressed as the percentage of control and represent the mean±SD. Control is set as 
100% and in the curve of mitotane alone the control is represented by vehicletreated cells, whereas in the 
curves of mitotane combined with sirolimus the control is represented by treated cells with sirolimus alone.
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erative effects potentially increasing the in vivo antineoplastic effects and/or potentially 
reducing the concentration of each drug required to obtain a desired antineoplastic 
effect and consequentially decreasing the risks of adverse events. On the other hand, in 
absence of appropriate predictors of clinical response that can help to select patients for 
the most appropriate treatment, the combination of two drugs, both potentially effec-
tive, but acting with different mechanisms, could increase the chance of patients to get 
a clinical benefit from at least at one of the two treatments. Additionally, in particular in 
the case of mitotane, the combined treatment with other active drugs could reduce the 
risk of tumor progression during the treatment phases in which mitotane plasma level is 
still below the therapeutic range.
Recently, mTOR inhibitors have been suggested as a new potential treatment for ACC. 
Preclinical data suggest sirolimus, temsirolimus and everolimus can inhibit ACC cell 
proliferation.6-8 However, preliminary experience with the use of everolimus as salvage 
treatment in few ACC patients did not show promising results,11 whereas combined 
treatment of an IGF1R antibody with temsirolimus in a phase I study including ACC pa-
tients, showed more promising results.13 Therefore, combination treatment with mTOR 
inhibitors and other drugs might have higher effects than mTOR inhibitors alone. To our 
knowledge there are no in vitro studies evaluating the effects of mitotane in combina-
tion with mTOR inhibitors.
In the current study all the concentrations of mitotane used (from 10-7 to 10-5M) were 
lower than the concentrations (4.3-6.3x10-5M) corresponding to the mitotane plasma 
level at the therapeutic range.18 The addition of sirolimus to these low concentrations 
of mitotane showed higher antiproliferative effects than mitotane alone suggesting 
that combined treatment might have additive effects to the antineoplastic action of 
mitotane, permitting to reduce the dose required to obtain desired clinical effects. This 
additivity was higher when the concentration of mitotane used were lower, suggesting 
that combined treatment might be particularly useful during the phases of treatment in 
which mitotane plasma level are below the therapeutic range, such as during the initial 
dose titration and/or for those subjects in which the therapeutic range of mitotane is 
hardly maintained due to bad tolerance or other reasons.
mTOR inhibitors are antineoplastic compounds largely developed for clinical use, 
with an acceptable safety profile.19-22 Among the mTOR inhibitors, sirolimus can be 
considered as a referral compound since it is the first drug that has been discovered 
in this category, and because other mTOR inhibitors have been developed starting 
from it. Additionally, the in vitro effects of sirolimus in H295 and SW13 ACC cell lines 
cultured in similar experimental conditions had already been demonstrated, showing 
that H295 were significantly less sensitive than SW13 to sirolimus.9 Based on the results 
of this previous report, in the current study two different concentrations of sirolimus 
were selected for each cell line. With the exception of 10-6M sirolimus used in H295 cells, 
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all the tested concentrations where within the range of blood drug levels reached in 
humans during sirolimus treatment (maximal concentration about 10-7M).23, 24 In both 
cell lines, the addition of mitotane to sirolimus showed some significant additivity as 
compared with sirolimus alone, but only at some of the experimental conditions tested. 
Particularly, in the H295 cell model that is more sensitive to mitotane but less sensi-
tive to sirolimus than the SW13 cell model, the additivity was more pronounced and 
observed at all concentration of mitotane tested with the exception of the lowest one. 
Conversely, in SW13 cells that were very sensitive to sirolimus, the addition of mitotane 
showed a significant additive inhibitory effect as compared to sirolimus alone, only 
when the highest mitotane concentration was combined with a very low sirolimus 
concentration. This results might be related to the potent inhibitory effects of sirolimus 
alone in SW13 cells, that induced already a near maximal inhibition of cell proliferation. 
While H295 cells are well accepted as a good model of ACC, a large debate is still open 
about the appropriateness of SW13 cells as a model for this type of cancer.25 Taking in 
account this and the other potential limitations of ACC cell lines as preclinical model of 
ACC, the results of the current study might suggest that among ACC patients it could 
be possible to find subgroups of patients with a high sensitivity to sirolimus, in which 
the use of combined treatment could induce an important antineoplastic effect even in 
absence of mitotane effect, such as in mitotane resistant patients. If this condition would 
be confirmed in vivo, it could represent an additional reason to obtain an increased 
tumor respose rate by using combined treatment strategies rather than monotherapy, 
regardless the presence or absence of additivity. Future studies should also examine 
the antiproliferative and antisecretory effects of mitotane combined with sirolimus on 
primary cultures of human functional and non-functional ACC.
Among the potential limitations of the current study there is the lack of possibility to 
explore pharmacokinetic interaction between drugs. In the in vivo setting, mitotane is 
a well known inducer of microsomal liver enzyme cytochrome P450 (CYP3A4/5).26 The 
induction of this enzyme can reduce the circulating concentrations of drugs metabo-
lized by it, including mTOR inhibitors.27 This pharmacokinetic interaction should be kept 
in mind when translating the in vitro results to the potential in vivo applications, and 
attention should be used in monitoring the blood concentrations of drugs to reach the 
desired therapeutic levels.
In conclusion, this study suggests a potential advantage of combining mitotane with 
sirolimus, but these data are still preliminary. Clearly, additional studies, including ani-
mal models, are mandatory before moving from the bench to the bedside.
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AbsTRACT
Context: adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant 
treatment options. In ACC, no personalized approach has emerged but no extensive 
molecular screening has been performed to date.
Objective: to evaluate the presence of a large number of potentially targetable molecu-
lar events in a large cohort of advanced ACC.
Design, setting, and participants: we used hotspot gene sequencing (Ion Torrent, 40 
patients) and comparative genomic hybridization (CGH, 28 patients; a subset of the en-
tire cohort) in adult stage III-IV ACC samples, to screen for mutations and copy number 
abnormalities of potential interest for therapeutic use in 46 and 130 genes respectively.
Results: At least one copy number alteration or mutation was found in 19 patients 
(47.5%). The most frequent mutations were detected on TP53, ATM and CTNNB1 (6/40 
[15%], 5/40 [12.5%] and 4/40 [10%] respectively). The most frequent copy number 
alterations identified were: amplification of the CDK4 oncogene (5/28; 17.9%) and dele-
tion of the CDKN2A (4/28; 14.3%) and CDKN2B (3/28; 10.7%) tumor suppressor genes. 
Amplifications of FGFR1, FGF9 or FRS2 were discovered in 3 subjects (10.7%). Associated 
alterations were: deletions of CDKN2A, CDKN2B with ATM mutations and TP53 mutations 
with CTNNB1 mutations.
Conclusions: No simple targetable molecular event emerged. Drugs targeting the 
cell cycle could be the most relevant new therapeutic approach for patients with ad-
vanced ACC. Inhibitors of the fibroblast growth factor receptor pathway could also be 
a therapeutic option in a subset of patients, while other targeted therapies should be 
considered on a case-by-case basis.
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inTRODuCTiOn
Adrenocortical cancer (ACC) is one of the most aggressive solid tumors in humans, as 
evidenced by a 5-year survival rate of below 15% at the metastatic stage.1, 2 Its incidence 
is about 1-2 new cases/million/year, with an increased occurrence during childhood 
and the fourth to fifth decades of life. Surgery remains the only curative treatment in 
patients diagnosed at an early stage while treatment options for patients with advanced 
ACC are still scant.1-4
A personalized approach to cancer treatment is based on the use of drugs able to tar-
get specific molecular alterations playing pivotal roles in oncogenesis which are targe-
table in a given patient. The study of ACC-associated syndromes has suggested that the 
IGF2 signaling pathway (Beckwith-Wiedemann syndrome), p53 (Li-Fraumeni syndrome) 
or Wnt/β-catenin signaling (Familial Adenomatous Polyposis) are currently the most 
attractive targets for ACC.2 Among these targets, only IGF1 receptor antagonists are 
currently under investigation in ACC. The results of phase I studies evaluating the effects 
of IGF1 receptor antagonists have already been published, demonstrating that drugs 
targeting the IGF1receptor can induce tumor stabilization in a subset of patients, but 
objective tumor response are rare.5 Regarding p53 or Wnt/β-catenin signaling, drugs 
targeting these pathways are still in early development phases. Preliminary studies us-
ing antiangiogenics or epithelial growth factor (EGFR)-targeted drugs in patients with 
ACC have yielded disappointing results.2, 6-11 However, both the lack of screening for the 
relevant targeted events and the full demonstration of the relevance of such targets in 
ACC may explain these results.
In sporadic ACC, several studies have used gene expression microarrays or compara-
tive genomic hybridization (CGH), mainly to establish criteria aimed at differentiating 
benign from malignant tumors or to identify prognostic markers.12, 13 Few studies have 
evaluated the presence of putative biomarkers for new targeted agents in ACC. Indeed, 
small numbers of molecular alterations (up to five per series) were screened in 8-35 
ACC patients among whom only 11 exhibited indisputable criteria of malignancy, as 
evidenced by the presence of extraadrenal disease.6, 14-16
We hypothesize that testing a large number of potentially targetable molecular events 
in patients with indisputably malignant ACC could accelerate the drug development 
process in this rare and aggressive solid tumor. To achieve this goal, we collected a large 
number of primary or locally recurrent well-characterized malignant ACCs. We used 
hotspot gene sequencing and comparative genomic hybridization (CGH) to evaluate 
the presence of mutations and copy number abnormalities in, respectively, 46 and 130 
genes of potential interest.
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MATeRiAls AnD MeThODs
Patient population and sample acquisition
Samples from different ACC patients were collected in four centers of the French 
COMETE network (Institut National du Cancer): the “Institut Gustave Roussy”, the “Centre 
Hospitalier Régional et Universitaire-Tumorothèque-CRRC de Lille”; the “Hospices Civils 
de Lyon”; the “Hôpital Cochin, Paris”. Samples were snap frozen and stored in tumor 
biobanks according to national ethics recommendations and local procedures. The forty 
samples selected for the present study and processed for DNA extraction had to meet 
the following inclusion criteria: ACC diagnosis confirmed by a local expert pathologist,17 
indisputable malignancy (stage III-IV) based on the ENSAT staging definition,18 the 
presence of more than 50% of tumor cells based on histological examination, age older 
than 17 years. The following clinical parameters were recorded: date of diagnosis, age, 
gender, Weiss score,17 mitotic count (available in 39 patients and calculated in 50 or 10 
high-power fields [HPF] for 29 or 10 patients, respectively), hormonal status based on 
hormonal measurements, tumor node metastasis stage and previous systemic treat-
ments. Informed consent was obtained from each patient.
DNA isolation
Genomic DNA was extracted from several 10-20 µm sections of each tumor specimen 
after digestion with proteinase K (3 hours), using the DNeasy Tissue Kit (QIAGEN), ac-
cording to the manufacturer’s protocol. DNA concentrations were assessed with the 
Qubit fluorometer (Invitrogen).
Mutational analysis
DNA sequencing was performed with the Ion Torrent technique (PGM-Sequencer Life 
Technologies). Ten nanograms of each sample were amplified with multiplex PCR based 
on the Cancer-Panel primers pool followed by library preparation according to recom-
mendations of the Ion AmpliSeq Library Kit 2.0 protocol (Life Technologies), using 17 
cycles for multiplex PCR and adding Ion Xpress barcode adapters during the ligation 
step to allow for subsequent pooling of the samples. The list of sequences covered by 
multiplex PCR (.bed file) is available on www.ampliseq.com. Each individual library was 
quantified using the Qubit fluorometer (Invitrogen) and controlled using a Bioanalyzer 
(Agilent Technologies). Libraries were diluted to obtain a final dilution of 3ng/µL for each 
library, and 8 or 16 libraries were pooled together for amplification on spheres using 
the Ion OneTouch 200 Template Kit version 2 (Life Technologies). Spheres obtained by 8 
different libraries were loaded onto an Ion 316 chip and spheres obtained by the remain-
ing 32 libraries were loaded onto an Ion 318 chip for sequencing using the Ion PGM 200 
Sequencing Kit for 520 flows.
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Using 190 primer pairs, this approach allowed the simultaneous study of hotspot 
regions of 46 critical oncogenes or tumor suppressor genes of potential interest to 
predict drug sensitivity (reported in supplementary table 1). All reported somatic ge-
netic variants were compared with the relative GRCh37 (h19) reference sequences using 
Torrent Suite version 2.2 software (variantCaller v2.2.3-31149; Life Technologies) and 
annotated using Alamut version 2.2 software (Interactive Biosoftware). The variants with 
a read frequency higher than 10%, none synonymous with and not known as common 
polymorphisms, were retained as interesting variants (mutations), and were confirmed 
by Sanger direct sequencing, as previously described.19 Moreover AKT1 (exon 4), PI3KCA 
(exons 5-10-21) and CTNNB1 (exon 3) were sequenced in all samples to complete the 
information obtained with the Ampliseq Cancer Panel.
Oligonucleotide CGH microarrays.
For microarray hybridizations, 400 ng of DNA from each DNA sample was digested and 
sample integrity was measured using an Agilent bioanalyzer. The test DNA samples were 
labeled with Cy5 fluorescent dye and the reference DNA samples were labeled with Cy3 
fluorescent dye using the Genomic DNA Enzymatic Labeling Kit (Agilent Technologies), 
following the manufacturer’s protocol. Cy3-labeled and Cy5-labelled DNAs were hybrid-
ized to the SurePrint G3 Human CGH Microarray 4x180K (Agilent Technologies), prior to 
washing and scanning with Agilent Scanner G2565CA.
Oligonucleotide CGH microarray analysis.
Oligonucleotide CGH array processing was performed as detailed in the manufacturer’s 
protocol (version 7.1, December 2011; http://www.agilent.com). Data were extracted 
from scanned images using the Feature Extraction software (version 10.7.3,1, Agilent 
Technologies), along with protocol CGH_107_Sep09. Acquired signals were normalized 
according to their dye and local GC percentage content using in-house scripts under 
the R statistical environment (http://cran.r-project.org). The resulting log2(ratio) values 
were segmented using the circular binary segmentation algorithm20 implementation 
from the DNAcopy package for R. Aberration status calling was automatically performed 
for each profile according to its internal noise (absolute variation of log2(ratio) values 
across consecutive probes on the genome). All genomic coordinates were established 
on the University of California Santa Cruz build hg19 Homo Sapiens genome.21 The analy-
sis focused on 130 genes of potential interest to predict drug sensitivity, including the 
46 genes studied by sequencing and additional genes involved in the IGF pathway as 
reported in supplementary table 1. We described all copy number alterations above zero 
as gains and all the alterations below zero as losses. However, only copy number gains 
with log2 ratio values higher than 1 were considered as amplified, and copy number 
losses with a log2 ratio value lower than 1 were considered as deletions.
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Statistical analysis.
Descriptive parameters were calculated using statistical software (SPSS v 15.0). Quanti-
tative data were expressed using means and standard deviations (SD) and medians and 
ranges. Qualitative data were expressed using percentages.
ResulTs
Study population
The study population included 40 adult patients. The main clinical characteristics of 
these patients are reported in table 1. Malignancy was ascertained by the stage: 10 and 
30 patients had stage III or IV, disease respectively. All samples were collected from pri-
mary tumors (34 samples) or local recurrences (6 samples). Each sample corresponded 
to a different patient. In two patients with stage IV disease, a complete Weiss score could 
not be assigned because of insufficient available material.
Hotspot gene sequencing
Using the Cancer-Panel primers pool for Ion Torrent sequencing, all 40 samples were 
informative for the analysis of sequence variants of the evaluated hotspot regions. The 
mean number of mapped reads per tumor was 167680±122768 (mean ± SD); base cov-
erage depth per tumor was 835X ±598; mean read on-target was 90%±6 (median 93%; 
61-95%); the average coverage at 100x was 93.4±2% (median 93%; 89-99%) and the 
median of 8 variants (range 5-16) was detected. Variants were reported per tumor. The 
interesting variants retained were all confirmed by Sanger sequencing.
More than one quarter (14/40, 35%) of the samples exhibited at least one mutation, 
as defined above (details reported in supplementary table 2). Single mutations in the 
TP53 gene were found in six samples (15%). All of these mutations are predicted to be 
associated with a disruption of p53 function (www-p53.iarc.fr). Single mutations in the 
ATM gene were found in five samples (12.5%). Single mutations of CTNNB1 were found 
in four samples (10%), all located in exon 3.
In individual cases (1/40; 2.5%), single mutations in the genes coding for ERBB4, FLT3, 
STK11, SMO, and GNAS were found (supplementary table 2). A GNAS-activating mutation 
was found in a patient presenting with an isolated Cushing’s syndrome (stage III ACC, WS 
6) and no clinical evidence of fibrous dysplasia. A STK11 mutation was found in a patient 
presenting with an isolated non-secreting ACC (stage III, WS 6).
DNA copy number changes
Twenty-eight of the 40 evaluated samples (a subset of the entire cohort) generated 
informative profiles by CGH. The average profile of the 28 samples is reported in fig-
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ure 1. Most samples exhibited gains of oncogenes or loss of tumor suppressor genes, as 
reported in supplementary table 3.
Twelve of these profiles (42.9%) contained at least one deletion or amplification in 
the expression of the 130 evaluated genes. Among these genes, the recurrent retained 
abnormality was the amplification of the CDK4 oncogene (Chr12q14) observed in 5 of 
Table 1. Patient clinical characteristics
P arameters C las s Number F requenc y (% )
G ender 40
F emale 29 72,5
Male 11 27,5
19-29 years 3 7,5
30-39 9 22,5
40-49 4 10
50-59 8 20
60-69 12 30
≥70 4 10
4 2 5
5 4 10
6 10 25
7 10 25
8 4 10
9 8 20
Unknown 2 5
≤5 3 7,7
>5 but <10 9 23,1
≥10 27 69,2
Unknown 1 2,5
Hormonal s ec retion  
P res ent 26 65
C ortis ol 13 32,5
C ortis ol and androgens  9 22,5
Androgens 3 7,5
Androgens  and es trogens 1 2,5
Abs ent 14 35
S tage III 10 25
IV 30 75
Origin of s ampling P rimary tumors 34 85
R ecurrence 6 15
P revious  s ys temic  treatment 
yes 14 35
Mitotane 9 22,5
Mitotane and C hemotherapy 5 12,5
no 26 65
Age: median 55 (19-77) years ; mean 52±16
Weis s  s c ore : median 7 (4-9) ; mean 6,9±1,4
Mitotic  index
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the 28 evaluated samples (17.9%); the deletion of the CDKN2A tumor suppressor gene 
(Chr9p21) observed in four other samples (14.3%) and the deletion of the tumor suppres-
sor gene CDKN2B (Chr9p21) observed in 3 samples. All these 3 patients with deletion of 
CDKN2B were also deleted for CDKN2A (figure 2 and supplementary table 3). Overall 32.1% 
of the samples exhibited an amplification/deletion (figure 2 and 3) of one of these genes. 
Amplification of three different components of the fibroblast growth factor (FGF) pathway 
(FGFR1; FGF9 and FRS2) was found in 3 different samples (3/28; 10.7%) (figure 2).
Integrated results of hotspot gene sequencing and DNA copy number variation
Taken together, the results of DNA copy number variation and hotspot gene sequencing 
data (figure 2), showed that almost half of the evaluated samples exhibited at least one 
molecular event (19/40; 47.5%).
Some alterations were recurrently associated, such as the ATM mutation and loss of 
CDKN2A observed in 3 of the 5 samples harboring ATM mutations. Three of the four 
patients with a CTNNB1 mutation were also carrying a TP53 mutation.
figure 1. Frequency of chromosome gains and losses in 28 adult advanced ACC samples as detected by 
comparative genomic hybridization. The X-axis shows each numbered chromosome region, starting from 
chromosome 1 and ending with chromosome X with short-arm regions (p) preceding the long-arm regions 
(q). The Y-axis shows the frequency of samples exhibiting a gain (blue and upper part of the graph) or a loss 
(red and lower part) of each hybridized chromosome region. The arrows indicate the chromosome regions 
containing CDK4, CDKN2A/B, MDM2, and ATM.
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DisCussiOn
To the best of our knowledge, this is the first study to screen a large series of indisput-
ably malignant ACC for the presence of a large number (more than 40) of structural 
DNA changes that could help to select new targeted drugs. The strengths of this study 
include a selective use of malignant ACC samples based on documented local or distant 
invasion and the use of an innovative sequencing system, the Ion Torrent which allows 
one to generate results concerning a large set of genes in a time span compatible with 
clinical needs. None of the previous studies evaluated more than 5 potential targets by 
DNA sequencing and none of them were able to integrate the results of DNA sequenc-
ing with the study of DNA copy number alterations in this type of malignancy. Thirty-five 
percent of the samples exhibited at least one mutation and 42.9% had at least one dele-
tion or amplification in the evaluated genes. Overall, almost half of the samples (47.5%) 
had at least one molecular abnormality. The present study provides evidence that drugs 
targeting the cell cycle represent the most relevant potential new therapeutic strategy 
for patients with advanced ACC. Inhibitors of the FGFR pathway could be a potential 
target for treatment in a subset of ACC patients, whereas treatment with other targeted 
therapies could be considered exclusively on a case-by-case basis. The rarity of the mo-
lecular alterations usually used in personalized oncology, suggests that no short-term 
results can be expected from the use of new available licensed agents in the majority of 
ACC patients.
figure 2. Molecular abnormalities detected by CGH and hot spot gene sequencing (Ion Torrent; Life Tech-
nologies)) in a cohort of 40 adult ACC samples. The left panel shows the mutated genes in pink (according 
to the definition described in the text). The right panel shows the copy number variations detected by CGH 
in the screened genes. Amplifications are in red and deletions (according to the definition described in the 
text) in green.
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Based on DNA sequencing of 46 potentially actionable oncogenes or tumor sup-
pressor genes, we identified alterations including mutations in ERBB4 and FLT3 genes 
(figure 2). No mutations were identified on EGFR, BRAF, KIT, PIK3CA, RET or PDGFR-A. Pre-
viously, two studies evaluated the results of EGFR (exons 18-21) sequencing in ACC and 
reported a mutation frequency of respectively 0 (0/30) and 11% (4/35) in the cases.6, 14 
A previous study conducted by our group found no mutation in EGFR (exon 18,19 and 
21), BRAF, PIK3CA and JAK2 in 18 ACCs, which is in line with the present results.15 Because 
some target gene regions were not well explored by Ampliseq Cancer-Panel primers, 
we further validated our results by direct sequencing and we confirmed the absence of 
AKT1 (exon 4) mutations and PI3KCA mutations (exons 5, 10 and 21) in all of our samples 
(data not shown). 
Using CGH, different components of the FGFR pathway were found to be amplified 
in three different samples. A growing number of studies indicate that inhibition of the 
FGFR pathway may be an effective therapeutic option against cancer and several drugs 
targeting the FGFR pathway are under clinical development (phase I-III).22 A microarray 
gene expression analysis performed in 11 ACC samples evidenced frequent up-regula-
tion of FGFR1 and 4 in one study.23 A recent study suggested that FGFR-4 overexpression 
and gene amplification have a prognostic value in ACC.24 In the present study FGFR1-4 
were not frequently amplified, but gains of FGFR 1-4 were frequently observed (22 of 
28 [78.6%] samples exhibited gains in at least one of these receptors; supplementary 
table 3). Conversely, the study of copy number variations suggests that HER2 (ERBB2) 
amplification is not present in ACC, in accordance with previous reports.25-27 In addition, 
many other putative biomarkers of targeted treatments such as PTEN, AKT, ALK, c-MET/
HGFR, EGFR, PDGFR, and ESR1 did not exhibit amplification/deletion, which completes 
the negative results of the mutation screening approach.
CTNNB1 and TP53 mutations are genetic alterations well known to play a role in the 
pathogenesis of ACC.2 Based on DNA sequencing, we identified CTNNB1 mutations in 
four samples (10%) and TP53 mutations in 6 samples (15%). Interestingly, both CTNNB1 
and TP53 mutations (figure  2) were found in three samples. Moreover, CTNNB1 gains 
were observed in all abnormal (mutated or deleted) TP53 samples (supplementary 
table 3), while they were rare (9%) in wild-type TP53 samples. This observation, which is 
very intriguing from the pathogenic point of view, and hitherto never clearly described 
in ACC, suggests an association between the status of TP53 and CTNN1B genes. CTNNB1 
mutations are early events in adrenocortical oncogenesis.16, 28 Previously published stud-
ies reported CTNNB1 mutations in 20-30% of the evaluated samples.16, 28 The frequency 
of CTNNB1 mutations in our population was in the low range of previously published 
reports. Because some rare CTNNB1 exon 3 mutations previously described in ACC were 
outside the hotspot regions investigated in our study, we performed direct sequencing 
of exon 3 of the CTNNB1 gene in all ACC samples. This technique allowed us to detect 
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CTNNB1 mutations in two additional patients. This led to a whole CTNNB1 mutation rate 
of 15%, which is still in the low range of previously published reports. 
TP53 mutations were suggested to be late events in adult adrenocortical oncogen-
esis.29 Previously published studies reported TP53 mutations in 10-70% of the evaluated 
samples.30 The frequency of TP53 mutation in our population was also in the low range 
of previously published reports. The difference in the frequency of CTNNB1 and TP53 in 
our study compared to previously published reports could be due to the low sample size 
and the heterogeneity of the ACC patient population. Interestingly, based on CGH, one 
sample exhibited a TP53 deletion and another MDM2 amplification (figure 2 and supple-
mentary table 3). The MDM2 gene has been reported to be overexpressed in ACC13 and is 
a potential target for treatment ( www.clinicaltrials.gov). Regarding the IGF pathway, no 
major alteration was found with the methods used in our (study supplementary table 3).
DNA-damage response and G1 cell cycle progression are new pathways whose explo-
ration could be interesting in ACC patients. By sequencing, we demonstrated for the first 
time the presence of ATM mutations/interesting variants in five ACC patients. ATM plays 
a role in cell response to DNA damage and genome stability. Mutations in this gene 
are associated with ataxia telangiectasia, a disorder associated with high frequency of 
cancer.31 All the detected ATM variants are considered of interest because they have 
been described as potentially involved in malignancy.32-34 The frequencies of these ATM 
variants in our series is higher than that expected in the general population (relative 
database dbSNP [build 137]; supplementary table 2). A recent study demonstrated ATM 
gene copy number is reduced in ACC compared with adrenal adenomas.35 We detected 
alterations of several key components of the cell cycle by CGH analysis: CDK4 amplifica-
tion and CDKN2A and CDKN2B deletion. CDK4 encodes for a cyclin-dependent kinase 
that plays a crucial role in G1-S phase cell cycle progression. CDK4 has already been 
suggested to be overexpressed in ACC as compared to normal adrenals.36 By alternative 
splicing, CDKN2A can encode for two different gene products: the tumor suppressor 
protein p16 (a CDK4 inhibitor) and ARF (a stabilizer of p53) (figure 3).37 CDKN2B encodes 
for p15, another CDK4/6 inhibitor. Loss of nuclear immunostaining for p16 has been 
reported in three out of seven ACCs.38 The integration of data obtained by sequencing 
and CGH allowed us to discover that three of the five ATM mutated samples also had a 
CDKN2A deletion and one had CDK4 amplification suggesting a functional synergism 
between DNA damage checkpoints and G1 cell cycle progression pathways in the 
pathogenesis of ACC (figure 2 and 3).
Finally, by sequencing, we detected two mutations described as part of well-
characterized genetic disorders and hitherto never reported in adult ACC: mutations 
in GNAS and STK11 genes. Activating mutations in the GNAS gene have been described 
in sporadic ACTH-independent macronodular adrenal hyperplasia (AIMAH) and rarely 
in benign adrenal tumors. These mutations can cause the McCune Albright (MAS) syn-
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drome which is associated with AIMAH.39 A single case of ACC with a somatic mutation 
of GNAS was recently reported in a child unaffected by MAS. Mutations in the STK11 
tumor suppressor gene are associated with Peutz-Jegher’s Syndrome (PJS). A single case 
of ACC was recently reported in a child with PJS.40 We did not find signs or symptoms 
respectively suggestive of MAS or PJS in either of these patients nor in their family mem-
bers. We suspect that both of these mutations could play a role in ACC oncogenesis in 
the affected patients.
Our study suffers from several limitations: 35% of the patients had received previous 
medical treatment and we were unable to discriminate between germline and somatic 
mutations. In addition, we did not explore mRNA and protein expression and protein 
figure 3. Schematic representation of the G1 cell cycle progression pathway. Using CGH (28 samples) and 
hot spot gene sequencing (Ion Torrent;Life Technologies; 40 samples) in a large cohort of malignant adre-
nocortical cancer samples, we detected several abnormalities in this pathway. Oncogenes are represented 
in red frames; tumor suppressor genes are represented in green frames. The abnormalities detected are 
indicated as follows: amplified genes are represented with a red filling, deleted genes are represented with 
a green filling, and mutated genes are represented with a pink filling. Red arrows signify stimulation and 
green and black lines signify inhibition. Some cell processes are represented in blue (eg,apoptosis). The 
percentage of samples that exhibit an abnormality in a given gene is in the lower part of some boxes (in 
black). The percentage in green in the lower part of the TP53 box refers to a case of TP53 deletion. p14ARF 
is encoded by the same gene as p16. Two drugs (in black) potentially interfering with this pathway and cur-
rently being used in phase I clinical trials (www.clinicaltrials.gov).
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function. Finally, we used a sequencing system that detects many, but not all, mutations 
in the evaluated genes. However, we decided to focus on the selected genomic events 
that are already widely used in oncology as predictors of drug responses.
COnClusiOns
In conclusion, we identified 47.5% mutations or CGH alterations in a large series of ACC 
patients. To our knowledge, this is the first time that ATM, STK11 and GNAS mutations 
have been reported in adult ACC patients. No relevant molecular alteration suggests the 
likelihood of a simple molecular-driven targeted approach in ACC patients in the short 
term. However, our study predicts a potential future role for new compounds targeting 
DNA-damage responses, G1 cell cycle progression and the FGFR pathway.
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supplementary table 1
Supplementary table 1
Gens eveluated by Ion Torrent (hotspot gene sequencing) and            
Comparative Genomic Hybridization [CGH] (copy number alterations)
Sy
mb
Na
me
Ch
r
Cy
to
ba
nd
Ion
 To
rre
nt
 
CG
H
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 9 9q34.1 yes yes
AKT1 v-akt murine thymoma viral oncogene homolog 1 14 14q32.32 yes yes
AKT2 v-akt murine thymoma viral oncogene homolog 2 19 19q13.1-q13.2 no yes
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 1 1q44 no yes
ALK anaplastic lymphoma receptor tyrosine kinase 2 2p23 yes yes
APC adenomatous polyposis coli 5 5q21-q22 yes yes
ATM ataxia telangiectasia mutated 11 11q22-q23 yes yes
ATR ataxia telangiectasia and Rad3 related 3 3q23 no yes
BRAF v-raf murine sarcoma viral oncogene homolog B1 7 7q34 yes yes
BRCA1 breast cancer 1, early onset 17 17q21 no yes
BRCA2 breast cancer 2, early onset 13 13q12.3 no yes
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B 15 15q15 no yes
CCNA1 cyclin A1 13 13q12.3-q13 no yes
CCNA2 cyclin A2 4 4q27 no yes
CCNB1 cyclin B1 5 5q12 no yes
CCNB2 cyclin B2 15 15q22.2 no yes
CCNB3 cyclin B3 23 Xp11 no yes
CCND1 cyclin D1 11 11q13 no yes
CCND2 cyclin D2 12 12p13 no yes
CCND3 cyclin D3 6 6p21 no yes
CCNE1 cyclin E1 19 19q12 no yes
CCNH cyclin H 5 5q13.3-q14 no yes
CDC6 cell division cycle 6 17 17q21.3 no yes
CDC7 cell division cycle 7 1 1p22 no yes
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 16 16q22.1 yes yes
CDK1 cyclin-dependent kinase 1 10 10q21.1 no yes
CDK2 cyclin-dependent kinase 2 12 12q13 no yes
CDK4 cyclin-dependent kinase 4 12 12q14 no yes
CDK6 cyclin-dependent kinase 6 7 7q21-q22 no yes
CDK7 cyclin-dependent kinase 7 5 5q12.1 no yes
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 6 6p21.2 no yes
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) 12 12p13.1-p12 no yes
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 11 11p15.5 no yes
CDKN2A cyclin-dependent kinase inhibitor 2A 9 9p21 yes yes
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 9 9p21 no yes
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 1 1p32 no yes
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 19 19p13 no yes
CHEK1 checkpoint kinase 1 11 11q24.2 no yes
CHEK2 checkpoint kinase 2 22 22q12.1 no yes
CSF1R colony stimulating factor 1 receptor 5 5q32 yes yes
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 3 3p21 yes yes
E2F1 E2F transcription factor 1 20 20q11.2 no yes
EGFR epidermal growth factor receptor 7 7p12 yes yes
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 8 8p12 no yes
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)17 17q12 yes yes
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 2 2q33.3-q34 yes yes
ESR1 estrogen receptor 1 6 6q25.1 no yes
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 4 4q31.3 yes yes
FGF4 fibroblast growth factor 4 11 11q13.3 no yes
FGF9 fibroblast growth factor 9 (glia-activating factor) 13 13q11-q12 no yes
FGFR1 fibroblast growth factor receptor 1 8 8p12 yes yes
FGFR2 fibroblast growth factor receptor 2 10 10q26 yes yes
FGFR3 fibroblast growth factor receptor 3 4 4p16.3 yes yes
FGFR4 fibroblast growth factor receptor 4 5 5q35.1-qter no yes
FLT3 fms-related tyrosine kinase 3 13 13q12 yes yes
FRS2 fibroblast growth factor receptor substrate 2 12 12q15 no yes
GNAS GNAS complex locus 20 20q13.3 yes yes
GSK3B glycogen synthase kinase 3 beta 3 3q13.3 no yes
HDAC9 histone deacetylase 9 7 7p21.1 no yes
HNF1A HNF1 homeobox A 12 12q24.2 yes yes
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 11 11p15.5 yes yes
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 14 14q32.33 no yes
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 2 2q33.3 yes yes
IGF1 insulin-like growth factor 1 (somatomedin C) 12 12q23.2 no yes
IGF1R insulin-like growth factor 1 receptor 15 15q26.3 no yes
IGF2 insulin-like growth factor 2 (somatomedin A) 11 11p15.5 no yes
IGF2R insulin-like growth factor 2 receptor 6 6q26 no yes
IGFBP1 insulin-like growth factor binding protein 1 7 7p13-p12 no yes
IGFBP2 insulin-like growth factor binding protein 2, 36kDa 2 2q33-q34 no yes
IGFBP3 insulin-like growth factor binding protein 3 7 7p13-p12 no yes
IGFBP4 insulin-like growth factor binding protein 4 17 17q12-q21.1 no yes
IGFBP5 insulin-like growth factor binding protein 5 2 2q33-q36 no yes
IGFBP6 insulin-like growth factor binding protein 6 12 12q13 no yes
INS insulin 11 11p15.5 no yes
INSR insulin receptor 19 19p13.3-p13.2 no yes
IRS1 insulin receptor substrate 1 2 2q36 no yes
IRS2 insulin receptor substrate 2 13 13q34 no yes
IRS4 insulin receptor substrate 4 23 Xq22.3 no yes
JAK2 Janus kinase 2 9 9p24 yes yes
JAK3 Janus kinase 3 19 19p13.1 yes yes
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) 4 4q11-q12 yes yes
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4 4q11-q12 yes yes
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 12 12p12.1 yes yes
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase 5 5q11.2 no yes
MDM2 Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse) 12 12q14.3-q15 no yes
MDM4 Mdm4 p53 binding protein homolog (mouse) 1 1q32 no yes
MET met proto-oncogene (hepatocyte growth factor receptor) 7 7q31 yes yes
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 3 3p21.3 yes yes
MPL myeloproliferative leukemia virus oncogene 1 1p34 yes yes
MTOR mechanistic target of rapamycin (serine/threonine kinase) 1 1p36.2 no yes
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 8 8q24.21 no yes
NOTCH1 notch 1 9 9q34.3 yes yes
NOTCH4 notch 4 6 6p21.3 no yes
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) 5 5q35.1 yes yes
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 1 1p13.2 yes yes
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 11 11q13-q14 no yes
PDGFRA platelet-derived growth factor receptor, alpha polypeptide 4 4q12 yes yes
PDPK1 3-phosphoinositide dependent protein kinase-1 16 16p13.3 no yes
PGR progesterone receptor 11 11q22-q23 no yes
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 3 3q26.3 yes yes
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta 3 3q22.3 no yes
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 5 5q13.1 no yes
PLK1 polo-like kinase 1 16 16p12.2 no yes
PSMA2 proteasome (prosome, macropain) subunit, alpha type, 2 7 7p13 no yes
PSMA3 proteasome (prosome, macropain) subunit, alpha type, 3 14 14q23 no yes
PSMA4 proteasome (prosome, macropain) subunit, alpha type, 4 15 15q25.1 no yes
PSMA6 proteasome (prosome, macropain) subunit, alpha type, 6 14 14q13 no yes
PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 14 14q11.2 no yes
PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) 6 6p21.3 no yes
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) 6 6p21.3 no yes
PSMD5 proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 9 9q33.2 no yes
PSME3 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) 17 17q21 no yes
PTEN phosphatase and tensin homolog 10 10q23.3 yes yes
PTK2 protein tyrosine kinase 2 8 8q24.3 no yes
PTPN11 protein tyrosine phosphatase, non-receptor type 11 12 12q24 yes yes
RB1 retinoblastoma 1 13 13q14.2 yes yes
RET ret proto-oncogene 10 10q11.2 yes yes
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 17 17q23.1 no yes
RPTOR regulatory associated protein of MTOR, complex 1 17 17q25.3 no yes
SMAD4 SMAD family member 4 18 18q21.1 yes yes
SMARCB1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 22 22q11 yes yes
SMO smoothened, frizzled family receptor 7 7q32.3 yes yes
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 20 20q12-q13 yes yes
STK11 serine/threonine kinase 11 19 19p13.3 yes yes
TOP2A topoisomerase (DNA) II alpha 170kDa 17 17q21-q22 no yes
TP53 tumor protein p53 17 17p13.1 yes yes
TSC1 tuberous sclerosis 1 9 9q34 no yes
TSC2 tuberous sclerosis 2 16 16p13.3 no yes
VEGFA vascular endothelial growth factor A 6 6p12 no yes
VHL von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase 3 3p25.3 yes yes
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supplementary table 3: CGH results in 28 ACC samplesSupplementary table 3: CGH results in 28 ACC samples
Patiets 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Gene
ABL1 0,24 -0,36 0,00 0,31 0,00 0,62 0,10 0,00 0,49 0,50 0,00 0,10 0,00 0,41 0,00 0,08 -0,07 0,00 0,08 0,00 -0,25 1,07 0,42 0,33 -0,12 0,68 0,00 -0,26
AKT1 0,00 0,28 0,31 0,05 0,00 0,00 0,36 0,00 0,00 0,11 -0,08 0,00 0,00 0,00 0,00 0,06 0,08 0,00 0,00 0,00 -0,25 0,00 0,17 0,18 0,00 0,07 0,00 -0,29
AKT2 0,18 0,26 0,61 0,00 0,63 0,63 0,65 0,19 0,00 0,13 0,50 0,50 0,00 0,00 0,00 0,29 -0,58 0,00 0,08 0,00 0,35 0,58 0,00 -0,47 -0,73 0,00 0,24 0,34
AKT3 0,00 -0,41 0,00 0,33 0,00 0,35 0,41 0,00 0,00 0,18 0,00 0,00 0,42 0,41 0,00 0,00 0,06 0,00 0,00 0,00 -0,24 0,00 0,44 0,62 0,00 0,00 0,00 -0,38
ALK 0,00 -0,41 0,00 0,33 0,00 0,00 0,00 -0,17 0,00 0,20 0,25 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,67 -0,26 0,00 -0,48 0,41 0,00 0,29 0,06 -0,37
APC 0,54 0,31 0,00 0,00 0,67 0,44 0,61 0,12 0,00 0,47 0,00 0,44 0,00 0,28 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 -0,48 -0,73 -0,44 0,42 0,30
ATM -0,21 -0,44 0,00 0,00 0,00 0,00 -0,12 -0,19 0,00 0,15 0,00 0,00 0,00 0,00 0,00 0,00 -0,44 0,00 0,00 -0,67 -0,13 0,00 0,00 -0,48 0,00 -0,45 0,00 -0,40
ATR 0,00 -0,42 -0,38 -0,41 0,00 0,00 0,56 0,06 0,00 0,30 0,00 0,00 0,00 0,12 0,00 0,00 -0,50 0,00 0,00 0,00 0,00 0,15 0,13 0,00 -0,14 0,32 0,00 0,00
BRAF -0,20 0,00 0,00 0,00 0,67 0,53 0,64 0,15 0,00 0,36 0,00 0,78 0,00 0,00 0,00 0,15 0,12 0,00 0,47 0,00 0,41 0,40 0,12 0,00 0,00 0,31 0,40 0,23
BRCA1 0,00 -1,00 0,00 -0,40 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 -0,57 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 0,23 -0,06 -0,45 0,00 0,00
BRCA2 0,00 -0,43 0,00 -0,40 0,00 0,17 -0,46 -0,18 0,00 0,31 -0,34 0,47 0,00 0,00 0,00 0,00 -0,62 0,00 0,46 -0,67 0,00 0,14 0,00 -0,42 0,00 -0,41 0,00 -0,92
BUB1B 0,00 0,00 0,00 0,00 0,00 0,18 0,00 -0,18 0,80 -0,15 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,47 -0,67 -0,39 0,69 -0,46 0,00 0,00 -0,46 0,00 -0,37
CCNA1 0,00 -0,43 0,00 -0,40 0,00 0,17 -0,46 -0,18 0,00 0,31 -0,34 0,47 -0,64 0,00 0,00 0,00 -0,62 0,00 0,46 -0,67 0,00 0,14 -0,47 -0,42 0,00 -0,41 0,00 -0,92
CCNA2 -0,17 0,31 -0,37 -0,14 0,64 -0,23 -0,09 0,00 0,00 0,00 0,00 0,00 -0,66 0,00 0,00 0,00 -0,38 0,00 0,48 0,00 0,00 0,16 -0,17 0,34 0,00 -0,46 0,00 0,00
CCNB1 0,54 0,31 0,00 0,00 0,67 0,44 0,61 0,12 0,00 -0,15 0,00 0,44 0,00 0,00 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 -0,48 0,00 -0,21 0,18 0,30
CCNB2 0,00 0,00 0,00 0,00 0,00 0,18 0,00 -0,18 0,54 -0,15 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,47 -0,67 -0,39 0,69 -0,46 0,00 0,00 -0,46 0,00 -0,37
CCNB3 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
CCND1 -0,17 -0,41 0,00 0,00 0,00 0,00 0,05 -0,09 0,00 0,23 0,00 0,00 0,07 0,00 0,00 0,07 -0,44 0,00 0,00 -0,67 0,00 0,23 0,00 -0,46 -0,09 0,56 0,00 -0,25
CCND2 0,14 0,32 0,34 -0,38 0,71 0,40 -0,07 0,21 0,75 -0,18 0,36 0,00 0,00 -0,58 0,00 0,23 0,00 0,74 0,52 0,00 0,42 0,89 -0,48 -0,39 0,00 0,38 0,69 0,00
CCND3 0,43 -0,40 -0,37 0,00 0,00 0,00 0,05 0,15 0,00 0,74 0,31 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,24 0,97 0,00 0,00 0,00 0,37 0,23
CCNE1 0,10 0,26 0,61 0,00 0,63 0,63 0,65 0,19 0,00 0,00 0,49 0,41 0,00 0,00 0,00 0,29 0,00 0,00 0,48 0,00 0,35 0,58 0,00 -0,48 -0,18 0,00 0,40 0,34
CCNH 0,54 0,31 0,00 0,00 0,67 0,44 0,61 0,12 0,00 -0,15 0,00 0,44 0,00 0,00 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 -0,48 -0,73 -0,44 0,00 0,30
CDC6 0,00 -1,00 0,00 -0,40 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 -0,57 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 -0,51 -0,06 -0,45 0,00 0,00
CDC7 -0,19 -0,42 -0,38 0,15 0,00 0,00 0,00 -0,19 0,00 -0,14 -0,33 0,00 -0,64 -0,62 0,00 0,00 0,08 0,00 0,00 -0,71 -0,27 0,00 -0,48 -0,48 -0,73 0,00 0,00 -0,39
CDH1 0,16 0,00 0,00 0,00 0,63 -0,17 0,00 0,15 0,00 0,00 0,00 0,44 0,00 0,00 0,00 0,25 0,00 0,68 0,47 0,00 0,43 0,64 0,00 0,23 0,00 0,30 0,00 0,29
CDK1 0,00 0,32 0,30 0,28 0,08 0,18 0,33 0,00 -0,72 -0,16 0,00 0,44 0,00 0,00 0,00 0,23 0,11 0,00 0,48 0,00 0,00 0,25 -0,49 0,00 0,00 0,00 0,00 0,00
CDK2 0,28 0,29 0,34 0,00 0,66 0,44 0,44 0,14 0,37 0,07 0,41 0,00 0,00 0,25 0,00 0,23 0,10 0,70 0,44 0,00 0,42 0,68 0,21 0,00 -0,09 0,32 0,57 0,00
CDK4 0,28 0,29 0,34 0,00 1,53 0,68 0,44 0,87 2,31 1,01 0,73 1,39 0,00 0,25 0,00 0,22 0,10 0,71 1,14 0,00 0,42 0,68 0,22 0,00 0,00 0,32 0,71 0,00
CDK6 -0,20 0,31 0,00 0,00 0,67 0,53 0,64 0,16 0,00 0,34 0,00 0,79 0,00 0,00 0,00 0,13 0,15 0,00 0,48 0,00 0,41 0,28 0,12 0,00 0,00 0,32 0,42 0,23
CDK7 0,54 0,31 0,00 0,00 0,67 0,44 0,61 0,12 0,00 -0,15 0,00 0,44 0,00 0,00 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 -0,48 0,00 -0,21 0,18 0,30
CDKN1A 0,00 -0,40 -0,37 -0,39 0,00 0,00 0,05 0,15 0,00 1,04 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,69 0,00 0,00 0,43 0,00 0,00 0,00 0,37 0,00
CDKN1B 0,16 0,32 0,34 -0,39 0,66 0,38 -0,05 0,16 0,50 -0,11 0,42 0,00 0,00 -0,58 0,00 0,23 0,00 0,70 0,48 0,00 0,43 0,89 -0,91 -0,51 0,00 0,33 0,72 0,00
CDKN1C -0,20 -0,42 0,00 0,13 0,00 -0,08 0,00 0,00 0,95 -0,17 0,00 0,00 0,00 0,35 0,00 0,06 -0,45 0,00 0,14 -0,39 0,00 0,00 0,00 -0,47 -0,07 0,50 0,00 -0,40
CDKN2A 0,33 -0,42 -2,23 0,00 0,00 -0,53 0,19 -0,40 0,00 0,00 -1,59 0,00 0,00 -1,92 0,00 0,00 0,00 0,00 0,00 -0,60 -0,25 0,00 -0,45 -2,91 -0,73 0,63 0,00 -0,38
CDKN2B 0,33 -0,42 -2,23 0,00 0,00 -0,53 0,19 -0,40 0,00 0,00 0,00 0,00 0,00 -1,92 0,00 0,00 0,00 0,00 0,00 -0,60 -0,25 0,00 -0,45 -2,91 -0,73 0,63 0,00 -0,38
CDKN2C -0,19 -0,42 -0,38 0,37 0,00 0,00 0,00 -0,19 0,00 -0,20 -0,31 0,00 -0,65 -0,62 0,00 0,00 -0,42 0,00 0,00 -0,69 -0,23 0,00 -0,48 -0,59 -0,73 0,00 0,00 -0,38
CDKN2D 0,10 0,26 0,61 0,00 0,59 0,60 0,65 0,07 0,15 0,15 0,51 0,63 0,09 0,00 0,00 0,29 0,34 0,00 0,49 0,00 0,35 0,58 0,00 0,12 -0,16 0,00 0,17 0,34
CHEK1 -0,21 -0,38 0,00 0,00 0,00 0,00 -0,12 -0,17 0,00 0,07 -0,09 0,00 0,00 0,00 0,00 0,00 -0,44 0,00 0,00 -0,67 -0,13 0,00 0,00 -0,43 0,00 -0,45 0,00 -0,39
CHEK2 -0,19 -0,40 -0,38 -0,40 0,00 -0,18 0,00 -0,38 0,00 0,21 -0,28 0,00 -0,59 -0,58 0,00 0,00 -0,47 0,00 0,00 -0,64 -0,21 0,22 -0,85 -0,09 -0,08 -0,45 -0,56 -0,35
CSF1R 0,54 0,32 0,00 0,00 0,67 0,45 0,61 0,13 0,00 -0,18 0,00 0,44 0,00 0,25 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 -0,45 -0,73 -0,44 0,42 0,32
CTNNB1 0,00 -0,42 -0,38 -0,42 0,00 0,68 0,64 -0,10 0,00 0,21 0,00 0,44 0,00 0,60 0,00 0,00 -0,50 0,00 0,00 -0,68 0,00 0,29 0,33 0,00 -0,13 0,32 0,00 0,00
E2F1 0,71 -0,40 0,00 0,31 0,67 0,19 0,72 0,17 0,00 0,48 0,00 0,45 0,00 -0,59 0,00 0,22 0,00 0,71 0,00 -0,28 0,74 0,69 -0,07 0,00 -0,76 0,62 0,54 0,54
EGFR -0,20 0,81 0,00 0,00 0,67 0,37 0,64 0,16 0,00 0,30 0,00 0,79 0,00 0,00 0,00 0,00 0,11 0,00 0,48 0,00 0,41 0,27 0,12 0,00 0,00 0,32 0,42 0,23
EIF4EBP1 -0,18 -0,40 0,18 0,00 0,00 0,50 0,00 -0,18 0,00 0,54 0,07 0,43 0,00 0,00 0,00 0,00 0,17 0,00 0,00 0,00 0,75 1,17 -0,96 0,00 0,00 -0,41 0,00 0,30
ERBB2 0,00 -1,00 0,00 -0,40 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 -0,57 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 -0,51 -0,06 -0,45 0,00 0,00
ERBB4 0,00 -0,43 0,00 0,33 0,00 0,00 0,00 0,00 0,00 -0,14 0,27 0,00 0,00 0,42 0,00 0,00 0,00 0,00 0,00 -0,54 -0,26 0,00 0,22 0,00 0,00 0,31 0,00 -0,39
ESR1 0,18 -0,42 -0,37 0,00 0,00 -0,24 0,00 0,15 0,00 0,10 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,47 0,00 0,00 0,00 0,71 0,00
FBXW7 -0,17 0,31 -0,37 -0,14 0,64 -0,23 -0,09 0,00 0,00 0,00 0,00 0,00 -0,66 0,00 0,00 0,00 -0,38 0,00 0,48 0,00 0,00 0,16 0,15 0,34 0,00 -0,46 0,00 0,00
FGF4 -0,17 -0,41 0,00 0,00 0,00 0,00 0,05 -0,09 0,00 0,23 0,00 0,00 0,07 0,00 0,00 0,07 -0,44 0,00 0,00 -0,67 0,00 0,23 0,00 -0,46 -0,09 0,56 0,00 -0,25
FGF9 0,00 -0,40 0,00 -0,40 0,00 1,59 -0,46 -0,16 0,00 0,28 -0,30 0,47 0,00 0,00 0,00 0,00 -0,62 0,00 0,46 -0,67 0,00 0,14 -0,47 -0,42 0,00 -0,41 0,00 -0,87
FGFR1 -0,18 -0,40 0,18 0,00 0,00 0,50 0,00 -0,18 0,00 0,54 0,07 0,43 0,00 0,00 0,00 0,00 0,17 0,00 0,00 0,00 0,75 1,17 -0,96 0,00 0,00 -0,41 0,00 0,30
FGFR2 0,00 0,00 0,30 0,32 0,10 0,00 0,33 0,00 0,00 -0,17 0,00 0,44 0,00 0,00 0,00 0,23 -0,58 0,00 0,47 0,00 0,00 0,36 0,49 0,00 0,00 0,00 0,00 0,00
FGFR3 -0,13 -0,37 -0,44 0,00 0,69 0,00 -0,09 0,19 0,39 0,00 0,00 0,00 0,00 0,00 0,04 0,28 0,18 0,73 0,50 0,00 0,00 0,82 -0,15 -0,16 -0,08 0,00 0,00 0,00
FGFR4 0,54 0,32 0,00 0,00 0,66 0,45 0,50 0,16 0,82 -0,18 0,00 0,43 0,00 0,25 0,00 0,13 0,00 0,75 0,00 0,00 0,74 0,27 0,00 -0,45 -0,09 0,25 0,61 0,32
FLT3 0,00 -0,43 0,00 -0,40 0,00 1,32 -0,46 -0,18 0,00 0,28 -0,30 0,47 0,00 0,00 0,00 0,00 -0,62 0,00 0,46 -0,67 0,00 0,14 -0,47 -0,42 0,00 -0,41 0,00 -0,87
FRS2 0,28 0,31 0,34 0,00 0,67 0,45 0,44 0,16 1,70 0,00 0,41 0,00 0,00 0,25 0,00 0,22 0,10 0,71 0,48 0,00 0,42 0,68 0,22 0,00 0,00 0,32 0,71 0,00
GNAS 0,71 -0,39 -0,06 0,30 0,67 0,12 0,72 0,17 0,00 0,21 0,00 0,45 0,00 0,00 0,00 0,22 0,00 0,71 0,51 -0,28 0,74 0,69 -0,07 0,00 -0,71 0,62 0,73 0,54
GSK3B 0,00 -0,42 -0,38 -0,41 0,00 0,00 0,57 0,07 0,00 0,30 0,00 0,00 0,00 -0,42 0,00 0,00 -0,49 0,00 0,00 0,00 0,00 0,15 0,13 0,00 -0,14 0,32 0,00 0,00
HDAC9 -0,20 0,33 0,00 0,00 0,67 0,37 0,42 0,16 0,00 0,00 0,00 0,79 0,00 0,00 0,00 0,14 0,00 0,00 0,48 0,00 0,41 0,27 0,15 0,00 0,00 0,32 0,42 0,23
HNF1A 0,22 0,00 0,34 0,00 0,65 0,00 0,44 0,16 0,00 0,07 0,40 0,00 0,00 0,25 0,00 0,25 0,00 0,71 0,46 0,00 0,42 0,68 0,22 0,00 -0,08 0,32 0,51 0,00
HRAS -0,20 -0,32 0,09 0,13 0,00 -0,08 0,07 0,00 0,95 -0,17 0,00 0,00 0,00 0,00 0,12 0,21 -0,45 0,00 0,14 -0,39 0,11 0,09 0,00 -0,47 -0,07 0,50 0,00 -0,19
HSP90AA1 0,00 0,28 0,31 0,05 0,00 0,00 0,36 0,00 0,00 0,28 0,06 0,00 0,00 0,00 0,00 0,06 0,08 0,00 0,00 0,00 -0,25 0,00 0,17 0,18 0,00 0,07 0,00 -0,29
IDH1 0,00 -0,43 0,00 0,33 0,00 0,00 0,00 0,00 0,00 -0,14 0,27 0,00 0,00 0,42 0,00 0,00 0,00 0,00 0,00 -0,54 -0,26 0,00 0,22 0,00 0,00 0,31 0,00 -0,39
IGF1 0,28 0,00 0,34 0,00 0,67 0,00 0,44 0,16 0,00 0,00 0,41 0,00 0,00 0,25 0,00 0,22 0,10 0,71 0,48 0,00 0,42 0,68 0,22 0,00 0,00 0,32 0,71 0,00
IGF1R 0,00 -0,38 0,00 0,00 0,00 0,17 0,00 -0,18 0,11 -0,18 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,47 -0,61 -0,39 0,69 0,20 0,00 0,00 -0,45 0,00 -0,38
IGF2 -0,20 -0,42 0,00 0,13 0,00 -0,08 0,07 0,00 0,95 -0,17 0,00 0,00 0,00 0,00 0,00 0,06 -0,45 0,00 0,14 -0,39 0,00 0,09 0,00 -0,47 -0,07 0,50 0,00 -0,19
IGF2R 0,18 -0,42 -0,37 0,00 0,00 -0,24 0,00 0,15 0,00 0,10 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,47 0,00 0,00 0,00 0,71 0,00
IGFBP1 -0,20 0,81 0,00 0,00 0,67 0,37 0,64 0,16 0,00 0,00 0,00 0,79 0,00 0,00 0,00 0,13 0,11 0,00 0,48 0,00 0,41 0,27 0,12 0,00 0,00 0,32 0,42 0,23
IGFBP2 0,00 -0,40 0,00 0,33 0,00 0,00 0,00 0,00 0,00 -0,14 0,27 0,00 0,00 0,42 0,00 0,00 0,00 0,00 0,00 -0,54 -0,26 0,00 0,22 0,00 0,00 0,31 0,00 -0,34
IGFBP3 -0,20 0,81 0,00 0,00 0,67 0,37 0,64 0,16 0,00 0,00 0,00 0,79 0,00 0,00 0,00 0,13 0,11 0,00 0,48 0,00 0,41 0,27 0,12 0,00 0,00 0,32 0,42 0,23
IGFBP4 0,00 -1,00 0,00 -0,40 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 -0,57 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 0,23 -0,06 -0,45 0,00 0,00
IGFBP5 0,00 -0,40 0,00 0,33 0,00 0,00 0,00 0,00 0,00 -0,14 0,27 0,00 0,00 0,42 0,00 0,00 0,00 0,00 0,00 -0,54 -0,26 0,00 0,22 0,00 0,00 0,31 0,00 -0,34
IGFBP6 0,28 0,29 0,34 0,00 0,66 0,44 0,44 0,14 0,79 0,07 0,41 0,00 0,00 0,25 0,00 0,23 0,10 0,70 0,44 0,00 0,42 0,68 0,21 0,00 -0,09 0,32 0,57 0,00
INS -0,20 -0,42 0,00 0,13 0,00 -0,08 0,07 0,00 0,95 -0,17 0,00 0,00 0,00 0,00 0,00 0,06 -0,45 0,00 0,14 -0,39 0,00 0,09 0,00 -0,47 -0,07 0,50 0,00 -0,19
INSR 0,10 0,26 0,61 0,00 0,59 0,35 0,65 0,07 0,15 0,15 0,51 0,63 0,09 0,00 0,00 0,29 0,34 0,00 0,49 0,00 0,35 0,58 0,00 0,12 -0,16 0,65 0,17 0,34
IRS1 0,00 -0,40 0,00 0,33 0,00 0,00 0,00 0,00 0,00 -0,14 0,27 0,00 0,00 0,42 0,00 0,00 0,00 0,00 0,00 -0,54 -0,26 0,00 0,22 0,00 0,00 0,31 0,00 -0,38
IRS2 0,00 -0,37 0,00 -0,40 0,00 0,15 -0,50 -0,18 -0,69 0,29 -0,34 0,47 0,00 0,00 0,00 0,00 0,19 0,00 0,46 -0,67 0,00 0,14 0,46 0,38 0,00 -0,41 0,00 -0,94
IRS4 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
JAK2 0,33 -0,42 0,00 0,00 0,00 -0,53 0,19 0,00 0,46 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 0,00 0,00 -0,60 -0,25 0,00 -0,45 -0,48 0,00 0,63 0,00 -0,38
JAK3 0,10 0,26 0,61 0,00 0,59 0,60 0,65 0,07 0,15 0,15 0,51 0,41 0,09 0,00 0,00 0,29 0,34 0,00 0,49 0,00 0,35 0,58 0,00 0,12 -0,16 0,00 0,17 0,34
KDR -0,17 -0,42 -0,37 -0,14 0,64 0,00 -0,09 0,00 0,00 0,00 0,00 0,00 -0,66 0,00 0,00 0,00 -0,38 0,00 0,48 0,00 0,00 0,66 -0,17 0,34 0,00 -0,46 0,00 0,00
KIT -0,17 -0,42 -0,37 -0,14 0,64 0,00 -0,09 0,00 0,00 0,00 0,00 0,00 -0,66 0,00 0,00 0,00 -0,38 0,00 0,48 0,00 0,00 0,66 -0,17 0,34 0,00 -0,46 0,00 0,00
KRAS 0,16 0,32 0,34 -0,39 0,66 0,38 -0,05 0,16 -0,71 -0,11 0,42 0,00 0,00 -0,64 0,00 0,23 0,00 0,70 0,48 0,00 0,42 0,68 0,63 0,00 0,00 0,33 0,72 0,00
MAP3K1 0,54 0,31 0,00 0,00 0,67 0,44 0,61 0,12 0,00 -0,15 0,00 0,44 0,00 0,00 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 0,00 0,00 -0,18 0,71 0,30
MDM2 0,28 0,31 0,34 0,00 0,67 0,45 0,44 0,16 2,54 0,00 0,41 0,00 0,00 0,25 0,00 0,22 0,10 0,71 0,48 0,00 0,42 0,68 0,22 0,00 0,00 0,32 0,71 0,00
MDM4 0,00 -0,41 0,00 0,32 0,00 0,35 0,41 0,00 0,00 0,24 0,00 0,00 0,42 0,41 0,00 0,00 0,06 0,00 0,00 0,00 -0,24 0,00 0,67 0,62 0,00 0,00 0,00 -0,38
MET -0,20 -0,05 0,00 0,00 0,67 0,53 0,64 0,15 0,00 0,32 0,00 0,78 0,00 0,00 0,00 0,10 0,14 0,00 0,47 0,00 0,41 0,28 0,12 0,00 0,00 0,31 0,40 0,23
MLH1 0,00 -0,42 -0,38 -0,42 0,00 0,68 0,64 -0,10 0,45 0,21 0,00 0,44 0,00 0,60 0,00 0,00 -0,50 0,00 0,00 -0,68 0,00 0,29 0,33 0,00 -0,13 0,32 0,00 0,00
MPL -0,20 -0,42 -0,38 0,14 0,00 0,00 0,00 -0,15 0,00 -0,10 -0,12 0,00 -0,56 -0,62 0,00 0,00 -0,42 0,00 0,00 -0,69 -0,23 0,00 -0,48 -0,50 -0,73 0,00 0,00 -0,31
MTOR -0,20 -0,42 -0,38 -0,40 0,00 0,00 0,00 -0,15 0,00 -0,10 0,00 0,00 -0,56 -0,62 0,00 0,06 -0,38 0,00 0,00 -0,63 -0,23 0,00 -0,48 -0,50 -0,73 0,00 -0,08 -0,31
MYC -0,18 -0,42 0,18 0,00 0,00 0,94 0,00 -0,18 0,00 0,24 0,07 0,44 0,00 0,00 0,00 0,00 0,17 0,00 0,00 0,00 0,75 1,17 0,00 0,00 0,00 -0,37 0,00 0,29
NOTCH1 0,24 -0,36 0,00 0,00 -0,11 0,62 0,10 0,00 0,17 0,31 -0,11 0,00 0,00 0,00 0,05 0,08 0,00 0,00 0,08 0,00 -0,22 0,68 0,42 0,33 -0,12 0,68 0,00 -0,26
NOTCH4 0,00 -0,40 -0,33 -0,39 0,00 0,00 0,00 0,15 0,00 0,25 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,22 0,00 0,00 0,00 0,37 0,00
NPM1 0,54 0,32 0,00 0,00 0,66 0,45 0,61 0,13 0,82 -0,18 0,00 0,43 0,00 0,25 0,00 0,13 0,00 0,75 0,00 0,00 0,74 0,27 0,00 -0,45 0,00 -0,44 0,61 0,32
NRAS -0,19 -0,42 -0,37 0,00 0,00 0,00 0,00 -0,18 0,00 -0,14 -0,32 0,00 -0,61 -0,57 0,00 0,00 0,07 0,00 0,00 -0,67 -0,25 0,00 -0,48 -0,43 -0,73 0,00 0,00 -0,36
PAK1 -0,17 -0,41 0,00 0,00 0,00 0,00 0,00 -0,15 0,00 0,23 0,00 0,00 0,00 0,00 0,00 0,00 -0,44 0,00 0,00 -0,67 0,00 0,00 0,00 -0,48 -0,09 0,56 0,00 -0,34
PDGFRA -0,17 -0,42 -0,37 -0,14 0,64 0,00 -0,09 0,00 0,00 0,00 0,00 0,00 -0,66 0,00 0,00 0,00 -0,38 0,00 0,48 0,00 0,00 0,66 -0,17 0,34 0,00 -0,46 0,00 0,00
PDPK1 0,16 -0,38 0,00 0,11 0,63 0,36 0,00 0,21 0,00 0,28 0,07 0,60 0,12 0,00 0,07 0,25 0,00 0,68 0,49 0,00 0,29 0,64 -0,09 -0,12 -0,14 0,43 0,00 0,29
PGR -0,21 -0,44 0,00 0,00 0,00 0,00 -0,12 -0,19 0,00 0,15 0,00 0,00 0,00 0,00 0,00 0,00 -0,44 0,00 0,00 -0,67 0,00 0,00 0,00 -0,48 0,00 -0,45 0,00 -0,40
PIK3CA 0,00 -0,42 -0,38 -0,41 0,00 0,00 0,56 0,06 0,00 0,13 0,00 0,00 0,00 -0,63 0,00 0,00 -0,53 0,00 0,00 0,00 0,00 0,00 -0,10 0,00 -0,15 0,32 0,00 0,00
PIK3CB 0,00 -0,42 -0,38 -0,41 0,00 0,00 0,57 0,06 0,00 0,30 0,00 0,00 0,00 0,82 0,00 0,00 -0,50 0,00 0,00 0,00 0,00 0,15 0,13 0,00 -0,14 0,32 0,00 0,00
PIK3R1 0,54 0,31 0,00 0,00 0,67 0,44 0,61 0,12 0,00 -0,15 0,00 0,44 0,00 0,00 0,00 0,13 0,00 0,75 0,48 0,00 0,74 0,41 0,00 -0,48 0,00 -0,21 0,43 0,30
PLK1 0,16 -0,38 0,00 0,00 0,63 0,36 0,00 0,15 0,00 0,18 0,00 0,44 0,00 0,00 0,00 0,25 0,00 0,68 0,47 0,00 0,00 0,64 -0,16 -0,12 0,00 0,30 0,00 0,29
PSMA2 -0,20 0,81 0,00 0,00 0,67 0,37 0,64 0,16 0,00 0,00 0,00 0,79 0,00 0,00 0,00 0,13 0,12 0,00 0,48 0,00 0,41 0,27 0,12 0,00 0,00 0,32 0,42 0,23
PSMA3 0,00 0,31 0,34 0,00 0,00 0,00 0,36 -0,16 0,00 0,16 0,00 0,00 0,00 0,00 0,00 0,00 0,22 0,00 0,00 0,00 -0,25 0,00 0,10 0,32 0,00 0,00 0,00 -0,38
PSMA4 0,00 0,00 0,00 0,00 0,00 0,18 0,00 -0,18 0,78 -0,18 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,47 -0,67 -0,39 0,69 0,20 0,00 0,00 -0,45 0,00 -0,38
PSMA6 0,00 0,31 0,34 0,00 0,00 0,00 0,36 -0,16 0,00 0,16 0,00 0,00 0,00 0,00 0,00 0,00 0,22 0,00 0,00 0,00 -0,25 0,00 0,10 0,32 0,00 0,00 0,00 -0,38
PSMB5 0,00 0,31 0,46 0,00 0,00 0,41 0,36 -0,16 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,36 0,00 0,00 0,00 -0,25 0,00 0,00 0,32 0,00 0,00 0,00 -0,38
PSMB8 0,00 -0,40 -0,37 -0,39 0,00 0,00 0,05 0,15 0,00 0,25 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,69 0,00 0,00 0,43 0,00 0,00 0,00 0,37 0,00
PSMB9 0,00 -0,40 -0,37 -0,39 0,00 0,00 0,05 0,15 0,00 0,25 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 -0,69 0,00 0,00 0,43 0,00 0,00 0,00 0,37 0,00
PSMD5 0,16 -0,39 0,00 0,31 0,00 0,53 0,08 0,00 0,41 0,39 0,00 0,00 0,00 0,41 0,00 0,00 0,00 0,00 0,00 0,00 -0,25 0,71 0,11 0,33 0,00 0,63 0,00 -0,37
PSME3 0,00 -1,00 0,00 -0,40 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 -0,57 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 0,23 -0,06 -0,45 0,00 0,00
PTEN 0,00 0,00 0,30 0,57 0,10 0,19 0,33 0,00 -0,69 -0,17 0,00 0,44 0,00 0,00 0,00 0,23 -0,58 0,00 0,47 0,00 0,00 0,25 -0,49 0,00 0,00 0,00 0,00 0,00
PTK2 -0,18 -0,40 0,18 0,00 0,00 -0,19 0,00 -0,09 -0,65 0,40 -0,10 0,44 0,00 0,00 0,00 0,00 0,12 0,00 0,00 0,00 0,75 1,17 0,00 0,00 -0,11 -0,37 0,00 0,29
PTPN11 0,22 0,00 0,34 0,00 0,65 0,00 0,44 0,16 0,00 0,07 0,40 0,00 0,00 0,25 0,00 0,25 0,00 0,71 0,46 0,00 0,42 0,68 0,22 0,00 -0,08 0,32 0,57 0,00
RB1 0,00 -0,43 0,00 -0,40 0,00 0,18 -0,46 -0,18 0,00 0,29 -0,34 0,47 -0,63 0,00 0,00 0,00 0,00 0,00 0,46 -0,67 0,00 0,14 -0,47 -0,42 0,00 -0,41 0,00 -0,87
RET 0,00 0,32 0,30 0,32 0,08 0,31 0,33 0,00 -0,75 -0,16 0,17 0,44 0,00 0,00 0,00 0,23 0,11 0,00 0,46 0,00 0,00 0,25 0,00 0,00 0,00 0,00 0,00 0,00
RPS6KB1 0,00 -0,42 0,00 0,00 0,00 0,00 0,00 0,00 0,38 0,37 0,00 0,00 -0,64 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 0,23 0,00 0,29 0,00 0,00
RPTOR 0,15 -0,36 0,00 0,00 0,00 0,32 0,61 0,08 0,40 0,37 0,00 0,09 -0,41 0,00 0,05 0,09 -0,47 0,00 0,10 -0,69 0,00 0,00 -0,51 1,22 -0,13 0,39 0,00 0,07
SMAD4 -0,42 -0,41 -0,39 0,00 0,00 0,23 0,00 -0,18 -0,69 0,15 0,14 0,00 0,00 -0,54 0,00 0,00 0,07 0,00 0,00 -0,66 -0,59 0,18 -0,43 0,37 0,00 -0,42 0,00 -0,92
SMARCB1 -0,11 -0,40 -0,38 -0,37 0,00 -0,18 0,00 -0,30 0,00 0,21 -0,28 0,00 -0,48 0,25 0,00 0,07 -0,47 0,00 0,00 -0,64 -0,21 0,00 -0,50 -0,09 -0,11 -0,38 -0,56 -0,29
SMO -0,20 0,00 0,00 0,00 0,67 0,53 0,64 0,15 0,00 0,36 0,00 0,78 0,00 0,00 0,00 0,15 0,12 0,00 0,47 0,00 0,41 0,40 0,12 0,00 0,00 0,31 0,40 0,23
SRC 0,71 -0,39 0,00 0,30 0,67 0,19 0,72 0,17 0,00 0,48 0,00 0,45 0,00 -0,59 0,00 0,00 0,00 0,71 0,00 -0,28 0,74 0,69 -0,07 0,00 -0,76 0,62 0,54 0,54
STK11 0,10 0,40 0,61 0,00 0,59 0,35 0,65 0,07 0,15 0,15 0,51 0,52 0,09 0,00 0,00 0,29 0,34 0,00 0,49 0,00 0,00 0,58 0,00 0,12 -0,16 0,15 0,17 0,34
TOP2A 0,00 -1,00 0,00 -0,40 0,00 0,00 0,00 0,00 -0,67 0,00 0,00 0,00 -0,57 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,51 -0,51 -0,06 -0,45 0,00 0,00
TP53 -0,20 -0,41 0,00 -0,40 0,00 0,00 0,00 -0,14 -0,53 0,34 0,00 -1,58 0,00 0,00 0,00 0,00 -0,47 0,00 0,00 -0,69 0,00 0,00 -0,50 0,25 -0,12 -0,42 0,00 0,00
TSC1 0,24 -0,36 0,00 0,31 0,00 0,62 0,10 0,00 0,49 0,50 0,00 0,10 0,00 0,00 0,05 0,08 -0,07 0,00 0,08 0,00 -0,22 1,07 0,42 0,33 -0,12 0,68 0,00 -0,26
TSC2 0,16 -0,38 0,00 0,11 0,63 0,36 0,00 0,21 0,00 0,28 0,07 0,60 0,12 0,00 0,07 0,25 0,00 0,68 0,49 0,00 0,29 0,64 -0,09 -0,12 -0,14 0,43 0,00 0,29
VEGFA 0,17 -0,40 -0,37 0,00 0,00 0,00 0,05 0,15 0,00 0,56 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,97 0,00 0,00 0,00 0,37 0,00
VHL 0,00 -0,42 -0,38 -0,42 0,00 0,68 0,64 -0,10 0,00 0,28 0,00 0,44 0,00 0,00 0,00 0,00 -0,50 0,00 0,00 -0,68 0,00 0,29 -0,45 0,00 -0,13 0,32 0,00 0,00
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AbsTRACT
Context. Dysregulation of the IGF and mTOR pathways have been suggested to be in-
volved in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, as sirolimus 
and everolimus, as well as IGF1-Receptor [IGF1-R] antagonists, such as OSI-906 could be 
a novel treatment option for malignant PCC.
Objective. To evaluate the expression of the main components of the IGF/mTOR path-
way in human PCC and to investigate the effects of sirolimus, everolimus and OSI-906 
(IGF1-R/Insulin receptor [IR] blocker), alone and in combination, in a rat PCC cell model.
Design and Methods. mRNA expression of IGF1, IGF2, IGF1-R, IR subtypes A and B, 
IGF2R, IGF-Binding-Proteins 1, 2, 3 and 6, mTOR, 4EBP1 and S6K1 was evaluated in 24 
human PCC by quantitative-PCR. In PC12 cells, the effect of mTOR inhibitors and OSI-906 
on cell growth and apoptosis were tested by measurement of total DNA-content and 
DNA-fragmentation, respectively.
Results. All investigated components were expressed in human PCC. A high expression 
of IGF2 mRNA and an increased IRA/IRB ratio was found. mTOR inhibitors and OSI-906 
were able to suppress PC12 proliferation in a dose and time-dependent manner. After 
a 6 days, maximal inhibitory effects of sirolimus, everolimus and OSI-906 on PC12 cell 
proliferation were 52%, 43%, and 69% respectively. OSI-906 strongly stimulated cell 
apoptosis. Combined treatment of sirolimus with OSI-906 had additive antiproliferative 
effects.
Conclusion. The results of the current study suggest the use of OSI-906, alone or in com-
bination with mTOR inhibitors, as a new treatment option in progressive PCCs patients.
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inTRODuCTiOn
Pheochromocytomas (PCCs) and paragangliomas PGLs are rare neuronal crest- derived 
neuroendocrine tumors arising from the adrenal medulla or the extra-adrenal para-
ganglia.1, 2 During the last 20 years important progress has been made in discovering 
genetic alterations that can lead to development of PCCs and PGLs in the context of 
familial syndromes and in some sporadic cases.1, 2 Malignant PCCs are rare and can be 
defined only based on the presence of metastatic disease.1 Conversely, scant progress 
has been made in treating patients with malignant PCCs. In progressive PCCs, treatment 
with meta-iodobenzylguanidine (131I-MIBG) or certain types of systemic chemotherapy 
are used, but a low rate of response and frequent recurrences underline the need of new 
treatment approaches.1, 3
The mammalian target of rapamycin (mTOR) is a protein kinase of the PI3Ks/AKT sig-
naling pathway that mediates the pro-growth effects of several growth factors including 
insulin and insulin-like growth factors (IGFs).4, 5 Dysregulation of the mTOR pathway 
has been found in many human tumors, including neuroendocrine tumors (NETs).4-6 
Recently, everolimus, an mTOR inhibitor has been approved for the treatment of pancre-
atic NETs.6 PCCs and pancreatic NETs share some common pathogenic molecular events 
(NF1 and VHL mutations), therefore mTOR inhibitors have been suggested as a potential 
new treatment modality for progressive metastatic PCCs.7, 8
The insulin/IGF system plays a pivotal role in the regulation of growth, lifespan and 
metabolism. This system is composed of circulating ligands, i.e. insulin IGF1 and IGF2 
(IGFs); circulating and tissue binding proteins (BP1-6 that modulate the bioavailability 
of IGFs) and multiple receptors.9 The circulating ligands can exert their effects as endo-
crine and/or paracrine factors. Among the receptors, the IGF1 receptor (IGF1R) and the 
insulin receptor isoforms A and B (IR-A and IR-B) are tyrosine-kinase receptors. The IGF2 
receptor (IGF2R) is a scavenger receptor involved in the internalization and degradation 
of IGF2. In adult humans, insulin predominantly exerts metabolic effects through the 
activation of IRB and IGFs. Particularly IGF1, mainly exerts pro-growth effects through 
the activation of IGF1R receptors. IGF2 and IRA are predominantly expressed during 
fetal development, while their expression in cancer tissues could contribute to cancer 
growth. Currently, the efficacy of several IGF1R and IGF1R/IR antagonists is evaluated 
in clinical trials alone or in combination with other agents for the treatment of several 
malignant disorders.10, 11 IGF1R, IR and IGF2 are expressed in PCCs and IGF1R seems to be 
overexpressed in PCCs compared with normal adrenals.12-14 Therefore, insulin and IGFs 
could be part of autocrine/paracrine loops and play a role in the pathogenesis of PCCs/
PGL. To the best of our knowledge the expression of IRA in human PCCs and the effects 
of an IGF1R/IR antagonist alone or in combination with mTOR inhibitors in preclinical 
models of PCCs/PGL have not been described to date.
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The aim of this study was to describe the mRNA expression of the main components 
of the IGF/mTOR pathways in human PCC and to evaluate the in vitro effects of mTOR 
inhibitors (sirolimus end everolimus) and the IGF1R/IR antagonist OSI-906 on cell prolif-
eration and apoptosis in the PC12 rat pheochromocytoma cell line.
MATeRiAls AnD MeThODs
Subject
Twenty-four human PCCs (including one paraganglioma) samples were collected at the 
Erasmus Medical Center, Rotterdam (The Netherlands), between 2001 and 2009.
The following clinical parameters were recorded: date of diagnosis, age, gender, pres-
ence of hormonal hyper-secretion, genetic cause, tumor size, origin of samples, local 
invasion (vaso-, capsule- and periadrenal fat-invasion), presence of metastatic disease 
(local lymph nodes, distant metastases) at sampling time, and systemic antineoplastic 
treatment or radiotherapy before tumor collection.
According to the current World Health Organization (WHO) classification, malignant 
PCCs were defined by the presence of metastases to a site where pheochromocytoma/
paraganglionic tissue is not normally present. Genetic tests for genes predisposing to 
a genetic syndrome associated with PCCs were performed only in patients with clinical 
suspicion of genetic syndromes, according with local clinical practice at time of clinical 
diagnosis. Clinical data were obtained from medical records. This study was approved by 
the Medical Ethics Committee of the Erasmus Medical Center.
Total RNA isolation
From snap frozen PCC tissues, total-RNA was isolated using a commercially available kit 
(High Pure RNA Tissue kit; Roche, Almere, The Netherlands). The cDNA synthesis from 
total-RNA and quantitative PCR were performed as previously described.15
Quantitative RT-PCR
In all selected samples we evaluated the mRNA expression of: IGF1, IGF2, IGF1-Receptor 
[IGF-R], Insulin-Receptor[IR]A, IRB, IGF2R, IGF-Binding-Proteins [BP] 1, 2, 3 and 6, mTOR, 
4EBP1, S6K1 and of the housekeeping gene hypoxanthine phosphoribosyltransferase 
(HPRT) by quantitative RT-PCR.
The primers and probes were purchased from Sigma-Aldrich (Zwijndrecht, The Neth-
erlands). The sequence of the primers and probes used are reported in the supplemental 
material-table  1. Samples were normalized to the expression of HPRT as previously 
reported.15
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Drugs and reagents
Sirolimus, everolimus and OSI-906 were purchased by LC Laboratories (Inc. Woburn, MA, 
USA) and prepared as a 10-3M stock solution in dimethylsulfoxide (DMSO). Compounds 
were stored at -20°C and further diluted in 40% DMSO before the use. Final DMSO con-
centration, also added as vehicle to controls, was 0.4%.
Cell lines and culture conditions
The rat pheochromocytomas cell line PC12 cell line were an obtained from from Clon-
tech and grown as specified by the manufacturer.
The cells were cultured in 75-cm2 culture flasks at 37°C in a humidified incubator at 5% 
CO2. The culture medium consisted of DMEM medium, supplemented with 10% horse 
serum, 5% fetal calf serum (FCS), penicillin (1x105 U/liter), and streptomycin (100 mg/L). 
Cells were harvested with trypsin (0.05%)-EDTA (0.53 mM) and resuspended in culture 
medium. Cell viability always exceeded 95%. Media and supplements were obtained 
from Invitrogen (Breda, The Netherlands).
Measurement of total DNA content assay
Measurement of total DNA content assay was used to determine the effects of the com-
pounds on cell proliferation. Cells were plated in 1 ml of medium in 24-well plates at the 
density necessary to obtain a 65-70% cell confluence in the control groups at the end 
of the experiment. Twenty-four hours later compounds were added to wells in quadru-
plicate. The concentrations of sirolimus and everolimus tested in PC12 ranged between 
10-12M and 10-6M. The concentrations of OSI-906 tested in PC12 ranged between 10-9M 
and 10-5M. In combination experiments the concentration of compounds tested were 
selected according on 6 days-cell proliferation experiments. For a 6 day incubation 
experiment, medium was refreshed at day 3 with fresh compounds added. After 3 and 6 
days of treatment, the cells were harvested for DNA measurement, as a measure of cell 
number. Measurement of total DNA content was previously described in detail.16
DNA fragmentation assay
DNA fragmentation assay was used to determine the effects of the compounds on 
apoptosis. The cells were plated in 24-well plates and treated as above described for 
the cell proliferation assay. After 24 hours and 3 days of incubation, DNA fragmenta-
tion was determined using a commercially available ELISA kit (Roche Diagnostic GmbH, 
Penzberg, Germany). The standard protocol supplied by the manufacturer was used. The 
same plates were also analyzed for the measurement of total DNA content. The amount 
of DNA-fragmentation (apoptosis) was corrected for the total DNA content in each well.
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Statistical analysis
For the statistical analysis statistical software of SPSS (SPSS 15.0; SPSS Inc., Chicago,IL) 
and GrafPad Prism 3.0 (GraphPhad Software, San Diego, CA) was used.
Non-parametric tests were used to evaluate the differences among groups (Mann-
Whitney test and Kruskall-Wallis test for comparison among two or more groups, respec-
tively). The Spearman’s rank coefficient was used to test correlation.
The comparative statistical evaluations among treatment groups were performed by 
ANOVA, followed by a multiple comparative test (Newman-Keuls).
ResulTs
Study population
The IGF and mTOR pathway components were examined in tumor tissue obtained from 
24 adult PCC patients. The main clinical characteristics of these patients are reported in 
table 1. Three patients with PCC had metastatic disease, 20 had benign PCC and 1 had a 
benign paraganglioma. Among benign PCC only two had some unfavourable features 
(local invasion) at pathology. Four patients had multiple endocrine neoplasia type II 
(MEN2A), 2 patients had Von Hippel Lindau disease (VHL) and 2 patients had neurofibro-
matosis type 1 (NF1). Following the cluster definition as described by Dahia P.M.L. et al.17 
and based on the available genetic information, our study population could be divided 
in three groups: sporadic/genetic-unknown-background; cluster 1 (including the 2 VHL 
patients) and cluster 2 (including the 4 patients with MEN2A and 2 with NF1) (table 1).
mRNA expression of IGF and mTOR pathway components in human 
pheochromocytoma tissue
Figure 1 shows the mRNA levels of IGF1, IGF2, IGF1-Receptor [IGF1-R], Insulin-Receptor[IR]
A, IRB, IGF2R, IGF-Binding-Proteins [BP] 1, 2, 3 and 6, mTOR, 4EBP1 and p70S6K1 (S6K1) 
as assessed by quantitative RT-PCR in the full study population. The examined IGF and 
mTOR components were expressed in all examined PCC tissue samples, but in particular 
a high expression of IGF2 mRNA was found. Indeed, mean IGF2 expression levels, nor-
malized to HPRT, were about 80 to 30000 fold higher than the mean expression levels 
of any of the other evaluated components, normalized to HPRT. The majority of samples 
presented higher mRNA levels of IRA than IRB (0,109±0.016 vs 0.047±0,019; p=0.0097). 
Indeed IRA/IRB ratio was equal or higher than 1 in all samples but three. Among these last 
three samples both VHL samples were included. Median mRNA levels of IRA were similar to 
IGF1R (0.078±0,010; p=0.15), but significantly higher than IGF2R (0.035±0,005; p<0.0001). 
Overall, positive correlations were found between the mRNA levels of components of the 
IGF pathway with those of mTOR pathway components (table 2). In particular, the mRNA 
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figure 1. mRNA levels expression of the main component of the IGFs and mTOR pathways in a cohort of 24 
human pheochromocytomas (expressed as relative mRNA expression as normalized to the house-keeping 
gene HPRT).
Table 2. Main correlation observed between the components of the IGF and mTOR pathways
Corelation 
with
Coefficient P value
mTOR S6K1 ,803** ,000
IGF-IR ,451* ,027
IR-A ,746** ,000
IR-B ,643** ,001
IGF-IIR ,850** ,000
BP-1 ,475* ,019
BP-3 ,464* ,022
4EBP1 IGF-I ,423* ,039
IGF-II ,703** ,000
IR-A ,621** ,001
IR-B ,674** ,000
BP-1 ,522** ,009
BP-3 ,620** ,001
S6K1 mTOR ,803** ,000
IGF-IR ,556** ,005
IR-A ,725** ,000
IR-B ,598** ,002
IGF-IIR ,764** ,000
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level of all evaluated components of the mTOR pathway strongly correlated with IRA 
and IRB mRNA expression. No correlation was observed between the mRNA levels of the 
evaluated components of the IGF or mTOR pathway and clinical features including the age 
of diagnosis and tumor diameter. In addition, no statistical significant differences were 
observed in IGF- and mTOR component mRNA expression between benign and malignant 
tumors and between PCCs associated with genetic syndromes, nor between samples 
belonging to cluster 1 or 2 and the apparently sporadic ones.
However, samples of the same cluster (1 or 2) showed similarities in terms of increased 
expression or reduced expression of some components of the IGF/mTOR pathways 
(figure 2). Of note, both VHL samples (cluster 1) and the PGL studied had very high IGF2, 
BP3 levels and IRA/IGF1R ratio, while low levels of these parameters were observed in 
most MEN2A and NF1 samples (cluster 2). Conversely, cluster 1 samples had low IRA/IRB 
ratio and low IGF1R levels, while often high levels of these parameters were observed 
in cluster 2. Anyway this observation are very speculative because the genetic test had 
been performed only in few cases.
Effects of sirolimus and everolimus in rat pheochromocytomas PC12 cell line
In the PC12 cell line sirolimus and everolimus significantly suppressed the cell growth in 
a dose and time-dependent manner (figure 3). After 6 days of treatment sirolimus was 
slightly, but significantly, more potent than everolimus in terms of EC50 (EC50: 2x10-9 M 
vs 1.5x10-8 M; p<0.0001) and with respect to the maximal effect observed at the high-
figure 2. Graphic representation of the relative mRNA expression of the main component of the IGFs and 
mTOR pathways in a subgroup of 8 human pheochromocytoma with proven genetic syndrome as com-
pared with the expression levels of the same components in the whole population of human pheochromo-
cytoma evaluated (24 cases). The different colors represent different quartiles of expression levels.
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est dose used (p=0.007). The effects of sirolimus after 6 days ranged between 52.4% 
inhibition (p<0.001) at the maximal dose (10-6M) and 14% (p<0.05) at the dose of 10-12M. 
The effects of everolimus after 6 days ranged between 43% inhibition (p<0.001) at the 
maximal dose (10-6M) and 29.6% (p<0.05) at the dose of 10-8M.
Three- days treatment with both compounds induced apoptosis in PC12 cells, only at 
the highest dose used (10-6M; data not shown).
Effects of OSI906 alone or in combination with sirolimus or everolimus in rat 
pheochromocytomas PC12 cell line
To evaluate the in vitro effects of IGF1R/IR antagonist in PCC, we tested the effects of 3 
and 6 days treatment with OSI-906 on DNA content (representing cell number) and of 3 
days on DNA fragmentation in PC12 cells.
OSI-906 significantly suppressed cell growth in a dose and time-dependent manner 
(figure 4A). Maximal inhibition by 98.6% (P<0.001) was observed at a dose of 10-5M; EC50 
was 2.7x10-7M.
OSI-906 significantly increased the apoptosis in a dose-dependent manner (figure 4B). 
These effects ranged between 33% stimulation (p<0.01) at the dose of 10-7M and 1249% 
(p<0.001) at the dose of 10-5M.
The anti-proliferative effects of 6 days combined treatment with OSI-906 (2.5x10-7M 
and 10-7M; approximately corresponding to the EC50 and EC25) and sirolimus (10-8M and 
5x10-9M, approximately corresponding to the EC50 and EC25) or everolimus (10-6M and 
10-8M, approximately corresponding to the maximal concentration tested and the EC50) 
were evaluated. Combination of both mTOR inhibitor with the OSI-906 showed statisti-
cally significant additive effects (figure 4C-F).
figure 3: Dose/time-dependent effect of sirolimus (O) and everolimus (▲) treatment on PC12 cell prolifera-
tion, espresse as DNA content/well after 3 days (upper panel) and 6 days (lower panel). Data are expressed 
as the percentage of control and represent the mean± DS. Control is set as 100%.
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figure 4: Effects of OSI-906 alone or in combination with mTOR inhibitors on PC12 cells. Panel A: dose/
time-dependent effect of OSI-906 treatment on PC12 cell proliferation, expressed as DNA content/well. 
Panel B: dose-dependent effect of OSI-906 treatment on PC12 cell apoptosis, normalized versus the DNA 
content of each well. Panel C-F: additive effects of combined treatment OSI-906 and sirolimus or everolimus 
on PC12 cell proliferation. Data are expressed as the percentage of control and represent the mean±.S. D.. 
Control is set as 100%. **p<0,01; *** p<0,001.
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DisCussiOn
In the present study we examined the interrelationship between IGF and mTOR pathways 
in PCC tissues, as well as the antiproliferative in vitro effects of mTOR inhibitors, an IGF1R/
IRA inhibitor, and their combination in a PCC cell line model. This study demonstrates 
the presence of IGF/mTOR pathway components and a high IRA/IRB mRNA ratio in the 
majority of human PCCs, suggesting the existence of an IGF2-IRA autocrine/paracrine 
loop in human PCCs, in addition to the already suggested IGF2-IGF1R loop.12-14 Drugs 
inhibiting mTOR or IGF1R/IRA suppress cell proliferation in the rat PCC cell line PC12. 
OSI-906, an IGF1R/IRA inhibitor, strongly induces cell apoptosis and combining OSI-906 
with mTOR inhibitors shows additive antiproliferative effects.
The mTOR pathway is considered as a potential target for treatment of PCC patients 
with progressive disease.7, 8 The mTOR, 4EBP1 and S6K1 mRNA levels were not signifi-
cantly different in 2 VHL patients (cluster 1) as compared with the group including the 
MEN2A and NF1 (cluster 2) patients or in malignant versus benign PCCs. However, this 
could depend on the small study population. Several positive correlations between the 
mRNA levels of the different components of the IGF and mTOR pathways were observed. 
Particularly, both kinases of the mTOR pathway, mTOR and S6K1, showed a significant 
positive correlation with all the IGF receptors evaluated, suggesting that the expres-
sion of these genes share common mechanisms of regulation. Conversely 4EBP1, the 
negative regulator of the mTOR pathway activation is positively correlated with both 
IGF1 and IGF2, also suggesting that the expression of these genes share common 
mechanisms of regulation and that the increased expression of 4EBP1, in parallel with 
the increased expression of IGFs, could be a mechanism to balance the activation of 
mTOR pathway induced by IGFs. IRA is an isoform of the IR with higher affinity for IGF2 
than IGF1R. IRA expression in malignant tumor tissue has been suggested to be involved 
in cancer development.9 To our knowledge this is the first study demonstrating the 
presence of comparable levels of IRA and IGF1R mRNA and an increased IRA/IRB ratio 
in PCCs, suggesting a potential role of IGF2-IRA autocrine loop in PCC proliferation. In 
the samples for which genetic testing was available we could identify some similari-
ties among samples belonging to the same cluster. Both VHL mutated PCC (cluster 1) 
presented a down-regulation of IGF1R and an up-regulation of BP3, while an inverse 
profile was observed in MEN2A and NF1 mutated samples (cluster 2), in agreement with 
previous reports.18 IGF/insulin pathway could thus play a role in both cluster 1 and 2 PCC 
proliferation, although through potentially different mechanisms. In MEN2A and NF1 
mutated samples (cluster 2) a high level of IGF1R and IRA/IRB ratio was observed in the 
majority of PCC (figure 2), whereas in VHL mutated samples (cluster 1) in particular high 
levels of IGF1, IGF2, IRA and IRA/IGF1R ratio were found.
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In an animal model for pheochromocytoma, temsirolimus, an mTOR inhibitor, was able 
to inhibit tumor progression.19 Few studies have evaluated the effects of mTOR inhibi-
tors in PCC cell lines.7 Rapamycin, evaluated as a single dosage (10-8M), has been found 
to significantly inhibit cell growth in normal chromaffin rat cells, but not in the PC12 cell 
line.20 Short term treatment with rapamycin or everolimus were found to have modest 
inhibitory effects on cell viability in MTT cells, a more recently established mouse PCC 
cell line.21, 22 The present study confirmed that short term treatment (up to 3 days) with 
rapamycin or everolimus has only modest antiproliferative effects in the PC12 cell line, 
but it also showed that longer treatment (up to 6 days) results in a stronger inhibition 
of PC12 growth, already at a doses that can be achieved in vivo in humans (maximal 
concentration about 10-7M).23, 24 However, the observed anti-proliferative effects did not 
exceed 50% cell growth inhibition and were not associated to a significant induction 
of cell apoptosis. It was previously reported that S6K1 silencing induces apoptosis in 
PC1225 whereas in the present study mTOR inhibitors induced significant apoptosis in 
PC12 only at high dose (10-6M). Another study demonstrated by western-blot that high 
doses of rapamycin (10-6M) were required to strongly inhibit pS6 phosphorylation (target 
of S6K1) in MTT PCC cells.21 These results suggest that the inhibition of S6K1 can induce 
cell apoptosis in PCC cells, but the concentration of rapamycin required to stimulate 
cell apoptosis is probably too high. These results are consistent with the early clinical 
experience with the use of everolimus in PCC patients suggesting that everolimus can 
induce disease stabilization in some patients but it does not induce objective tumor 
response.26, 27
Similar to human PCC, PC12 cells express both IGF1R and IR and IGF2.28 IGF1, IGF2 
and insulin can stimulate PC12 proliferation.28 Therefore, there is evidence of a potential 
autocrine/paracrine loop of IGFs in these cells. The pro-growth and anti-apoptotic ef-
fects of IGF1 have also been demonstrated in MPC cells, a more recently established 
mouse PCC cell line.29 In both MPC and PC12 cells, IGF1 activates both AKT and ERK 
pathways.29 Fernández et al. demonstrated that liver-IGF1-deficient mice (LID) were 
less predisposed to develop PCC than control mice when injected with MPC cells, but 
the administration of IGF1 to LID mice could accelerate PCC growth. Interestingly, the 
authors demonstrated an increased IR expression in PCC developing in LID mice as 
compared with controls,29 suggesting a possible role of IR as well in PCC growth. This 
observation is in line with our hypothesis of a role of IRA in human PCCs. NVP-AEW541, 
an IGF1R antagonist with higher affinity for IGF1R than IR,30 was shown to possess 
significant in vitro and in vivo antiproliferative activity in neuroblastoma cancer cell 
lines,31 a tumor generally considered to be related with PCC. OSI-906 is a selective and 
orally bioavailable dual IGF-1R/IR kinase inhibitor which is currently evaluated alone or 
in combination with other compounds in several types of malignancy.32 The present 
study demonstrates that OSI-906, used at a dose reached in human plasma as measured 
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after administration in vivo,33 strongly inhibits cell proliferation and strongly stimulates 
cell apoptosis in PC12 cells, suggesting that OSI-906 could be a potential new treatment 
option for PCC patients with metastatic disease. Conversely, a recent study showed that 
high doses of NVP-AEW541 were required to inhibit cell viability in MPC and MTT PCC 
cell lines.22 These different results could depend on the different cell lines and/or on 
the compound used. PC12 cells are generated by a spontaneously developed PCC in 
rats, while both MPC and MTT are derived from tumors in heterozygous neurofibromin 
(NF1) knockout mice.29, 34-36 NF1 defective tumors could have an activation of AKT and 
ERK pathways independent of the growth factor receptor stimulation responsible for 
a reduced sensitivity to the IGF1R blocker. Alternatively, NVP-AEW541, considered to 
be a selective IGF1R blocker, could be less effective than OSI-906 in inhibiting PCC cell 
proliferation because it does not disrupt the IR induced cell proliferation.
In several experimental models, including neuroblastoma models, it has been dem-
onstrated that combining mTOR inhibitors with IGF1R antagonists may have additive 
effects37 and clinical trials combining compounds that belong to these two categories 
of drugs are ongoing.38 To our knowledge there are no clinical studies or case reports 
evaluating the effects of IGF1R antagonist alone or in combination with mTOR inhibi-
tors in PCC patients. In patients with PCCs there is a suggested rationale to use mTOR 
inhibitors. The present study showed potent in vitro antiproliferative effects of OSI-906 
in PC12. If the data from PC12 cells can be extrapolated to human PCC, the combination 
of these two drugs could be an attractive strategy to treat these patients. Further studies 
are required to confirm this data in animal models of PCC. Moreover, in such a preclinical 
setting it would also be interesting to evaluate whether the expression levels of the 
different components of the mTOR and IGF pathways can influence the sensitivity of PCC 
to these treatments.
Conclusions
In PCCs, IGF- and mTOR pathways are simultaneously activated. In particular IGF2 
is highly expressed and the subtype A of the IR is expressed at a comparable level of 
IGF1R and could play an important role in the autocrine/paracrine loop of IGFs in these 
tumors. mTOR inhibitors inhibit PC12 PCC cell line proliferation but do not stimulate 
cell apoptosis. Targeting of the IGF pathway with OSI-906 inhibits PC12 PCC cell line 
proliferation and strongly stimulates cell apoptosis. OSI-906 and mTOR inhibitors have 
additive antiproliferative effects on PCC cells. The current study suggests that the use of 
OSI-906 alone or in combination with mTOR inhibitors may be a potential future treat-
ment option in progressive PCCs patients.
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Table 1 
Oligo 
Name 
               Forward                 Reverse                      Probe 
IGF1R CCAAAACTGAAGCCGAGAAG GGGTCGGTGATGTTGTAGGT AAGCAGGAACACCACGGCCG 
IGF2R ACCGACCCCTCCACGC CCTCCAAGGCCACCTTCAG AGCAGTACGACCTCTCCAGTCTGGCAAA 
IGF1 TTGTGATTTCTTGAAGGTGAAGATG CGTGGCAGAGCTGGTGAAG TACCTGGCGCTGTGCCTGCTCA 
IGF2 CCAAGTCCGAGAGGGACGT TTGGAAGAACTTGGCCACG ACCGTGCTTCCGGACAACTTCCC 
IRA CGTTTGAGGATTACCTGCACAA GCCAAGGGACCTGCGTTT TGGTTTTCGTCCCCAGGCCATC 
IRB CCCAGAAAAACCTCTTCAGGC GGACCTGCGTTTCCGAGA CTGGTGCCGAGGACCCTAGGCC 
mTOR TGCTGCGTGTCTTCATGCAT GGATTGCAGCCAGTAACTTGATAG ACAGCCCAGGCCGCATTGTC 
p70S6K TGGAAGACACTGCCTGCTTTT TGATCCCCTTTTGATGTAAATGC CTTGGCAGAAATCTCCATGGCTTTGG 
4EBP1 GGCGGCACGCTCTTCA TCAGGAATTTCCGGTCATAGATG ACCACCCCGGGAGGTACCAGGA 
HPRT TGCTTTCCTTGGTCAGGCAGTAT AAATCCAACAAAGTCTGGCTTATATC CAAGCTTGCGACCTTGACCATCTTTGGA 
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The main purpose of this thesis was to explore the role of the mammalian target of 
rapamycin (mTOR) pathway as a potential target for a novel treatment option in patients 
with adrenal tumors (AT).
While benign tumors of the adrenal cortex (adrenal adenomas, ACA) and medulla 
(pheochromocytomas, PCC) are generally cured by surgery, both adrenocortical carci-
noma (ACC) and malignant PCC are rare tumors with scant treatment options. Therefore, 
new treatment options for these malignancies are required.1-3
The limited efficacy of conventional antineoplastic treatment in malignant ATs 
increases the need for novel effective treatment options. During the past 15 years, 
progress in understanding the pathogenesis of tumors has encouraged the develop-
ment of so-called “targeted drugs”, which are compounds that specifically interfere with 
molecular mechanisms involved in tumor cell growth and/or tumor vascular supply, 
leading to major advances in oncology.4, 5
Included in this category of drugs there are compounds interfering with growth factor 
receptors and their related signaling pathways. Alterations of growth factors and their 
cognate receptors are considered to be involved in the pathogenesis of both ACCs and 
PCCs.6-10 Therefore, compounds interfering with tumor angiogenesis and growth factor 
signaling pathways represent a potential novel treatment options for the management 
of patients with malignant ATs. The mTOR pathway, being involved in both these pro-
cesses, could represent a potential target for treatment of these malignancies (chapter 
1).2, 3
Most research described in this thesis is focused on adrenocortical tumors (ACT) 
(chapters 2, 3, 4, 5 and 6), while the research described in one chapter (chapters 7) has 
focused on PCCs. For this reason, the following discussion is more extensively dedicated 
to the research described ACTs and to a lesser extent to PCCs.
The mTOR PAThwAy in nORMAl ADRenAls
The expression of the main components of the mTOR pathway in the normal adrenal 
gland has not been addressed before (chapter 1). This represented the starting point 
to understand whether this pathway could play a role in the normal physiology of 
the adrenal gland and whether alterations within the mTOR pathway (activity) could 
play a role in the pathogenesis of ATs. In chapter 3 of the current thesis the mRNA and 
protein expression of the main components of the mTOR pathway in normal adrenals is 
described. A layer-specific protein expression pattern of the major components of the 
mTOR pathway was found, suggesting a specific role of the mTOR pathway in particular 
adrenal functions. For example, the stronger expression of several components [i.e 
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total-mTOR, total- /phospho- eukaryotic translation initiation factor 4E binding proteins 
(4EBP1) and total- /phospho- protein kinase p70 ribosomal protein S6 kinase 1 (S6K1)] 
of the mTOR pathway in the zona reticularis could suggest a role of this pathway in 
androgen production and the stronger expression of these components in the zona 
glomerulosa may be related to angiotensin II induced activation of the mTOR pathway.11 
Further studies are required to clarify the specific role of the mTOR pathway in regulat-
ing steroid production. In this respect it is interesting to note that in chapter 2 we show 
an anti-secretive effect (e.g. inhibition of cortisol production) of mTOR inhibitors (drugs 
inhibiting the mTOR pathway) in ACC cell lines, whereas the use of mTOR inhibitors in 
the clinical setting appears not to result in signs or symptoms of hypo-adrenalism.12
exPRessiOn Of The MAin COMPOnenTs Of The mTOR PAThwAy in ACTs
The expression of the main components of the mTOR pathway in ACTs has not extensively 
been investigated before (chapter 1). The study of the expression of these components 
in benign (ACA) and malignant (ACC) ACTs is an important step for several reasons. 
First, the demonstration of an abnormal expression of these components in ACTs may 
support a potential role of the mTOR pathway in the pathogenesis of ACTs, increasing 
the interest of this pathway as a new potential target for treatment. In chapter 3 of the 
current thesis, the mRNA and protein expression of the main components of the mTOR 
pathway was evaluated, showing that ACC present a highly variable protein expression 
of these components and a lower protein S6K1 mRNA expression than normal adrenals. 
These data suggest that up-regulation of the mTOR pathway is not ubiquitously ob-
served in ACC. Concomitantly, Doghman, M. et al reported that mTOR signaling is active 
in childhood ACTs.13 There is increasing body of evidence supporting that adult ACC 
and childhood ACTs are different entities.14, 15 Therefore, when comparing the results of 
the current thesis (chapter 3) with the study of Doghman, M. et al, it is important to keep 
in mind that most of our samples were adult ACC while all the samples used by Dogh-
man, M. et al were childhood ACTs.13 The results of the current thesis are in line with the 
results reported by Nakamura, M. et al, who did not find a significant over-expression of 
phospho-S6K1 and phospho-4EBP1 in ACCs (including both adult and childhood ACTs) 
as compared with ACAs and normal adrenals.16 The studies of chapter 3 also focused on 
the description of the heterogeneity of the protein expression of the main components 
of the mTOR pathway in ACCs tumors. Based on these data, the mTOR pathway should 
not be expected to be widely involved in the pathogenesis of in ACCs, but might be 
involved in a subset of them.
The description of the expression of the main components of the mTOR pathway in 
ACTs was also important to address the question whether a differential expression in 
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different subgroups of ACTs could have a prognostic value. In the chapter 3 of the cur-
rent thesis, it is shown that ACCs present with a lower S6K1 mRNA and protein level 
compared with ACAs, and ACCs which do not have an intermediate to high staining of 
phospho-S6K1 or phospho- 4EBP1 have a significantly higher Weiss score than others, 
suggesting that a subset of less differentiated ACCs could have an inactivation of the 
mTOR pathway. These data suggest that the down-regulation of the mTOR pathway in 
ACTs warrants further investigation as a potential prognostic factor.
In the era of personalized medicine the description of the main components of the 
mTOR pathway in ACTs is an important step to explore in ACCs, as their presence can 
be considered as potential markers for treatment with mTOR inhibitors (drugs acting 
on this pathway). In chapter 3 the protein expression of individual ACCs is described, 
demonstrating that 80% of carcinomas have an intermediate to high expression of 
phospho-S6K1 and/or phospho-4EBP1, which are considered as potential molecular 
biomarkers of mTOR pathway activation in human cancers.17, 18 In addition, in chapter 
6 of the current thesis, we demonstrate that the presence of genomic alterations, cur-
rently considered as potential predictor of response to mTOR inhibitors, are not com-
mon events in stage III-IV ACCs and these results have been very recently confirmed 
also by integrated genomic characterization in ACC samples of patients not selected 
on the basis of staging.19 Keeping in mind that molecular biomarkers capable to predict 
the clinical response to mTOR inhibitors have not been clearly identified yet, the data of 
this thesis suggest that a subset of patients have molecular evidence of mTOR pathway 
activation, but further studies are required to explore whether these molecular events 
could predict an increased sensitivity to mTOR inhibitors.
effeCTs Of mTOR inhibiTORs in ACTs
The effects of mTOR inhibitors in ACTs models have not been evaluated previously (chap-
ter 1). The testing of mTOR inhibitors in preclinical models of ACTs is a mandatory step to 
explore whether these compounds could represent a novel treatment opportunity for 
the management of ACCs. In chapter 2 the effects of two mTOR inhibitors, sirolimus and 
temsirolimus, on human ACC cancer cell lines (H295, their clone HAC15 and SW13) were 
studied. It was demonstrated that mTOR inhibitors inhibit the proliferation and cortisol 
production in ACC cells, but SW13 were significantly more sensitive than other cells to 
these compounds. In line with these results, Doghman, M. et al reported that everolimus, 
another mTOR inhibitor, inhibited ACC cell line proliferation and, used at high dose, 
inhibited H295 xenograft growth in mice.13 The results of the current thesis demonstrate 
that the antiproliferative effects of sirolimus at concentrations potentially reachable 
in vivo are predominantly cytostatic (chapter 2). Additionally, sirolimus was found to 
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significantly reduce cell survival and cortisol secretion only in selected ACT primary cul-
tures (chapter 3).20 These data suggest that based on preclinical studies evaluating the 
effects of mTOR inhibitors in ACT models, a subset of patients with ACCs might be more 
sensitive than others to this treatment. Therefore, further studies are warranted to find 
potential biomarkers predictive of response to treatment with mTOR inhibitors in ACTs. 
In an attempt to answer to this requirement, in the experiments described in chapter 3 
the protein expression of the main components of the mTOR pathway was investigated 
in relation to the in vitro effects of mTOR inhibitors in ACT primary cultures. However, 
the expression of none of the evaluated proteins correlated with the in vitro response to 
these drugs (chapter 3). This absence of a correlation could be due to the low number of 
primary cultures used. Only specifically designed clinical trials can appropriately evalu-
ate for biomarkers predictive of response to treatments, but this type of clinical trials is 
extremely difficult to perform in such a rare cancer as ACC. Therefore, progress in this 
direction can only be awaited from the results of clinical trials in other more common 
types of cancer. Once a clear predictive biomarker will be identified in other cancers, its 
value in ACC should be explored.
RelATiOnshiP beTween The mTOR AnD The igf PAThwAys in ACTs
The relationship between the mTOR and the IGF pathways in ACTs has not been specifi-
cally addressed before (chapter 1). The mTOR pathway is an intracellular pathway that 
mediates the effects of many growth factors, including the IGFs.21, 22 Therefore, the study 
of this relationship is important to understand whether the mTOR pathway could be 
involved in the mediation of the pathogenic effects of IGFs in ACC, whether a differential 
expression of the main components of the IGF pathway could influence the in vitro sen-
sitivity to mTOR inhibitors and whether there is a rational to combine drugs targeting 
the IGF and the mTOR pathways.
The relationship between the mTOR and the IGF pathways in the H295 and SW13 ACC 
cell lines is addressed in chapters 2 and 3, demonstrating that both ACC cell lines have a 
similar protein expression of IGF1R and the main components of the mTOR pathway, but 
both mRNA and protein expression of IGF2 were considerably higher in H295 compared 
with SW13. Next it was evaluated whether in both cell lines the effects of IGF stimula-
tion on the main components of the mTOR pathway is similar or not. In chapter 2 it was 
demonstrated that IGF1 significantly stimulated AKT and S6K1 phosphorylation in both 
H295 and SW13, demonstrating that the mTOR pathway acts as an intracellular media-
tor of IGFs in both human ACC cell lines (a schematic representation of the pathway is 
shown in figure  1). Therefore, the mTOR pathway could be involved in the mediation 
of the pathogenic effects of IGFs in ACC cell lines. However, the effects of the mTOR 
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inhibitor sirolimus on the IGF-activated intracellular pathways were diff erent between 
H295 and SW13 cells. At the experimental condition tested, IGF1 induced the activation 
of the AKT/mTOR pathway in both cell lines, but ERK activation only in H295. Sirolimus 
effi  ciently suppressed the mTORC1 activity in both cell lines. However, in H295, but not 
in SW13 cells, the inhibition of mTORC1 activity was associated with the activation of 
AKT, likely representing an escape pathway. This activation was further enhanced by 
IGFII
IGFIR IRA IRB IGFIIRGFR
GFs
PIP2 PIP3
AKT
PDK1
PTEN
TSC2
mTORC1
IRS1
PI3K
TSC1
mTORC2
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ERK1-2
GROWTH-PROLIFERATION-SURVIVAL-ANGIOGENESIS
G1 cell cycle  pathway
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IGF1R/IRA
inhibitors
Tyrosine-kinase
inhibitors
figure 1. Schematic representation of the potential molecular pathways representing potential targets for 
treatment in patients with ACC, based on the results presented in the current thesis. GFs: growth factors; 
GFR: growth factor receptor. Brown lines shows two potential escape pathways to the treatment with mTOR 
inhibitors: AKT and ERK activation.
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IGF1 administration which also induced ERK stimulation in the sirolimus treated H295 
cells. These data suggest the presence in H295 of two potential pathways of escape 
to treatment with traditional mTOR inhibitors: the AKT and ERK pathways (see figure 1 
for the potential escape pathways).21, 23 The activation of these escape pathways could 
be related, at least partially, to the IGF2 overexpression in H295, which is not found in 
the SW13 cell model. Therefore, it could be speculated that high IGF2 expression could 
negatively influence the in vitro sensitivity of ACC cell lines to mTOR inhibitors, support-
ing the rationale to combine mTOR inhibitors and drugs specifically targeting the IGF 
pathway in ACC (chapter 4).
IGF2 overexpression is very common in ACC (about 80%),10 whereas in the studies 
described in chapter 3 only a subset of ACC samples strongly expressed the evaluated 
components of the mTOR pathway, particularly the phospho-proteins. In the studies 
included in this thesis, a subgroup of 16 ACC samples was characterized for both the 
protein expression of the main components of the mTOR pathway (chapter 3) and the 
protein expression of IGF2, IGF1R and IGF2R (chapter 4). Within this subgroup of ACC 
samples we were not able to find correlations between these proteins. Therefore, the re-
sults of the current thesis show that the expression of the main components of the mTOR 
and the IGF pathways are not strongly related, arising the question whether in ACC there 
is a dissociation between the expression of IGF2 and the activation of the classical IGF 
stimulated intracellular pathways. Actually, the results of chapter 3 raises the doubt that 
the role of IGF2 in the pathogenesis of adult ACC may have been overestimated, in agree-
ment with some other recent speculations.24 However, it should also be considered that 
the complexity of the IGF system may have been underestimated. The study reported in 
chapter 4 points out that ACC express components of the IGF pathway as well, such as IRA 
and IGF2R, which were not considered before. As such, before to finally declare a “game 
over”24 for the role of IGF2 in adrenocortical tumorigenesis and as a potential target for 
novel treatment in ACC patients, it could be probably useful to return to the bench and 
try to better explore the IGF pathway in ACC in its whole complexity.
effeCTs Of mTOR inhibiTORs in COMbinATiOn wiTh OTheR DRugs in ACTs
The data derived from the use of the mTOR inhibitors alone in the preclinical studies (chap-
ter 2 and 3), together with the expected heterogeneity of ACC (chapter 3 and 6), suggested 
that caution is required before using this class of drugs in unselected ACC patients. Such 
caution was also suggested by preliminary clinical experience with the use of everolimus 
in some ACC patients with a late stage of disease.25 Unfortunately, due to the current ab-
sence of molecular biomarkers capable to predict the response to mTOR inhibitors in ACTs 
(chapters 3 and 6), it is difficult to define selection criteria for patients that are candidate for 
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treatment with this class of drugs. Therefore, combination of mTOR inhibitors with other 
drugs, potentially active in ACC, could be a more prudent clinical approach than the use of 
these inhibitors as monotherapy in unselected ACC patients.
During the development of this thesis the IGF pathway was considered the most at-
tractive target for new treatment in ACC (chapter 1).26, 27 Additionally, the early results 
of this thesis (chapters 1 and 2) suggested a rationale to combine mTOR inhibitors with 
drugs targeting the IGF pathway. Therefore, in the studies described in chapter 4, the ef-
fects of mTOR inhibitors were explored in combination with OSI-906. OSI-906 (linsitinib) 
is an IGF1-R/Insulin receptor [IR] blocker that during the development of the current the-
sis has been tested in a phase III trial in ACC patients (NCT00924989). The results of this 
study have been presented at ASCO meeting in 201428 and show that a small subgroup 
of patients seems to benefit from treatment with this drug, but the hoped improve-
ments in overall or progression-free survival were not observed. This observation again 
illustrates that ACC is a very heterogenous disease. However, whether combining drugs 
that target the IGF-system with other compounds such as mTOR inhibitors could be 
more effective requires further investigation. In chapter 4 it was reported that in selected 
conditions combined treatment with mTOR inhibitors and OSI-906 have additive growth 
inhibitory effects on ACC cells, supporting a potential role for treatment strategies com-
bining mTOR inhibitors and drugs targeting the IGF pathway in ACC. These results are in 
line with a recently published phase I study demonstrating that a subgroup (about 40%) 
of ACC patients treated with cixutumumab (IGF1R inhibitor) and temsirolimus (mTOR 
inhibitor) experienced long term disease stabilization.29
Another attractive candidate for new combination treatment strategies in ACC is mito-
tane, since this drug is currently considered as a referral drug in the treatment of patients 
with advanced ACC. However, unfortunately the majority of studies suggest that about 
two-thirds of patients do not respond and/or do not tolerate this drug.30, 31 Therefore, 
in chapter 5 of this thesis the effects of mTOR inhibitors in combination with mitotane 
were evaluated, demonstrating that in human ACC cell lines the addition of sirolimus 
to low concentrations of mitotane had stronger antiproliferative effects than mitotane 
alone. If these results can be translated to humans, they suggest that the addition of 
sirolimus might add to the antitumor action of mitotane, reducing the mitotane dose 
required to obtain a desired clinical effect with potentially less side effects. This additive 
effects were higher when the concentration of mitotane used was lower, suggesting 
that combined treatment might be particularly useful during the phases of treatment in 
which mitotane plasma levels are below the therapeutic range, such as during the initial 
dose titration and/or for those subjects in which the therapeutic range of mitotane is 
hardly maintained due to bad tolerance or other reasons. Although these data are still 
preliminary, they suggest a potential advantage of combining mitotane with sirolimus. 
Therefore, this combination treatment clearly warrants further investigation.
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new POTenTiAl TARgeTs fOR ACC in ADDiTiOn TO The igf AnD mTOR 
PAThwAys
During the development of the current thesis, most of the early clinical experience with 
targeted drugs, including drugs targeting the IGF pathway, failed to demonstrate the 
hoped effects in patients with ACC,3, 24, 28 thereby arising the questions whether molecu-
lar events, potentially targetable with currently developed targeted drugs, are present 
in at least a subset of ACC patients. This question is addressed in chapter 6. Using hotspot 
gene sequencing and comparative genomic hybridization the presence of a large num-
ber of mutations and copy number abnormalities of potential interest for therapeutic 
aims were evaluated in a large group of adult stage III-IV ACC samples. At least one 
copy number alteration or mutation was found in about half of the patients. The most 
frequently detected mutations were on TP53, ATM and CTNNB1 (15%, 12.5% and 10% 
respectively). The most frequently identified copy number alterations were: amplifica-
tion of the CDK4 oncogene (17.9%) and deletion of the CDKN2A (14.3%) and CDKN2B 
(10.7%) tumor suppressor genes. No relevant alteration in the evaluated components 
of the mTOR and IGF pathways were found with these techniques. No simple targetable 
molecular event emerged. Based on genomic alterations, the cell cycle appeared to be 
the most relevant new potential therapeutic target for patients with advanced ACC (fig-
ure1). Recently, a small-molecule CDK4/6 inhibitor (i.e. palbociclib or PD-0332991 and 
LEE011) has rekindled interest in the concept of blocking cell cycle progression to stop 
cancer cell growth.32, 33 Currently these compounds are under the phase I-III of clinical 
development and preliminary results suggest a safety profile in humans and promising 
anti-tumor activity in different cancer types (http://clinicaltrials.gov). Further studies to 
explore the effects of these compounds in preclinical models of ACCs are warranted.
Overall these data underline that, despite the fact that during the last 10 years many 
progresses have been made in describing the molecular alteration in ACTs, the transla-
tion of these progress from bench to the bedside with the aim to improve the treatment 
of patients with ACC has not been easy, so far.
exPRessiOn Of The MAin COMPOnenTs Of The mTOR PAThwAy AnD 
The RelATiOnshiP beTween The mTOR AnD The igf PAThwAys in 
PheOChROMOCyTOMAs (PCCs)
Dysregulation of the mTOR pathway have been suggested to be present at least in a 
subgroup of human PCCs.9, 34 However, relationships between the mTOR and the IGF 
pathways has been poorly investigated. In chapter 7 of the current thesis the mRNA 
expression of the main components of the mTOR and IGF pathways in a series of hu-
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man PCCs is explored. All the evaluated components of the mTOR and IGF pathways are 
expressed in human PCC samples, with a high expression of IGF2 mRNA and a high IRA/
IRB mRNA ratio in the majority of cases. These data suggest the existence of a potential 
IGF2-IRA autocrine/paracrine loop in human PCCs. This loop could play a role in the 
pathogenesis of these tumors representing a potential target for new treatment options 
in patients with malignant PCCs. Additionally, several correlations between the mRNA 
levels of the different components of mTOR and IGF pathways were found. In particular, 
the mRNA level of all evaluated components of the mTOR pathway strongly correlated 
with IRA and IRB mRNA expression, suggesting that the expression of these genes could 
share common mechanisms of regulation.
effeCTs Of mTOR inhibiTORs AnD Osi-906 in PCCs
The effects of mTOR inhibitors in PCC models had hardly been investigated before the 
project of this thesis started (chapter 1). In chapter 7 the effects of two mTOR inhibitors, 
sirolimus and everolimus, in PC12, a rat PCC cell line, are described, demonstrating that 
both compounds significantly suppress cell proliferation in a dose- and time-dependent-
manner. However, in this experimental model the observed anti-proliferative effects 
did not exceed 50% cell growth inhibition and were not associated with a significant 
induction of cell apoptosis. These results are consistent with the early clinical experi-
ences with the use of everolimus in PCC patients, suggesting that everolimus can induce 
disease stabilization in some patients, but to date no tumor objective response has been 
reported by using this drug in patients with this malignancy-
Additionally, during the development of this thesis some other studies explored the 
effects of mTOR inhibitors (particularly NVP-BEZ235 a dual PI3K/mTORC1/2 inhibitor 
and AZD8055, a dual mTORC1/2 inhibitor), alone or in combination with other drugs 
(particularly lovastatin, an ERK inhibitor), in preclinical PCC models adopting different 
PCC cell lines and methodologies as compared with the current thesis.37, 38 Preclinical 
and early clinical studies support a potential role of sunitinib, a tyrosine kinase inhibitor 
that targets several receptors [platelet-derived growth factor (PDGF-Rs) and vascular en-
dothelial growth factor receptors (VEGFRs)], in the treatment of PCC, giving the rationale 
for a phase II clinical trial in patients with progressive malignant PCC and paraganglioma 
(NCT01371201) that is currently ongoing.9, 39-41 Considering these data further investiga-
tions are also required to explore the feasibility and the potential effects of treatment 
strategies combining drugs targeting the mTOR inhibitor pathway with tyrosine kinase 
receptor inhibitors. All together these preclinical experiments suggest that in PCCs 
treatment strategies combining mTOR inhibitors with other drugs warrant further in-
vestigation.
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As above mentioned, in chapter 7 of the current thesis the existence of an IGF2-IRA 
autocrine/paracrine loop in human PCCs is hypothesized for the first time. In PCC 
models the effects of drugs targeting simultaneously the IGF1-R and IR, such as OSI-
906, have never been investigated before. Therefore, the effects of OSI-906 alone or in 
combination with sirolimus, were investigated in PC12 cells, demonstrating that OSI-906 
significantly increased the apoptosis and suppressed cell growth in a dose and time-
dependent-manner (chapter 7). These antiproliferative effects were further increased 
by combining OSI-906 with sirolimus or everolimus, demonstrating a clear additivity in 
the cell growth inhibitory effects of these two classes of compounds. The next step will 
be to examine the antiproliferative and antisecretory effects of these drugs, alone and 
in combination, in primary cultures of human malignant PCCs. If the data from PC12 
cells can be extrapolated to at least a subgroup of human PCCs, the combination of 
these two drugs could be an attractive strategy to treat patients with progressive PCCs. 
Therefore, future studies are warranted to define whether treatment with OSI-906 alone 
or in combination with mTOR inhibitors might be a potential future treatment option for 
patients with progressive PCCs.
COnClusiOn AnD fuTuRe DiReCTiOns
The results of the current thesis support a role for the mTOR pathway as a potential 
target for treatment of patients with ACCs, as well as for patients with malignant PCCs. 
However, in both types of tumors, treatment strategies combining mTOR inhibitors with 
other drugs might be more effective than the use of mTOR inhibitors alone. Additionally, 
considering the potential heterogeneity of these malignancies, treatment strategies 
based on the selection of patients with a potentially higher chance to respond to mTOR 
inhibitors based on their tumor characteristics, might be more effective than the use of 
mTOR inhibitors in unselected patients. Unfortunately, molecular biomarkers capable 
to predict a clinical response to mTOR inhibitors have not been clearly identified yet. 
Therefore, further preclinical and clinical investigation are required to find new mo-
lecular biomarkers useful to predict tumor response to both conventional and novel 
treatments for patients with ATs and to address the role of mTOR inhibitors, alone or in 
combination with other drugs, in selected subgroups of patients with these tumors. All 
these data could help to move into the direction of a more personalized approach to the 
treatment of malignant ATs, and hopefully this approach could lead to advantage in the 
clinical management of these rare but aggressive diseases.
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suMMARy
Adrenal tumors (AT) include benign and malignant cortical tumors named adrenocoti-
cal adenomas (ACA) and adrenocortical carcinomas (ACC), respectively and benign and 
malignant pheochromocytomas (PCC). The malignant ATs are aggressive tumors with a 
poor prognosis. The surgical removal of the tumor represents the treatment of choice for 
both benign and malignant hormone-secreting tumors, for all tumors suspected to be 
a PCC, as well as for all non hormone-secreting adrenal masses with clinical and radio-
logical suspicion of malignancy. However, in malignant ATs, surgery allows a complete 
remission only in a minority of cases with a diagnosis in early stage of the disease. The 
limited efficacy of conventional antineoplastic treatments in malignant ATs increases 
the need for novel and more effective treatment options.
The mammalian target of rapamycin (mTOR) pathway is one of the most important 
intracellular mediators of growth factor receptors, including insulin-like growth factors 
(IGFs), which have been suggested to play a role in AT pathogenesis. Dysregulation of 
the mTOR pathway has been found in many human tumors. Therefore, the mTOR path-
way is a target for antineoplastic therapy in several malignancies.
At time the studies presented in this thesis were initiated, the role and functions of 
mTOR pathway in the normal and pathological adrenal gland and the effects of mTOR 
inhibitors as novel treatment opportunity for the management of malignant ATs was 
not clarified.
The main aim of the present thesis was to explore the role of mTOR pathway as a poten-
tial target for new treatment options in patients with ATs.
Chapter 1 provides an overview of the pathophysiology and current treatment options 
for ATs, as well as an overview of the mTOR pathway. It also describes the background of 
the mTOR pathway as a potential novel target for treatment of patients with ATs.
Chapter 2 describes the effects of the mTOR-inhibitors sirolimus and temsirolimus on 
growth and cortisol production in cell line models of human ACC (H295, HAC15 and 
SW13 cell lines). This study demonstrated that mTOR-inhibitors inhibit the proliferation 
in a dose- and time-dependent manner in all three ACC cell lines. The antiproliferative 
effects appeared to be predominantly related to the inhibition of cell cycle. Moreover, 
sirolimus inhibits cortisol production in human secreting ACC cells. However, the differ-
ent ACC cell lines were found to have a differential sensitivity to the mTOR-inhibitors, 
suggesting that mTOR could be a target for the treatment of human ACCs, but with the 
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expectation of variable responses. This study also suggested that the overexpression of 
IGF2 might be a reason for a reduced sensitivity to mTOR inhibitors and it was demon-
strated that the blocking of endogenously produced IGF2 increased the antiproliferative 
effects of sirolimus on H295, a cell line that overexpresses IGF2. Therefore, this study 
suggested that in ACC, the combined targeting of mTOR and IGF2 may have stronger 
effects than treatment with mTOR-inhibitors alone.
Chapter 3 describes the mRNA, protein and phospho-protein expression of the main 
components of the mTOR pathway: mTOR, S6K1 and 4EBP1 in normal adrenal, adrenal 
hyperplasia and in benign and malignant adrenocortical tumors. This study demon-
strated a layer specific expression of the evaluated components in the normal adrenal 
gland, as well as in adrenal hyperplasia, which is suggestive for a specific role of the 
mTOR pathway in particular adrenal functions, such as the regulation of androgens or 
aldosteron production. Although the evaluated proteins of the mTOR pathway were 
found to be expressed in most ACTs, this study underlined the heterogeneous expres-
sion of the main components of the mTOR pathway in ACCs, and suggested that some 
more aggressive tumors could have a down-regulation of the mTOR pathway. Therefore, 
this study pointed out the importance to find biomarkers that are predictive for a re-
sponse to treatment with mTOR inhibitors in ACTs. Such biomarkers might drive the 
selection of patients candidate to this type of treatment. In our attempt, to answer to 
this requirement, in this study the protein expression of the main components of the 
mTOR pathway was also investigated in relation to the in vitro effects of mTOR inhibitors 
in ACT primary cultures. Unfortunately, the expression of none of the evaluated proteins 
correlated with the in vitro response to these drugs, although the number of primary 
cultures that were tested was low. As such, these preclinical data did not help to suggest 
a potential molecular biomarker capable of predicting a response to mTOR inhibitors in 
ACCs. Therefore, it is suggested that caution should be taken before using mTOR inhibi-
tors as monotherapy in unselected ACC patients.
The data derived from the use of the mTOR inhibitors alone in preclinical studies, 
together with the expected heterogeneity of ACCs and a lack of molecular biomarker ca-
pable to predict the response to mTOR inhibitors, suggested that combination of mTOR 
inhibitors with other drugs, potentially active in ACC, could be a more prudent clinical 
approach than the use of these inhibitors as monotherapy in unselected ACC patients. 
Since IGF was considered as one of the most attractive targets for a new treatment in 
patients with ACC, in chapter 4 the combination of drugs targeting the mTOR pathway 
and the IGF pathway was explored. This study showed that most ACC express IGF2, 
IGF1R and IGF2R proteins and we demonstrated IRA mRNA expression in these tumors. 
These data point out that ACCs express some components of the IGF pathway, such as 
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IRA and IGF2R, which were not considered before. As such, before to finally declare a 
“game over” for the role of IGF2 in adrenocortical tumorigenesis and as a potential target 
for novel treatment in ACC patients, it may probably be useful to return to the bench and 
try to better explore the IGF pathway in ACCs in its whole complexity. Additionally, we 
demonstrated that in human ACC cells, treatment with OSI-906, an IGF1R/IR antagonist, 
inhibits cell proliferation and that combined treatment with OSI-906 and mTOR inhibi-
tors has additive antiproliferative effects.
Since mitotane is currently considered as a referral drug in the treatment of patients 
with advanced ACC (although unfortunately not all patients respond and/or tolerate 
this drug), this drug represents another attractive candidate for new combined treat-
ment strategies in ACC. Therefore, in chapter 5 the combination of drugs targeting the 
mTOR pathway and mitotane was explored. These studies demonstrated that sirolimus 
has additive antiproliferative effects when combined with low doses of mitotane. These 
doses corresponded to concentrations lower than the therapeutic range of mitotane, 
suggesting that the addition of sirolimus to mitotane might be useful in ACC patients 
when the therapeutic range of mitotane is not reached.
In addition to the mTOR and IGF pathways, chapter 6 describes, in a large series of ACC 
samples, the presence of molecular events (detected by hotspot gene sequencing and 
comparative genomic hybridization), potentially targetable with currently developed 
targeted drugs. This study demonstrated that the presence of genomic alterations of 
the main components of the mTOR pathway are not common events in advanced ACCs. 
At least one copy number alteration or mutation was found in about half of the pa-
tients. The most frequent mutations were detected in TP53, ATM and CTNNB1. The most 
frequent copy number alterations identified were: amplification of the CDK4 oncogene 
and deletion of the CDKN2A and CDKN2B tumor suppressor genes. Therefore, no simple 
targetable molecular event emerged and based on genomic alterations, the cell cycle 
appeared to be the most relevant new potential therapeutic target for patients with 
advanced ACC.
Chapter 7 describes the expression of the main components of the mTOR pathway and 
the relationship between the mTOR and the IGF pathways in PCCs, as well as the effects 
of mTOR inhibitors, alone or in combination with OSI-906, in a rat PCC cell line (PC12). 
This study demonstrated that all the investigated components of the mTOR and the 
IGF pathways were expressed in human PCC. A high expression of IGF2 mRNA and an 
increased IRA/IRB ratio was found. mTOR inhibitors and OSI-906 were able to suppress 
PC12 proliferation in a dose- and time-dependent manner. OSI-906 strongly stimulated 
cell apoptosis. Combined treatment of sirolimus with OSI-906 had additive antiprolifera-
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tive effects. Therefore, this study suggested that OSI-906, alone or in combination with 
mTOR inhibitors, could represent a new treatment option in progressive PCC patients.
In chapter 8, the general discussion, the results of these studies are integrated and 
further discussed. Special emphasis is given to those issues which address the role 
of the mTOR pathway as a potential target for the treatment of patients with ACCs or 
malignant PCCs. A need to move into the direction of a more personalized approach for 
the treatment of patients with malignant ATs is emphasized.
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Bijnier tumoren omvatten benigne (goedaardige)- en maligne (kwaadaardige) tumoren 
uitgaande van de bijnierschors (bijnierschors adenomen en bijnierschors carcinomen), 
alsmede benigne- en maligne mergtumoren, de feochromocytomen. Maligne bijnier-
schors tumoren zijn zeer agressief en patiënten met deze tumoren hebben een slechte 
prognose. Chirurgische verwijdering van de tumor is de voorkeursbehandeling voor 
zowel debenigne- als maligne hormoonproducerende tumoren, voor alle als feochro-
mocytoom verdachte tumoren, alsmede voor niet-hormoon producerende ruimte-
innemende processen in de bijnier, die klinisch en radiologisch verdacht worden van 
maligniteit. Bij maligne bijnier tumoren resulteert chirurgie echter slechts in een klein 
deel van de patiënten met een vroege diagnose van de ziekte in complete genezing. 
Deze beperkte effectiviteit van de conventionele antitumor behandeling in patiënten 
met maligne bijniertumoren benadrukt de noodzaak voor nieuwe en effectieve behan-
delingsopties.
De “mammalian target of rapamycin (mTOR)” cellulaire route is een van de meest belang-
rijke mediatoren van de effecten van groeifactoren, waaronder insuline-achtige groei 
factoren (IGFs), die een mogelijke rol spelen bij de pathogenese van bijnier tumoren. 
Deregulatie van de mTOR route wordt gevonden in vele soorten menselijke tumoren. 
De mTOR route is daarom een doelwit voor anti-tumor therapie bij verschillende malig-
niteiten.
Op het moment dat de studies die gepresenteerd worden in dit proefschrift aanvingen, 
waren de rol en functies van de cellulaire mTOR route in de normale- en pathologische 
bijnier, alsmede de effecten van mTOR remmers als nieuwe behandelingsmogelijkheid 
bij patiënten met maligne bijnier tumoren niet bekend.
Het doel van het in dit proefschrift beschreven onderzoek is de rol van de mTOR route 
als mogelijk nieuw doelwit voor behandeling van patiënten met bijnier tumoren te 
onderzoeken.
hoofdstuk 1 geeft een overzicht van de pathofysiologie en huidige behandelings-
mogelijkheden voor bijnier tumoren, alsmede een gedetailleerde beschrijving van de 
cellulaire mTOR route. Tevens wordt het mechanisme van de mTOR route beschreven als 
mogelijk doelwit voor behandeling van patiënten met bijnier tumoren.
hoofdstuk 2 beschrijft de effecten van de mTOR remmers sirolimus en temsirolimus op 
de groei en cortisol productie in cellijn modellen van menselijke bijnierschorskanker 
(H295, HAC15 en SW13 cellijnen). Deze studie toont aan dat mTOR remmers de prolife-
ratie op een dosis- en tijdsafhankelijke wijze remmen in alle drie bestudeerde cellijnen. 
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De anti-proliferatieve effecten bleken voornamelijk gerelateerd aan het remmen van 
de celcyclus. Bovendien wordt aangetoond dat sirolimus de cortisol productie remt in 
gekweekte menselijke bijnierschorscarcinoom cellen. De gevoeligheid van de verschil-
lende bijnierschorskanker cellijnen voor het remmende effect van mTOR-remmers bleek 
echter verschillend, hetgeen suggereert dat mTOR een doelwit kan zijn voor behande-
ling van het bijnierschorscarcinoom, maar dat variabele responsen verwacht mogen 
worden. Deze studie suggereert tevens dat de over-expressie van IGF2 een mogelijke 
oorzaak kan zijn voor een verminderde gevoeligheid van de tumorcellen voor mTOR 
remmers. In dezelfde studie wordt aangetoond dat het blokkeren van endogeen gepro-
duceerd IGF2 de gevoeligheid voor het antiproliferatieve effect van sirolimus in H295 
cellen, een cellijn die een overmatige IGF2 expressie heeft, verhoogd. De in hoofdstuk 
2 beschreven resultaten suggereren dat een combinatie van geneesmiddelen die zowel 
mTOR als IGF2 als doelwit hebben in bijnierschorscarcinomen een sterker effect heeft 
dan behandeling met alleen mTOR-remmers.
In hoofdstuk 3 wordt de mRNA-, eiwit- en phospho-eiwit expressie van de belangrijkste 
componenten van de cellulaire mTOR route, te weten mTOR, S6K en 4EBP1, beschreven 
in de normale bijnier, in hyperplastisch bijnier weefsel, en in benigne- en maligne bij-
nierschors tumoren. Deze studie toont aan dat er een zone specifieke expressie van deze 
componenten aanwezig is in de normale- en hyperplastische bijnier, hetgeen suggestief 
is voor een specifieke rol van de mTOR route in bepaalde bijnierfuncties, zoals de regu-
latie van de androgeen- en/of aldosteron productie. Hoewel bovengenoemde eiwitten 
van de mTOR route tot expressie komen in de meeste bijnier tumoren, onderschrijven 
de bevindingen een heterogene expressie van deze eiwitten in bijnierschorskanker, 
alsmede een down-regulatie van de mTOR route in de meer agressieve tumoren. Deze 
studie benadrukt daarom het belang van het vinden van biomerkers in bijnierschors 
tumoren die voorspellend zijn voor een respons op behandeling met mTOR remmers. 
Dergelijke biomerkers zouden patiënten kunnen identificeren die kandidaat zijn voor 
dit type behandeling. In een poging om dergelijke biomerkers te vinden hebben we 
in deze studie tevens de expressie van componenten van de mTOR route onderzocht 
in relatie tot de in vitro effecten van mTOR remmers in primaire kweken van bijnier-
schors tumoren. Helaas bleek er geen correlatie te bestaan tussen de expressie van de 
onderzochte eiwitten en de in vitro respons op mTOR remmers. Het aantal onderzochte 
primaire kweken was echter relatief klein. Op basis van onze pre-klinische resultaten 
kunnen wij daarom niet een potentiele merker voorstellen die voorspellend is voor het 
effect van mTOR remmers in bijnierschors tumoren. Voorzichtigheid is daarom geboden 
voordat het gebruik van mTOR remmers als monotherapie overwogen wordt in niet-
geselecteerde patiënten met een bijnierschorscarcinoom.
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De huidige gegevens uit pre-klinische studies omtrent het gebruik van mTOR remmers 
als monobehandeling, in combinatie met de verwachte heterogeniteit van bijnier-
schorskanker, en het gebrek aan een moleculaire biomerker die een respons op mTOR 
remmers voorspelt, suggereren dat het combineren van mTOR remmers met andere 
geneesmiddelen die mogelijk werkzaam kunnen zijn in bijnierschorskanker, een meer 
voorzichtige klinische benadering is dan het gebruik van mTOR remmers als monothera-
pie in niet-geselecteerde patiënten met bijnierschorskanker. Aangezien IGF beschouwd 
wordt als een van de meest aantrekkelijke doelwitten voor een nieuwe behandeling van 
patiënten met bijnierschorskanker hebben wij in hoofdstuk 4 de combinatie van ge-
neesmiddelen die gericht zijn tegen zowel de mTOR route als de IGF-route onderzocht. 
Deze studie toont dat de meeste bijnierschorskankers IGF2, IGF1R en IGF2R eiwitten, 
maar ook IR-A, tot expressie brengen.
Als zodanig, en voordat definitief besloten wordt tot een “game over” voor de rol 
van IGF2 in bijnierschors tumorgenese en als potentieel doelwit voor behandeling van 
patiënten met bijnierschorskanker, is het waarschijnlijk nuttig om terug te gaan naar 
het laboratorium om de IGF route in bijnierschorskanker in zijn totale complexiteit te 
onderzoeken. Tevens hebben wij in hoofdstuk 4 aangetoond dat behandeling met OSI-
906, een IGF1R/IR antagonist, de proliferatie van menselijke bijnierschorskanker cellen 
remt en dat gecombineerde behandeling met OSI-906 en mTOR remmers resulteert in 
additieve anti-proliferatieve effecten.
Mitotaan is op dit moment het geneesmiddel dat wordt gebruikt bij de behandeling 
van patiënten met een vergevorderd stadium van bijnierschorskanker (ondanks het feit 
dat helaas niet alle patiënten reageren op de behandeling en/of intolerant zijn voor het 
geneesmiddel) en is daarom een andere aantrekkelijke kandidaat voor gecombineerde 
behandelingsstrategieën in bijnierschorskanker. In hoofdstuk 5 hebben wij daarom 
de effecten van behandeling met een combinatie van mTOR remmers en mitotaan 
onderzocht. Deze studies tonen aan dat sirolimus additieve antiproliferatieve effecten 
heeft wanneer dit middel gecombineerd wordt een lage dosering mitotaan. Deze on-
derzochte doseringen mitotaan komen overeen met concentraties die lager zijn dan de 
therapeutische concentraties van mitotaan, hetgeen suggereert dat het toevoegen van 
sirolimus aan mitotaan nuttig kan zijn bij patiënten met bijnierschorskanker, wanneer 
de therapeutische spiegel van mitotaan nog niet bereikt is of niet bereikt wordt.
Naast de eerder beschreven cellulaire mTOR en IGF routes wordt in hoofdstuk 6 in 
een grote serie bijnierschors tumoren het voorkomen van moleculaire veranderingen 
(aangetoond door middel van “hotspot gene sequencing” en “comparative genomic 
hybridization”) die een mogelijk doelwit zijn voor reeds ontwikkelde “targeted drugs” 
onderzocht en beschreven. Deze studie toont aan dat genetische veranderingen in 
de belangrijkste componenten van de mTOR route niet frequent voorkomen in bij-
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nierschors kanker in een vergevorderd stadium. In de helft van de tumoren werd een 
verandering in minstens een kopie aantal of een mutatie gevonden. De meest frequente 
mutaties werden gevonden in TP53, ATM en CTNNB1. De meest frequente kopie aantal 
veranderingen die gevonden werden zijn amplificatie van het CDK4 oncogen en deletie 
van de CDKN2A en CDKN2B tumor suppressor genen. Op basis van deze bevindingen 
werd geconcludeerd dat er niet een eenvoudig moleculair doelwit naar voren kwam 
gebaseerd op genetische veranderingen, en dat de cel cyclus het meest relevante 
therapeutische doelwit lijkt te zijn voor patiënten met een vergevorderd stadium van 
bijnierschorskanker.
hoofdstuk 7 beschrijft de expressie van de belangrijkste componenten van de mTOR 
route, alsmede de relatie tussen de mTOR- en IGF routes, in feochromocytomen. 
Tevens worden de effecten van mTOR remmers, alleen en in combinatie met OSI-906, 
beschreven in een ratten feochromocytoom cellijn (PC12). Deze studie toont aan dat 
alle onderzochte componenten van de mTOR- en IGF routes tot expressie komen in 
feochromocytomen. Een hoge expressie van IGF2 mRNA en een verhoogde IR-A/IR-B 
verhouding werd gevonden. mTOR remmers en OSI-906 remmen de proliferatie van 
PC12 cellen op een dosis- en tijdsafhankelijke wijze. OSI-906 heeft een sterk apoptose 
stimulerend effect in PC12 cellen. Gecombineerde behandeling met sirolimus en OSI-
906 resulteert in een additief antiproliferatief effect. Deze studie suggereert dat OSI-906, 
alleen of in combinatie met mTOR remmers, een mogelijk nieuwe behandelingsoptie 
kan worden bij patiënten met een maligne feochromocytoom.
In hoofdstuk 8, de algemene discussie, worden de resultaten van de in dit proefschrift 
beschreven studies geïntegreerd en nader bediscussieerd. Speciale aandacht wordt 
besteed aan de rol van de mTOR route als een mogelijk nieuw doelwit voor behandeling 
van patiënten met bijnierschorskanker of een maligne feochromocytoom. De noodzaak 
van een meer gepersonaliseerde, op tumor kenmerken gebaseerde aanpak bij de be-
handeling van patiënten met maligne bijnier tumoren wordt benadrukt.
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Lacroix, who gave me the opportunity to work in his Translational Research Lab where 
I learned new techniques, and to participate to weekly discussions on personalized 
medicine “from the bench-to-bedside”. “Cher Ludovic merci beaucoup” for your support 
during my period at Institut Gustave Roussy and your precious teaching. I would like to 
express gratitude also to Prof. Schlumberger, for having always been very kind with me 
and to Dr. Abir Al Ghuzlan, Prof. Jean-Yves Scoazec and other French colleagues who 
greatly contributed with their work and their knowledge in helping me to carrying out 
the part of this thesis that has been developed in France.
I would thank my French friends, who contributed to make my time in Paris great. Par-
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